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ABSTRACT 
Soybean isoflavones are one of major phytoestrogens in the human food supply. The 
proposed health effects of soy consumption include preventing hormone-dependent cancers 
and cardiovascular disease and lowering the risk of osteoporosis. But there also exist health 
concerns such as the potential hormonal effects in infants fed soy-based infant formula, and 
anti-thyroid effects in humans. Bioavailability of isoflavones must be better understood in 
order to better assess their potential health and adverse effects. Isoflavone degradation 
phenotype and gut transit time (GTT) may have great influence on their bioavailability. To 
characterize what forms have optimal bioavailability, isoflavone aglucons and glucosides 
were compared between high and low daidzein degradation phenotypes with various GTT in 
women. Daily urinary isoflavone excretion was similar for aglucons and glucosides (51.5 ± 
6.1 % and 50.8 ± 5.6 % of ingested amount, respectively). Apparent absorption of 
isoflavones was significantly greater in the low daidzein degradation phenotype coupled with 
shorter GTT than in the high phenotype with longer GTT as reflected in total urinary 
isoflavone excretion. 
To study the influence of dose on isoflavones bioavailability, high and low doses of 
isoflavone were fed crossover for 7 days in women of both high and low daidzein 
degradation phenotype with varying GTT. As reflected in urinary isoflavone excretion, dose-
dependent response was significant and expected (high vs. low dose: 197 ± 11 v. 72 ± 11 
|imol/d, P < 0.05); phenotypic difference coupled with GTT difference greatly influenced 
isoflavone bioavailability (low vs. high daidzein degraders: 189.0 ± 16.3 v. 119.0 ± 5.0 
|jmol/d, P < 0.05). Repeated dosing decreased urinary isoflavone excretion by 20-30%. 
vi 
Higher intakes of dietary fiber may accelerate GTT, therefore may increase apparent 
isoflavone absorption. High (45g/d) or moderate fiber (15g/d) diets were given to women of 
the low daidzein degraders with longer GTT (> 84 h) for 7 days as well as isoflavones in a 
randomized crossover feeding trial. Since GTT were decreased after both high fiber and 
moderate fiber diets, the apparent absorptions of isoflavones did not differed between the two 
fiber treatments. Repeated isoflavone feeding showed lower total urinary isoflavone 
excretion (week 1 vs. 2, 9.0 ± 0.9 vs. 4.8 ± 0.9 /imol/kg, P = 0.02) and plasma isoflavone 
(week 1 vs. 2, 4.8 ± 0.7 vs. 1.8 =t 0.7 pmol/L, P = 0.005). These data suggested that 
isoflavone degradation phenotype coupled with GTT is crucial in determining isoflavone 
bioavailability. Repeated dosing lowered isoflavone bioavailability. 
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GENERAL INTRODUCTION 
Introduction 
Soybeans are a major plant seed in human diets, the main source of isoflavones 
containing amounts of these compounds ranging from 1 to 3 mg/g. Due to the structural 
similarity to mammalian estrogen, 17 ^-estradiol, isoflavones exert weak estrogenic effect 
and are called "phytoestrogens". Two chemical forms of isoflavones are found in soybeans: 
the isoflavone aglucons, daidzein, genistein and glycitein, exist only in minor amount in 
soybeans; the isoflavone glucosides are predominant in soybeans, which include malonyl-, 
glucosyl- and acetyl-p-glucosides. More than 90% of isoflavones in soy products are in the 
glucosidic form except fermented soy products that contain considerable amounts of aglucons. 
The isoflavone contents in soy products and isoflavone supplements vary product byproduct. 
The consumption of soy products has been associated with decreased risk of hormone-
dependent cancers, coronary heart disease, osteoporosis and menopausal symptoms. But there 
are health concerns about the consumption of large amounts of isoflavones. Among the 
potential risks and adverse effects, possible endocrine effects in infants fed soy-based infant 
formula and anti-thyroid effects have been targeted. 
The bioavailability of isoflavones is clearly important in assessing the likely 
importance of these compounds to human health. Bioavailability has different interpretations 
from different research perspectives. It is not indicated entirely by the extent of absorption. 
Absorption, distribution, metabolism (biotransformation in the gut, liver and other tissues) 
and elimination all contribute to bioavailability following ingestion. Bioavailability thus 
quantifies the exposure of the body to the compound. Many studies suggest that 
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bioavailability of dietary isoflavones depends upon their chemical structures, dose and time 
course. Recently, it is also suggested that the interactions of isoflavones with gut microflora 
and gut transit time are important in determining their bioavailability. The activities of gut 
microorganisms play an important role in isoflavone metabolism and bioavailability because 
considerable interindividual variation of fecal isoflavone degradation was reported in a 
human feeding study in which the variation of urinary isoflavone excretion was 10- to 20-fbld 
within the same dose of dietary isoflavone treatment, vzfro human fecal isoflavone 
degradation phenotypes have been identified based on isoflavone degradation half-lives or 
degradation rate constants. Greater urinary isoflavone excretion has been associated with 
lower fecal isoflavone degradation rate constants and shorter gut transit time. Gut transit time 
reflects the residence time of substances passing through the gut and may be a crucial factor 
in influencing isoflavone bioavailability because with shorter GTT, the less isoflavones can 
be degraded, therefore the more isoflavones are absorbed. 
Isoflavone aglucons are suggested to be absorbed directly in the stomach and intestine. 
But isoflavone glucosides must undergo the hydrolysis of P-glucosidic bond by the action of 
mammalian or gut microbial (3-glucosidases before absorption. Seemingly, whether dietary 
isoflavones were present as aglucons or glucosides, the overall bioavailability of isoflavone 
was not aflected. Chronic exposure to isoflavones, e. g., feeding soymilk for one month, 
decreased the urinary isoflavone excretion, which suggested the induction of isoflavone 
degrading gut microbial enzyme activities after frequent consumption of soy foods; the more 
isoflavone being degraded, the lower the isoflavone bioavailability. Studies regarding the 
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influence of dietary factors on isoflavone bioavailability suggested neither soy food types nor 
background diet affect short-term isoflavone bioavailability. 
The objective of my research is to characterize the factors that influence isoflavone 
bioavailability. In a series of isoflavone feeding studies in women, I compared isoflavone 
bioavailability as reflected in urinary isoflavone excretion between aglucons and glucosides, 
between dietary isoflavones rich in glycitein and rich in genistein and between high dose and 
low dose of dietary isoflavones; the influence of isoflavone degradation phenotype coupled 
with GTT on isoflavone bioavailability was characterized in all the studies, especially in the 
last one, in which I attempted to modify GTT by increasing intake of dietary fiber to see if it 
would change urinary isoflavone excretion. 
Dissertation Organization 
This dissertation contains a general introduction, a literature review, three papers, a 
general conclusion and acknowledgements. All three papers "Comparative bioavailability of 
isoflavone glucosides and aglucons in women", "Gut transit time and gut microbial 
isoflavone degradation influence apparent isoflavone absorption in women and 
"Confounding effects of caloric intake and time course on modulation of apparent absorption 
of isoflavones by dietary fiber intake in women" will be submitted to Journal of Nutrition. 
The papers are followed the format of the journal to which will be submitted. 
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LITERATURE REVIEW 
Source, Chemistry, and Isoflavone Analysis 
Chemistry of isoflavones 
Isoflavones are phytochemicals mainly found in soybeans and other legume species, 
such as clover, peas and alfalfa. Soybeans are a major plant seed in human diets, which 
contain the highest amounts of isoflavones ranging from 1 to 3 mg/g (Wang and Murphy, 
1994). There are over 350 different naturally occurring isoflavones (Harbome and Baxter, 
1999), and soybeans contain 12 forms of isoflavones. These are aglucons daidzein, genistein, 
glycitein; glucosyl-^-glucosides, daidzin, genistin and glycitin (the glucosylation occurs at the 
7-O-position of aglucons); acetyl- and malonyl-^-glucosides (the acetylation and 
malonylation occur at the 6 position of the glucose moiety). The aglucons, daidzein and 
genistein were first isolated and identified in the soybean by Walter (1941). Glycitein was 
first isolated by Nairn et al. (1973). Kudou et al. (1991) reported the nine predominant (3-
glucosides isolated from soybean hypocotyls. 
Dietary sources and estimated intake of isoflavones 
Soy products and isoflavone supplements are the major dietary sources of isoflavones 
and the isoflavone contents vary product by product. For those soy products in which soy is 
used as an ingredient, such as soy flour, the isoflavone contents normalized to aglucons 
ranges from 1-2 mg/g (USDA Iowa State University isoflavone database). In soy-based 
infant formula, in which soy protein is used as a functional ingredient, isoflavones are -250 
pg/g in the non-reconstituted formulas (USDA Iowa State University isoflavone database). 
For those foods directly made from soy, such as soymilk, tofii, tempeh, and miso, consumed 
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as staple foods mainly in China and Japan, the isoflavone contents range from 400 to 2000 
jug/g (USDA Iowa State University isoflavone database). In the newly generated soy foods 
such as soy-based burger, hot dog, bacon, and soy cheeses, the isoflavone contents are as low 
as < 100 /ig/g (USDA Iowa State University isoflavone database). Isoflavones in soy 
products mainly exist as glucosides except in fermented soy foods such as tempeh and miso, 
which contain considerable amounts of aglucons since fermentation increases the aglucon 
contents. The distributions of individual isoflavones in soy foods depend on the natural 
distribution and the fractions used from the soybeans; genistein usually is in highest amount. 
Recently many kinds of isoflavone supplements are commercially available. Setchell 
et al. (2001) reported isoflavone contents in 33 of these products by HPLC and electrospray 
ionization-mass spectrometry (ESI-MS) analysis. A large variation was found in isoflavone 
contents in these supplements when the sum of individual aglucons and glucosides was 
calculated, ranging from 1,700 to 96,000 jwg/g of the supplement. The distributions of each 
aglucon and glucoside differed product by product. Overall, they grouped these supplements 
into four categories: 1) those in which daidzein plus glycitein is 2-fbld more than genistein, 
such as the products made from soy germ; 2) those products with this ratio lower than 1.5-
fbld and only a small portion of glycitein is present; 3) those made from extracts of clover 
containing mainly methoxylated isoflavones fbrmononetin and biochnin A; 4) those 
containing daidzein and puerarin made from extracts of kudzu (an Asian legume plant and 
noxious weed introduced into Southern US) (Setchell et al., 2001). 
The estimated dietary intakes of isoflavone differ significantly among populations. In 
adults eating typical Western diets without isoflavone supplements, the intakes are as low as 
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1-3 mg/d (Jones et al., 1989, Tham et al., 1998). In typical Eastern Asian diets, the intakes 
are 15-50 mg/d (Wakai et ai., 1999, Chen et al., 1999). For example, in Japanese diets, it is 
estimated at 30 mg/d (Watanabe et al., 2000). For isoflavone supplements users, the intakes 
would depend on isoflavone concentrations in individual products and compliance with 
instructions for daily use, probably ranging from 0.5 to 2 mg/kg body weight per day. The 
isoflavone contents in soy-based infant formulas range from 214 to 285 p,g/g in the dry 
fbimulas, and from 25 to 30 pg/mL in the reconstituted formulas (Murphy et al., 1997). The 
estimated intakes in infants (0-4-month of age) are 6-11 mg/kg body weight per day when 
they only consume soy-based formulas (Setchell et al., 1998). 
Isoflavone analysis 
The methods for isoflavone analysis have developed rapidly in recent years because 
the qualitative and quantitative data are greatly important for isoflavone research. Ideally, the 
method should have high sensitivity and selectivity; the equipment should be easily installed 
and the clean-up procedure should be relatively simple. But achieving all optimal conditions 
may not be easy; the choice of method is highly dependent on the research purpose and the 
nature of sample to be analyzed. 
The methods for isoflavone analysis include chromatographic and non-
chromatographic methods. Of chromatographic methods, gas chromatography-mass 
spectrometry (GC-MS) was the first one used for isoflavone analysis. GC-MS not only 
provides high sensitivity and resolution in analysis, but also is used as a tool to identify new 
peaks in chromatograms. It is particularly good for determining isoflavone content in 
biological samples such as blood, feces, urine and tissue where only low concentration of 
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isoflavones and their metabolites are present. But due to the nature of this analysis, a 
complicated clean-up using internal standard is needed before the injections. Adlercreutz et 
al. (1991a, 1991b, 1995) developed an isotope dilution GC-MS method, which had been used 
in detecting and determining isoflavones or their metabolites in biological samples: plasma, 
urine and feces. The detection limit of this method is in the range of ng/mL. For example, in 
feces, the limit of detection (LOD) was about 1 to 14 nmol/24h fecal sample (Aldercreutz et 
al., 1995). This multi-step method usually starts with a solid-phase extraction (SPE) after 
enzymatic hydrolysis of conjugated isoflavones, especially for biological samples urine and 
plasma; then followed by adsorption chromatography (Sephadex LH-20) to get the fraction of 
interest; derivatization of isoflavones to volatile analytes is necessary for GC methods. Each 
step could introduce errors and thus internal standard is highly recommended to monitor the 
loss during clean-up procedure (Heinonen et al., 1999). Due to these limitations, GC-MS may 
be applied to only a limited percentage of isoflavone analysis, mainly focused on the 
identification of isoflavones and their metabolites. 
Compared with GC-MS, another chromatographic method, high-performance liquid 
chromatography (HPLC) has been extensively used in isoflavone analysis with the 
characteristics of being less expensive, requiring no or simple clean-up procedure (usually 
SPE). In addition, HPLC can be combined with multi-detection methods, including 
ultraviolet (UV) detection, fluorescence detection, electrochemical detection (ECD), MS, and 
recently reported coulometric detection. Solid-phase extraction followed by reverse-phase 
HPLC-UV detection modified from Lundh et al. (1988) is used in our laboratory for 
isoflavone analysis in urine, plasma and feces with 2,4,4'-trihydroxydeoxybenzoin (THE, a 
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precursor of isoflavone synthesis) used as internal standard (Song et al., 1998). UV detection 
is monitored at 254 nm, the LOD is about 20-100 ng/mL, and the analytical recoveries from 
the spiked isoflavones range from 65 to 87% in the biological samples. Photodiode array 
detection (PDA) is applied to identify individual isoflavones and their metabolites through 
spectra under different wavelength (190-350 nm) for maximum UV absorption. One 
potential problem of UV detection is that it is not sensitive for some isoflavone metabolites 
such as equol and O-desmethylangolensin (ODMA). For example, the LOD for equol and 
ODMA was 151-201 ng/mL, respectively, but for daidzein and genistein, it was 1.3-2.4 
ng/mL, respectively in a SPE-HPLC-UV method (Franke and Custer, 1994). This problem 
could be solved by using HPLC-MS, HPLC with coulometric detection or HPLC-ECD, the 
detection limits of these methods are in the range of ng/mL to pg/mL (Franke et al., 2002, 
Nurmi et al., 2002, Setchell et al., 1987). Fluorescence detection is more sensitive than UV, 
but since not all isoflavones may have natural fluorescence response, this method is not 
widely used. One study showed that only daidzein and fbrmononetin but not genistein and 
biochanin A had fluorescence response, and the LOD for UV and fluorescence detection was 
2 and 0.5 ppm (mg/kg), respectively, in food samples (Wang et al., 1990). Now HPLC 
coupled with plenty of choices of detection is widely accepted and applied in isoflavone 
analysis. Among these methods, UV detection is less expensive and easily installed when 
working with soy food samples or biological samples after soy consumption. 
The non-chromatographic methods such as immunoassay methods include 
radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), and time-resolved 
fluoroimmunoassay (TR-FIA). Immunoassay methods offer a rapid analysis with high 
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sensitivity, specificity and relatively less expense. The detection limits of these assays 
reported in urine or plasma are 0.1-50 ng/mL (Lapcik et al., 1998, Uehara et al., 2000). It is 
suggested that these methods are suitable for large-scale studies or studies needing rapid 
scanning. 
Isoflavones are phytochemicals synthesized by plants. Over the past 15 years there has 
been a dramatic increase in isoflavone research due to the specific beneficial and toxicity-
related issues. This in turn encourages the development of new methods for the qualitative 
and quantitative measurement of isoflavones. In conclusion, various analytical methods have 
been used in isoflavone analysis based on different purpose of the study. Among these 
methods, HPLC-UV method is low-cost, but may be less sensitive especially for detection of 
isoflavone metabolites compared to other methods. HPLC with coulometric detection may be 
a better choice because it has the same cost but higher sensitivity than UV detection and 
much less expensive than GC-MS and BCD. Immunoassay is ideal for epidemiological 
studies with a large number of samples requiring high specificity. 
Phytoestrogen Isoflavones and Hormone-dependent Cancers 
Estrogens are steroidal hormones that play an important role in maintenance of good 
health in all vertebrates. Their biological effects are mainly found in influencing the growth, 
differentiation and functioning of target tissue or organs. In addition, estrogens may 
influence the cardiovascular system and bone health. The principal estrogen in animals is 
17|3-estradiol (E%), which interacts with the estrogen receptors (ERs) to exert its estrogenic 
effects in the body. Two subtypes of ERs, ERa and ERp have been identified. ERa is 
predominant in the testis, kidney, adrenal and non-pregnant myometrium; ER(3 is distributed 
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in bone, brain, thymus, prostate, lung, vascular endothelia, bladder and pregnant term 
myometrium (Kuiper et al., 1997). The binding affinity of Ez to the ERs is different in that 
the affinity of Ez to ERfS is one-quarter of that to ERa in synthesized human ERa and rat ER(3 
protein (Kuiper et al., 1997). 
Phytoestrogens refer to the compounds derived from plants that exert estrogenic 
effects. Isoflavones are one major class of phytoestrogens and their estrogenic effects were 
first reported in the 1940s when these compounds were found to cause infertility in 
Australian sheep eating red clover (Bennets et al., 1946). The major isoflavones found in red 
clover were biochanin A and fbrmononetin (Shutt, 1976). 
Epidemiology of hormone-dependent cancers and soy consumption 
Hormone-dependent cancers, such as those of breast, prostate and colon cancers, have 
higher incidence in Western countries. The relation between soy consumption and hormone-
dependent cancers was reported in several epidemiological studies in which the intake of soy 
foods shown to be inversely correlated with breast and prostate cancer incidence (Adlercreutz 
et al., 1991b, Lee et al., 1991, Yuan et al., 1995, Hirose et al., 1995, Zheng et al., 1999). Soy 
consumption is very high in Eastern Asia compared to the North America and Europe. In 
several breast cancer case-control studies done in Singapore, China and Japan, soy food 
intakes were estimated by soy-food frequency questionnaires or evaluated by urinary 
isoflavone excretions, the urinary isoflavone excretions were substantially lower in breast 
cancer cases compared to their control counterparts (Lee et al., 1991, Yuan et al., 1995, 
Hirose et al., 1995, Zheng et al., 1999). The factors associated with the decreased risk of 
hormone-dependent cancers include lower circulating reproductive hormones, higher level of 
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sex hormone binding-globulin (SHBG), longer menstrual cycle (for breast cancer, especially 
the length of follicular phase), and higher urinary isoflavone excretion. Soy isoflavones have 
been suggested to have estrogenic and anti-estrogenic effects in vivo, m vzfro and in humans. 
They may modify these risk factors, and therefore, exert cancer prevention effects. 
Estrogenic effects of isoflavone m wvo and in v#ro 
In classic estrogenicity assay, both m Wfro and m w'vo, isoflavones show weak 
estrogenic effect compared with 17(3-estradiol or synthetic estrogen diethylstilbestrol (DES). 
These assays include E-screen (the proliferation ofERa-positive cell lines), competitive 
binding of ERs, expressions of ER-regulated genes and proteins, rodent uterotrophic assay 
and the responses to the estrogen sensitive tissues such as ovary, vagina, uterus and 
mammary gland. For example, genistein has been shown to induce the proliferation of 
estrogen-dependent human breast cancer (MCF-7) cells m Wfro at a concentration as low as 
10 nM, and at 100 nM, the proliferation effect was similar to that of 1 nM 17^-estradiol 
(Hsieh et al., 1998). The expression of the estrogen-responsive gene pS2 was also induced in 
this cell line by 1 /iM genistein (Hsieh et al., 1998). This zn vzfro estrogenic effect found in 
MCF-7 cells was also reproduced m vzvo in ovariectomized athymic mice when MCF-7 cells 
were implanted subcutaneously (under the skin). When the athymic mice were fed either 750 
ppm of genistein or 1200 ppm of genistin (providing equal molar concentrations of aglucon 
equivalents) for 11 weeks, dietary genistein induced cell proliferations, pS2 gene expressions 
and tumor growth (Hsieh et al., 1998, Allred et al. 2001). Later the tumors regressed when 
these mice were switched to genistein-free diet for 9 weeks (Allred et al. 2001). Dose-
dependent (> 250 ppm) cell proliferation, pS2 gene expressions and tumor growth were also 
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reported with this model when mice were fed 125,250, 500 and 1000 ppm of genistein in 
diet (Ju et al., 2001). Furthermore, dietary genistein at 750 ppm for 5 days enhanced 
mammary gland growth in 28-day-old mice of this type (Hsieh et al., 1998). 
In competitive binding of estrogen receptors assay, the relative binding affinity of 
isoflavones was 0.01-0.9% of 17(3-estradiol (Shutt and Cox, 1972, Santell et al., 1997, Song 
et al., 1999). In addition, the binding affinity of genistein toward m Wfro synthesized ER(3 
protein was 8-fbld higher than for ERa protein (Kuiper et al., 1997). When genistein and 
l?P-estradiol were injected subcutaneously into ovariectomized female Wistar rats at doses 
of 2.5, 0.25, 0.025,0.0025 mg/kg body weight per day for 7 days, there was a 20-fbld higher 
binding affinity to ERp than to ERa for genistein, whereas for 17p-estradiol, there was no 
difference between the two receptors within this dose range (M8kel& et al., 1999). In the 
rodent uterotropic assay, genistein, daidzein and glycitein were roughly 10^- to 10^-fbld less 
effective than 17|S-estradiol or synthetic estrogen diethylstilbestrol (DES), but genistein and 
glycitein significantly increased rodent uterine wet and dry weight compared with the control 
group (Farmakalidis et al., 1985, Santell et al., 1997, Song et al., 1999). Results from these 
studies suggested that although isoflavones have weak estrogenic activity, they could act as 
estrogen agonists in vzvo and in vzfro. 
Early exposure to estrogens and progesterone has been suggested to induce 
differentiation in mammary tissue and reduce subsequent susceptibility to chemically induced 
mammary cancer (Grubbs et al., 1985, Russo et al., 1979). Isoflavones, acting as estrogen 
agonists, would be expected to have similar effects. Lamartiniere's research group initiated 
this type of study. In 1992, they reported that neonatal diethylstilbestrol treatment resulted in 
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reducing the incidence of spontaneous development of mammary tumors in Sprague-Dawley 
CD rats (Lamartiniere and Holland, 1992). Then they began to investigate the potential of 
genistein as a substitute for DES to exert a similar chemopreventive effect. Female Sprague-
Dawley CD rats were injected subcutaneously with 5 mg genistein, or 20 fiL of the vehicle, 
dimethylsulfbxide (DMSO), on days 2,4 and 6 postpartum. At day 50, rats were exposed to 
80 mg dimethylbenz[a] anthracene (DMBA)/kg body weight to induce mammary cancer. They 
found that neonatal injections of genistein suppressed the development of DMBA-induced 
mammary adenocarcinomas in rats (Lamartiniere et al., 1995a, 1995b). Neonatal treatment 
reduced the incidence and the number of tumors per rat. In addition, the subsequent studies 
showed that when genistein was injected into prepubertal rats at 500 fig/g body weight on 
days 16,18 and 20 postpartum, genistein also produced a protective effect against DMBA-
induced mammary cancer (Murrill et al., 1996). Later, they gave dietary genistein to rats 
perinatally in amounts likely to be found in diets and found that genistein protected against 
DMBA-induced mammary cancer in their offspring. At concentrations of 25 and 250 mg 
genistein/kg diet (AIN-76A), genistein reduced the number of mammary tumors by 20% and 
50%, respectively in dose-dependent manner (Fritz et al., 1998). These data are consistent 
with earlier data using pharmacologic doses of genistein (Lamartiniere et al., 1995a, 1995b, 
Murrill et al., 1996). Thus, early exposure of rats to nutritional concentrations of genistein 
exert a permanent protective effect against breast cancer, which suggests that genistein, like 
estrogen, enhances the differentiation and programming of mammary gland cells, resulting in 
reducing the susceptibility to mammary cancer. 
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Anti estrogenic effects of isoflavones m vhv and f« vifm 
Isoflavones could compete with endogenous estrogens in binding of ERs and act as 
estrogen agonist or antagonist m vzvo and m vzfro depending on many factors such as the 
presence of endogenous estrogens, the dose of isoflavones and the status of ERs. The 
preferential binding of genistein to ER|3, may be important in exerting biological effects of 
isoflavones. Since the circulating concentrations of isoflavones maybe 100-1000-fbld 
greater than that of 17(ï-estrodial in premenopausal women after consuming moderate amount 
of soy foods (Watanabe et al., 2000), isoflavones could have significant biological roles in 
humans. As discussed before, m vzfro at low concentrations, 10-100 nM, genistein acted as 
estrogen agonist to stimulate estrogen-dependent MCF-7 cells (Hsieh et al., 1998). However, 
at high concentration (> 20 /iM) or in the presence of I7(ï- estradiol, genistein significantly 
inhibited cell proliferations (Hsieh et al., 1998). This anti-estrogenic effect may due to the 
competition of isoflavones with endogenous estrogens for ERs binding sites, hence, 
preventing estrogen-stimulated cell proliferation. wvo, Fritz et al. (2002) reported that 
male Sprague-Dawley rats when fed 25 and 250 mg genistein/kg diet from conception to 70 
day postpartum, androgen receptor (AR), and ERa and p mRNA expressions in dorsolateral 
prostate were decreased in dose-dependent manner. Later when genistein was fed to adult rats 
(from day 56 to 70 postpartum) at 250 and 1000 mg/kg diet, similar results were found. In 
addition, ERa protein levels were significantly reduced in rats fed 1000 mg genistein /kg diet 
compared to the control animals. This down-regulation of ER and AR expression in prostate 
could be due to the anti-estrogenic effects of isoflavones and explain the lower incidence of 
prostate cancer in the countries where soy is consumed as a staple food. 
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Hormonal effects of soy consumption and hormone-dependent cancer in human 
Soy isoflavones exert hormonal effects in both men and women. But most of these 
types of studies were done in premenopausal women, focusing on the modification of risk 
factors related to breast cancer. The lower concentrations of blood reproductive hormone and 
the longer menstrual cycle especially the length of follicular phase have been associated with 
the lower risk of breast cancer. The influence of soy feeding on ovarian cycle was first 
reported by Cassidy et al. (1994). Soy protein (60 g/d) providing 45 mg total isoflavones for 
one cycle significantly (P < 0.01) increased follicular phase length and delayed menstruation 
about 1.5 days. In addition, the mid-cycle surges of luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) were significantly suppressed and follicular phase plasma 
estradiol increased. These responses are similar to the estrogen antagonist, tamoxifen, when 
given as an anti-breast cancer agent. Since then, many other feeding studies have been done 
but the results were not consistent. Lu et al. (1996a, 2000a) fed 6 or 10 healthy cycling 
women soymilk that contained 113-207 mg total isoflavone/d for one cycle. A significant 
reduction in plasma 17p-estradiol (P < 0.01), and progesterone (P < 0.001) were found, but 
no changes in LH and FSH were found. The cycle length was prolonged 3.5 day in the first 
study (Lu et al., 1996a) but only 0.6 day in the second one (Lu et al., 2000a). Duncan et al. 
(1999a) studied 3 cycles plus 9 days, which started on the 1^ day of cycle. Fourteen subjects 
consumed soy protein powder in a randomized crossover design with low-isoflavone (64 
mg/d) or high-isoflavone (128 mg/d) or a control diet (10 mg/d). The low-isoflavone diet 
significantly decreased plasma LH (P = 0.009) and FSH (P = 0.04) during the periovulatory 
phase. Only estrone was decreased during mid-fbllicular phase and the menstrual cycle length 
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did not change significantly. The results from these studies were in conflict because such 
studies must be very carefully controlled, i.e., if only one cycle is studied, it is not known if 
the soy is causing the effect or not. Therefore, multiple cycles, carefully controlled diets and 
control of cycle are recommended, i.e., feeding is begun on the same day of the cycle for all 
subjects, in order to sort this out. The characteristics of subjects and the bioavailability of 
isoflavones in the subjects may also be responsible for the observed differences. 
McMichael-Phillips et al. (1998) reported that daily consumption of 60 g of soy 
protein containing 45 mg isoflavones for 14 days in 48 premenopausal women with benign or 
m Alignant breast disease resulted in significantly increased proliferation rate of lobular 
epithelium and the expression of progesterone receptor when biopsy samples were examined. 
This suggested that soy feeding might also exert estrogenic effect in women. But since this 
study only lasted for 2 weeks, the relatively short feeding period may not reflect the changes 
for long-term. As seen when tamoxifen was given as anti-cancer agent to breast cancer 
patients, the increased pS2 gene expression after 6 weeks administration was reversed after 6 
months of treatment (Willsher et al., 1994). Petrakis et al. (1996) found that daily soy 
consumption (38 g of soy protein containing 38 mg genistein) for 6 months increased the 
secretion of breast nipple aspirate fluid (NAF) and breast cell hyperplasia in 7 of 24 
premenopausal women with the subjects as their own controls. Results from those two 
studies raised some important questions about effects of soy consumption on breast tissue. 
More clinical studies are needed to answer these questions. 
In postmenopausal women, the hormonal effects of soy consumption were not 
consistent. In one study (Duncan et al., 1999b), 18 postmenopausal women consumed control 
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(0.11 mg/kg body weight), low-isoflavone (1.0 mg/kg body weight) or high-isoflavone (2.0 
mg/kg body weight) diet in crossover design for 1 month each; only the high-isoflavone diet 
decreased plasma estrone-sulfate significantly, and the decreases of estradiol and estrone 
were not significant. No vaginal cytology and endometrial biopsy changes were found in 
these women. On the other hand, Baird et al. (1995) found no changes in serum FSH, LH, 
and estradiol, but estrogenic effect on vaginal cytology in 48 postmenopausal women after 
daily consumption of 165 mg total isoflavone for 4 weeks. In the study mentioned above 
(Petrakis et al., 1996), the secretion of NAF and changes of breast cancer cells were not 
found in 24 postmenopausal women after the same treatment as was used in premenopausal 
women. These results suggested that soy isoflavone intake in postmenopausal women may 
exert estrogenic or anti-estrogenic effects, but the reasons for such effects were not very clear. 
The studies about hormonal effects of soy consumption in men focused on both 
beneficial effects such as prostate cancer prevention and potential adverse effects such as the 
lower sperm quality. In 14 young men (18-35 y), daily intake of 40 mg total isoflavones from 
soy extract for 2 months had not effects on testicular volume, sperm concentration, count and 
motility, which suggested that isoflavone intake at physiological level, did not have adverse 
effect on sperm quality (Mitchell et al., 2001). Soy consumption has been suggested to reduce 
the risk of prostate cancer as seen in Eastern Asia and the lower incidence associated with 
lower reproductive hormones. Nagata et al. (2000) reported that the reproductive hormones, 
estradiol (r = -0.32, P = 0.009), estrone (r = -0.24, P = 0.05) and testosterone (r = -0.25, P = 
0.05) were inversely correlated with soy food consumptions in 69 Japanese men (mean age 
60 y) with intake of 22mg isoflavone/d estimated by a dietary questionnaire. But not all 
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studies showed similar reductions in these hormones. Habito et al. (2000) found no changes 
in blood concentrations of estradiol, testosterone, and dihydrotestosterone in 42 middle-aged 
men (mean age 45 y) when they switched from 150 g meat diet to 290 g tofii diet, providing 
70 mg total isoflavones daily for 4 weeks, but the mean testosterone-estradiol ratio was 
decreased 10% (P = 0.05) after tofu consumption. The different results from the two studies 
may due to the different study design in which the first one is a cross-sectional 
epidemiological study done in Eastern Asia and the second one is a short-term intervention 
study done in a Western country, ethnic difference also could be a confounding factor. The 
beneficial effect of soy consumption in prostate cancer prevention has not been fully 
understood. More solid evidence is needed. 
Other factors related to soy consumption and hormone-dependent cancer 
Higher levels of sex hormone binding globulin (SHBG) have been associated with 
decreased breast cancer risk. SHBG is a plasma protein that binds to steroid hormones 
(estrogen and androgens) in the circulating system. Since only free steroids exert their effects, 
the higher level of SHBG may lower the concentrations of the free form estrogens; hence 
lower the effects of estrogens. Adlercreutz et al. (1992) reported that significant positive 
correlation between urinary isoflavone excretions and plasma SHBG in 30 postmenopausal 
women. In the study mentioned above, Duncan et al. (1999a) found that 5 equol producers 
(equol is a metabolite of daidzein) among the 14 subjects had lower plasma estrone, estrone 
sulfate, androgens, and prolactin and higher SHBG, as well as trends toward longer menstrual 
cycle compared to non-equol producers. The observations of decreased estrogens and 
increased SHBG concentrations in the equol producers are consistent with zrz vzfro data 
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showing that equol is a weak inhibitor of aromatase, an enzyme catalyzing estrogen synthesis 
(Adlercreutz et al., 1993), and a stimulus for SHBG synthesis in HepG2 liver carcinoma cells 
(Loukovaara et al., 1995). There are epidemiological data showing a positive association 
between urinary equol and plasma SHBG concentrations (Adlercreutz et al., 1987). In the 
clinical trials discussed above, SHBG was increased significantly (P = 0.01) in men when 
switched to 290 g tofu diet (containing 70 mg isoflavones) for 4 weeks (Habito et al. 2000) 
and in postmenopausal women (P < 0.05) after they consumed high isoflavone diet (2 mg/kg 
body weight per day) for 1 month (Duncan et al., 1999b). These results suggested that 
isoflavones and their metabolites might affect the uptake of sex hormones by regulating 
plasma level of SHBG, therefore lowered free estrogens in circulation. 
The metabolites of estrogens may also play a role in hormone-dependent cancers. The 
two potentially carcinogenic metabolites of estradiol, 4-hydroxyestrogen and 16a-
hydroxyestrogen and the anti-carcinogenic metabolite 2-hydroxyestrogen have been 
implicated in breast cancer risk. In the study of Lu et al. (2000b), 8 women were given 
soymilk either containing 113-207 mg isoflavones/d or 4.5 mg isoflavones/d for a month 
with a 4-mo washout period in between. The high isoflavone soymilk increased mean daily 
urinary excretion of 2-hydroxyestrone by 47% (P = 0.03), but had no effect on 16a-
hydroxyestrone. Similar results were also reported by Xu et al. (1998). In this study, 14 
premenopausal women consumed soy protein diet with low-isoflavone (64 mg/d), high-
isoflavone diet (128 mg/d) or control diet (10 mg isoflavones/d) for 1 month in randomized 
crossover design. The ratios of 2:16 a-hydroxyestrogen and 2:4 a-hydroxyestrogen were 
increased by 67% and 33%, respectively after low- and high-isoflavone feeding compared to 
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control diet. This suggested that isoflavone consumption increased metabolism of 
endogenous estrogens to the protective 2-hydroxy form, therefore lowering cancer-promoting 
efGcacy of 17(3-estradiol. 
In conclusion, soy consumption is associated with lower incidence of hormone-
dependent cancers. Isoflavones found in soy foods have weak estrogenic activity compared to 
endogenous mammalian estrogens but their very high concentrations in circulation could 
cause estrogenic or antiestrogenic effects depending on the host hormonal milieu. EfGcacy as 
estrogen agonists or antagonists is crucial in understanding effects of isoflavones on 
carcinogenesis. 
The Role of Isoflavones in Cholesterol-lowering Effect of Soy Protein 
The hypocholesterolemic effect of soy protein has been known for more than 60 years 
(Meeker and Kesten, 1941). Many species including rabbits, rats, hamsters, guinea pigs, pigs, 
and cynomolgus monkeys have been used to test this effect when animal protein replaced 
with soy protein (Carroll and Kurowska, 1995, Anthony et al., 1996). In human clinical trials, 
a meta-analysis showed that soy protein intake, reduced plasma LDL cholesterol and 
triglycerides by 13% and 10%, respectively, and increased HDL cholesterol by 2% (Anderson 
et al., 1995). Recently, research interest has focused on identifying the components of soy 
protein responsible for the observed hypocholesterolemic effect. The amino acid composition 
of soy protein, phytoestrogens isoflavones, and other component such as saponins and plant 
sterol have been targeted. Since the intact soy protein contains all of these components, 
studies using intact soy protein as the source of isoflavones may not be able to explain the 
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role of isoflavones in hypocholesterolemic effect of soy protein. But so far, there are not 
many studies using isoflavones alone to test these effects. 
Effects of isoflavones in cholesterol-lowering in animals 
The type of study with isoflavones added to the casein-based diet was first done by 
Balmir et al. (1996). In this study, four diets were fed to male Sprague-Dawley rats for 4 
weeks in the first part of the study and in the second part, diets were fed to male Golden 
Syrian hamsters for 8 weeks. The diets were ethanol-acetone extracted isolated soy protein 
(ISP-), unextracted soy protein (ISP), casein (casein-), and casein with 0.36 mg ethanol-
acetone extract/g protein added (casein+). The ethanol-acetone extract is primarily an 
isoflavone-containing component because sugars, proteins and saponins were precipitated 
after acetone was added. They found that rats fed ISP and casein+ diets had significantly 
lower LDL cholesterol concentrations (P < 0.05) than did the casein- group. In the second 
part of this study, hamsters were fed ISP, ISP with 0.36 mg ethanol-acetone extract/g protein 
added (ISP+), casein-, casein+, and casein++ (with 0.72 mg ethanol-acetone extract /g protein 
added) diets, and the decreased total cholesterol and LDL cholesterol (P < 0.05) were found 
in ISP, ISP+ and caseinf groups but not in casein-H- group compared with casein-fed control 
group. These results suggested that the ethanol-acetone extract (isoflavones-containing 
extract) had hypocholesterolemic effects especially on LDL cholesterol concentration in both 
species and the higher dose of isoflavone may not exert further cholesterol-lowering effect. 
The potential problem of this type of study is that the ethanol extracts may contain other 
components from soy that are responsible for the cholesterol-lowering effect. For example, in 
the study discussed above, even after ethanol and acetone extraction, the isoflavone-rich 
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extract contained only 79% of isoflavones, the remaining 21% was unknown in composition, 
and therefore, the conclusion that the observed hypocholesterolemic effects were only due to 
the presence of isoflavones could not be drawn with certainty. To avoid these limitations, 
purified or pure isoflavones needed to be added to the experimental diets. Nogowsky et al. 
(1998) investigated the effects of genistein on cholesterol and triglyceride metabolism in 
ovariectomized female rats. Three experimental diets, animal protein diet (casein and fish 
meal) without isoflavones as the control diet, 0.01 and 0.1% genistein diet, were fed to rats 
for 14 days. Although no effect was found on the total cholesterolemia, rats fed genistein had 
lower plasma triglyceride concentration and increased hepatic cholesterol which suggested a 
long-term effect on the plasma lipids profile after isoflavone consumptions. The relatively 
short feeding period of this study may not be sufficient for genistein to exert effects on 
cholesterol. Song et al. (2003) studied the hypocholesterolemic effect of dietary isolated soy 
protein (ISP) with or without isoflavones (ISP-), daidzein along and soygerm in Golden 
Syrian hamsters. Sixty males and 60 females were fed six experimental diets for 10 weeks: 
casein control, ISP, ISP-, daidzein, soygerm and soygerm extract with 1.3 mmol total 
isoflavones /kg in the diet except for casein and ISP- groups which had 0.013 mmol total 
isoflavones /kg diet. Feeding ISP, ISP-, daidzein, soygerm and soygerm extract significantly 
lowered plasma total cholesterol by 16—28%, LDL cholesterol by 15-50% and the ratios of 
LDL/HDL compared with the casein control group (P < 0.01). These data suggested that soy 
protein, with or without isoflavones, daidzein and soy germ have cholesterol-lowering effects 
in hamsters. One potential problem in this study is that the relatively high dose of isoflavones 
used may not be relevant to physiological conditions (the isoflavone dose was similar to that 
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found in diet containing soy protein (25% of total diet) as the only protein source). But this is 
the first study to show that isoflavones alone have hypocholesterolemic effects in rodents. 
Non-human primates are considered to be good models to study the 
hypocholesterolemic effects of diet because they are similar to humans in cholesterolemia 
profiles. One research group is particularly interested in investigating the role of isoflavones 
in cholesterol-lowering effects of soy protein in monkeys. Anthony et al. (1996,1997) 
studied the effects of intact isolate soy protein (ISP), alcohol-washed ISP (ISP-), and casein 
diets on plasma cholesterol levels in male and female Rhesus monkeys (1996) and in young 
male cynomolgus monkeys (1997) for 14 months. Monkeys fed ISP had significantly lower 
total and LDL plus VLDL cholesterol concentrations and the decreased ratio of total 
cholesterol/HDL cholesterol compared with the other two groups. In the later study, monkeys 
fed ISP had the highest HDL cholesterol concentrations compared with the other groups; ISP-
fed group had intermediate and casein-fed had the lowest HDL cholesterol. But not all 
studies in monkeys showed similar results. When the isoflavone-rich extract added to casein 
diet (casein+) was fed to ovariectomized cynomolgus female monkeys for 12 weeks, the 
addition of isoflavones to casein did not have effects on plasma cholesterol levels compared 
with casein control group. Whereas, monkeys fed intact soy protein had significantly lower 
plasma total cholesterol, VLDL plus IDL and LDL cholesterol, and higher HDL cholesterol 
(Greaves et al., 1999). Again, questions are raised from those studies, for example, the 
alcohol-washed soy protein or isoflavone-rich extracts may also contain other components 
such as saponins co-extracted with isoflavones which could also have effects on plasma 
cholesterol. The 12-week feeding in the later study compared with the 14-month feeding in 
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the former one may also result in differences when the two studies were compared. Results 
from animal studies might not support the independent role of isoflavones in lowering plasma 
cholesterol, but do suggest there may be some synergic effects or additive effects between soy 
proteins and isoflavones or other unidentified components in soy in modulating cholesterol 
profiles. 
The role of isoflavone in hypocholesterolemic effects of soy protein in humans 
Controlled human feeding studies have been performed to investigate the role of 
isoflavones in hypocholesterolemic effects of soy protein in humans. The results from these 
studies suggested that the effect of soy protein on lowering LDL cholesterol concentrations is 
related to the amount of isoflavones contained in soy protein. In a 9-week randomized 
feeding trial, 156 mildly hypercholesterolemia men and women were given 25 g soy protein 
daily which containing different amount of isoflavones from 3 to 62 mg, an increasing 
reduction in LDL cholesterol concentrations found to be related to the increasing isoflavone 
contents and only when soy protein containing isoflavones >37 mg/d, the reductions of LDL 
cholesterol were significant compared with that of baseline (Grouse et al., 1999). In 13 
normocholesterolemic premenopausal women, 53 g soy protein, providing 129 mg total 
isoflavone daily for 3 months, significantly lowered the LDL cholesterol concentrations 
compared with the same amount of soy protein but containing 65 mg total isoflavones (Merz-
Demlow et al., 2000). In 18 mildly hypercholesterolemia and normocholesterolemic 
postmenopausal women, 63 g isolated soy protein (ISP) containing either 7.1 mg (control), 65 
mg (low isoflavone), or 132 mg (high isoflavone) isoflavones were given daily for 3 months, 
soy protein with 132 mg isoflavones was much better than that with 65 mg isoflavones in 
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lowering LDL cholesterol concentration (Wangen, et al., 2001). These results suggest that 
intact soy protein with considerable amount of isoflavones (depending on the cholesterolemia 
status of the subjects) has better hypochelesterolemic effect in humans. One clinical study 
failed to find the cholesterol-lowering effects of soy isoflavone extract. When peri- and 
postmenopausal women were given 80 mg/d isoflavone (from tablet) for 5 weeks, no effect 
was found on plasma HDL and LDL cholesterol (Nestel et al., 1997). The short feeding 
period of this study may have confounding effect on the expected results. Both animal studies 
and human clinical trails suggest that intact soy protein has the optimal plasma cholesterol-
lowering effects and at this point, it is not clear whether the plasma cholesterol-lowering 
effects of soy protein are related primarily to the presence of the isoflavones or not. Other soy 
components such as saponins may also contribute to plasma lipid lowering effect since in 
most of studies, saponins are co-extracted with isoflavones, such that one cannot distinguish 
an isoflavone-specific effect. But it seems that several factors may influence the results in 
human feeding studies: the higher the lipoproteins are in the subjects pretreatment, the more 
likely isoflavones will benefit. Also the higher isoflavone content (> 37 mg isoflavone/d) and 
the longer feeding period (> 5 weeks), the better plasma lipids profile in humans. 
Soy Isoflavones and Menopausal Symptoms Including Osteoporosis 
Osteoporosis is a metabolic bone disease, which affects postmenopausal women due 
to ovarian hormone deficiency after menopause. Currently, the most effective therapy for 
treating osteoporosis is the estrogen or hormone replacement therapy (ERT or HRT) 
(Lindsay, 1998). But due to the possible side effects, such as increased incidence of 
mammary and endometrial cancers (Scharbo-Dehaan, 1996), the acceptances of ERT or HRT 
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are not as good as expected (Groeneveld et al., 1994). Research interest focuses on seeking a 
substitution to the traditional therapy. 
Animal studies demonstrate that dietary isoflavones had a protective effect against 
bone loss in ovariectomized (OVX) animal models (Arjmandi et al., 1996,1998a, 1998b). 
Aijmandi initiated this type of study by using female rats ovariectomized at 95 days old. In 
the first study (Aqmandi et al., 1996), 32 female Sprague-Dawley rats (SD rats) were divided 
into 4 groups: sham-operated group (SHAM), OVX group, OVX + E% group and OVX + soy 
protein group. The first three groups were fed a casein-based diet, whereas the last group fed 
soy protein for 30 days. The soy protein diet improved bone mineral density (BMD) by 15% 
in OVX rats compared with OVX control group and this effect was comparable with the 
positive control OVX + E% group, suggested that soy protein diet prevented bone loss in OVX 
rats. The subsequent study tried to determine the role of isoflavones in soy protein in this 
bone-protective effect (Aijmandi et al., 1998a). Forty-eight SD rats with a SHAM groups fed 
a casein-based diet and 3 OVX treated groups fed either casein-based diet (OVX+CASEIN), 
soy protein with normal (OVX+SOY) or reduced isoflavone (OVX+SOY-) diets for 65 days. 
The SOY diet contained 1462 mg genistin, 25 mg genistein, 590 mg daidzin, and 11 mg 
daidzein /kg soy protein isolate and the SOY- diet contained 10% that of the SOY diet. The 
OVX+SOY group but not OVX+SOY- had significantly greater femoral bone density than 
that of the OVX+CASEIN group. They concluded that isoflavones in soy protein was 
responsible for the bone-protective effect of soy protein (Aijmandi et al., 1998a). 
Other studies by using either oral administration or subcutaneous injection of 
isoflavones to rodents showed that isoflavones improved BMD and the prevention of bone 
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loss was comparable to that of 17 (3-estuarial. These studies are: Fanti et al. (1998) with 
subcutaneous injection of genistein at 1, 5, or 25 mg/kg body weight in 2-month-old OVX 
rats for 21days; Ishida et al. (1998) with oral administration of daidzein at 50 mg/kg body 
weight per day in OVX rats for 4 weeks; Ishimi et al. (1999) with subcutaneous injection of 
genistein at 0.7 mg/d in OVX mice; Picherit et al. (2000) with oral administration of 
genistein and daidzein at 10 mg/kg body weight per day in 12-month-old OVX rats for 3 
months; and Ishida et al. (2000) with oral administration of daidzein, genistein and glycitein 
at 50 mg/kg body weight per day in 11-week-old OVX rats for 4 weeks. The last two studies 
also suggested that daidzein and glycitein were more effective than genistein in protecting 
OVX rodents from bone loss. 
Observational studies in humans also indicated that soy isoflavones in soy foods have 
a protective effect on bone. In one study (Mei et al., 2001), 650 Chinese women, ages 19-86 
y, enrolled to determine the relationship of their dietary isoflavones intake and lumbar spine 
and hip bone mineral density (BMD). Among the 357 postmenopausal women, significant 
differences in lumbar spine BMD and Ward's triangle BMD were found between the highest 
(53.3 mg isoflavone/d) and lowest (3.4 mg isoflavone/d) intake of isoflavone after adjusting 
factors including age, height, weight, years since menopause, smoking and alcohol 
consumption, HRT usage, and daily calcium intake. Other parameters such as serum 
parathyroid hormone, osteocalcin, and urinary N-telopeptide were significantly lower in 
women with the highest intake of isoflavone compared with those with the lowest intake. But 
these were not seen in 293 premenopausal women. 
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Human intervention studies suggest the bone-protective effect of isoflavones as well. 
Alekel et al. (2000) determined the effects of 24-week consumption of isoflavone-rich soy 
protein with 80 mg isoflavone/d (n = 24) and isoflavone-poor soy protein with 4 mg 
isoflavone/d (n = 24) and whey protein diet (control, n = 21) in attenuating lumbar spine bone 
loss during the menopause transition. Isoflavone-rich soy protein treatment attenuated bone 
loss and maintained higher BMD and bone mineral content (BMC) compared with control 
group and isoflavone-poor soy protein group. The protective effect of soy protein may be 
isoflavones dose-dependent. In another clinical trial (Potter et al., 1998), 66 postmenopausal 
women consumed daily either 40 g casein-based diet, 40 g soy protein diet with 56 mg 
isoflavones or soy protein diet with 90 mg isoflavones for 6 months, lumbar spine BMD was 
significantly increased by 2.2% in 90 mg isoflavones group compared with casein group 
(decreased 0.6%), and no changes were found in 56 mg isoflavones group. But not all studies 
came up with similar results. In Gallagher et al. (2000) and Violins et al. (2002), as 
isoflavones dose increased, 40 g soy protein with 0, 52, and 96 mg isoflavones for 9 months 
in the first study; 25 g soy protein with 5,42, and 58 mg isoflavones for 24 months in the 
second study, no significant changes were found in lumbar spine BMD or total-body BMD in 
65 and 172 postmenopausal women, respectively. Compared with Alekel's and Potter's 
studies, the latter two studies lasted longer, and the doses of isoflavones in Violins's study 
was relatively lower, which suggested the dose of isoflavones is crucial in exerting the bone 
protecting effect and long term feeding of isoflavones may induce some effect counteract the 
protecting effect. 
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In addition to maintaining good bone health, intake of isoflavone-containing soy 
products may also improve other menopausal symptom such as hot flushes. For example, in a 
3-month double-blind, parallel, randomized trial, 79 postmenopausal women were either 
given 60 g isolated soy protein (providing 76 mg isoflavone/d) or placebo. Soy treatment was 
significantly more effective than placebo in reducing the mean number of hot flushes per 24 h 
after 4, 8, and 12 weeks of treatment (Albertazzi et al., 1998). In the study mentioned above 
(Alekel et al., 2000), the frequency of hot flushes and night sweats declined significantly in 
all treatment groups compared with that of baseline. Messina et al. (2003) did a meta-analysis 
to sort out the relationship between soy isoflavones intake and frequency of hot flush. Based 
on 13 clinical trials, they found that initial hot flush frequency was positively and 
significantly correlated with treatment efficacy of soy foods (r = 0.46, P = 0.01). It is 
suggested that initial hot flush frequency explained 46% of the treatment effects. They also 
found that isoflavone supplementation had superior effect when given multiple times per day 
than given only once per day. A question raised from this analysis is that the estimated 20% 
of placebo effect in control group made the reduction of hot flush frequency in soy treatment 
group not statistically significantly different from that of control group, therefore, the placebo 
effect may lower the efficacy of soy when evaluating its influence on menopausal symptoms. 
Isoflavone supplementation may improve the menopausal symptoms and seemingly depend 
on the initial frequency of hot flushes. 
Potential Toxicity of Soy Isoflavones 
The beneficial effects of soy consumption, particularly isoflavones, have been widely 
publicized. But there are also health concerns about the consumption of large amounts of 
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isoflavones due to their hormonal and non-hormonal properties. Among these potential 
adverse effects, possible endocrine effects in infants fed soy-based infant formula (SBF), and 
effects on thyroid, immune system and carcinogensis have raised attention. 
Soy-based formula and infant health 
Soy-based infant formula (SBF), the substitution of cow milk-based formula, has been 
used for more than 60 years (Klein, 1998), and now account for 25% of infant formulas sold 
in the United States (Klein, 1998, Lonnerdal, 1994). Initially, SBF was made from soy flours 
and later in 1970s, soy flours were replaced with soy protein isolates with methionine 
fortification (Fomon, 1991, Fomon et al., 1979). Isoflavone content was lower in soy protein 
isolate compared with those in soy flours (Anderson and Wolf^ 1995). Setchell et al. (1997) 
analyzed the isoflavone concentrations in commercially available SBF. In powdered 
formulas, the total isoflavone was -300 mg/kg, and in prepared infant food was —42 mg/L. In 
liquid formula, total isoflavones ranged from 43-90 mg/L. Based on these data, the daily 
intake of isoflavones estimated in infants fed SBF is: 5.7—7.3 mg/kg body weight per day at 
1 -week, 6.0-11.9 mg/kg body weight per day at 1-4-month (Stechell et al., 1998). Compared 
with adults, infant exclusively fed SBF are exposed to 6-11-fold higher isoflavones relative 
to their weight. 
Due to the estrogenic properties of isoflavones, there is concern about the hormonal 
effects of isoflavone in infants. Several studies have examined the influence of modem SBF 
on infant growth and development (Hillman et al, 1988, Venkataraman et al., 1992, 
Giovannini et al., 1994, Mimouni et al., 1993, Lasekan et al., 1999). Generally speaking, the 
results from these studies suggested that SBF support the normal growth and development in 
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infants fed SBF and no adverse effect compared to infants fed cow's milk-based formula or 
human milk. The duration of these studies usually was less than 1 year, with SBF feeding 
exclusively at 0-4-month. 
Two studies reported reproductive development in humans fed SBF as infants. One 
retrospective cohort study (Strom et al., 2001) followed up at age 20-34 y. SBF and control 
groups came up with similar outcomes in terms of pubertal development, menstrual history, 
fertility and pregnancy, hormonal disorders and sexual orientation. SBF-fed women reported 
longer menstrual bleeding and discomfort compared with controls. A case-control study of 
early breast development found that SBF feeding at early age could not be responsible for the 
premature breast development because only 20% of cases were fed SBF (Freni-Titulaer et al., 
1986). In conclusion, there is no evidence that SBF feeding in infancy adversely affects 
human health. In addition, in light of the studies ofLamartiniere's laboratory (Lamartiniere 
et al., 1995a, 1995b, Murrill et al., 1996, Fritz et al., 1998), which found that early exposure 
to isoflavones might result in later protection from chemical-induced cancer development in 
rats, SBF feeding in infancy may actually be health beneficial, but this remains to be proven 
in humans. 
Soy isoflavones and thyroid health 
Soy consumption may influence thyroid health because goiters were seen in SBF-fed 
infants, and reversed when iodine supplemented to SBF or a switch to cow or human milk. 
Rats fed an iodine-deficient diet containing 20% defatted soybean diet developed hypothyroid 
condition compared with control group fed gluten as the protein source and the group fed 
20% defatted soybean diet (Ikeda et al., 2000). Ishizuki et al. (1991) reported after consumed 
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30 g soybean/d for 1 month, thyroid hormones triiodothyronine, T3 and thyroxine, T4 did not 
change but thyroid stimulating hormone (TSH) was increased but still within the normal 
range in 37 healthy adults with iodine-sufficient diet. The elevated TSH decreased to the 
original levels one month after the experiment. Duncan et al. (1999a) also reported the 
decreased T3 in 14 premenopausal women, but not in 18 postmenopausal women after 
consuming 128 mg isoflavones/d for 3 moths. Watanabe et al. (2001) found soy isoflavone 
supplementation resulted in decreased T3 and T4 levels in luteal phase, but increased in 
follicular phase of the menstrual cycle. 
The effect of soy and isoflavones intake on thyroid function was not very clear. A 
research group has been working in this area using the model of inactivation of thyroid 
peroxidase (TPO) m vivo and zn vzfro (Chang and Doerge, D. R. 2000, Doerge and Chang, 
2 0 0 2 ) .  T P O ,  a  h e m e - c o n t a i n i n g  e n z y m e ,  i s  c r i t i c a l  i n  s y n t h e s i s  o f  T 4  a n d  T 3 . W f r o ,  
genistien at 10/iM, inactivated microsomal rat TPO by 53%, porcine TPO by 62%, and 
human TPO by 66%, respectively (Chang and Doerge, 2000). Wvo, dose-dependent 
decreased microsomal TPO activity was found in male and female Sprague-Dawley rats fed 
soy-iree basal diet supplemented with genistein at doses of 5,100, and 500 ppm, which 
corresponded to 0.4, 8, 40 mg/kg body weight per day of intake. As much as 80% loss of 
TPO activity in thyroid was seen in female rats fed 500 ppm genistein and the loss was 
greater in females than in males but this difference was not significant. Interestingly, although 
TPO activity lost significantly, thyroid hormone levels, as well as the gland weights and 
histopathological examination of thyroid sections, did not change compared to the untreated 
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controls (Doerge and Chang, 2002). These findings were paradoxical in light of the dramatic 
effects of genistein administration on TPO activity. 
The possible effects of soy intake on thyroid health may largely depend on iodine 
status. The above results suggest that iodine deficiency has synergic effect with soy 
consumption in inducing thyroid disease in rats (Ikeda et al., 2000). Peri- and 
postmenopausal women may benefit from using soy products to counteract the symptoms of 
menopause (Duncan et al., 1999b), but close attention should be paid to this group regarding 
hypothyroidism and a subclinical hypothyroid state, but so far, there are no clinical studies on 
the topic. 
Effects of isoflavones on immune function 
Yellayi et al. (2002,2003) showed immuno-suppression in humoral and cell-mediated 
immunity and thymic atrophy when genistein was administered to ovariectomized mice by 
injection or in the diet. Daily subcutaneous injections of genistein (2—200 mg/kg body 
weight) for 21 days induced dose-dependent decreases of thymic weight and size in female 
C57BL/6 mice and the decreased thymocyte numbers was seen in mice fed 200 mg/kg for 21 
days. Genistein treatment also impaired humoral immunity at 80 mg/kg per day as reflected 
in lowering antibody titers. When dietary genistein fed to mice at 1000 or 1500 ppm for 21 
days, decreased thymic weight and cell-mediated immunity were found with plasma genistien 
in the physiological range compared to humans. 
Zhang et al. (1999a) showed that daidzein, genistein and their metabolites, daidzein 
and genistein glucuronides (DG and GG), may activate or inhibit natural killer cell (NK) 
activity Wfro. In human peripheral blood NK cells, genistein at < 0.5 /iM, DG and GG at 
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0.1-10 pM, enhanced NK cell-mediatedK562 cancer cell killing signiGcantly (P < 0.05). At 
> 5.0 /iM, genistein inhibited NK cytotoxicity significantly (P < 0.05). The glucuronides only 
inhibited NK cytotoxicity at 50 pM. Although the plasma concentrations of isoflavones could 
reach 5 after soy consumption (Xu et al., 1994 and 1995), isoflavones would be present 
mainly as glucuronides, which is less toxic than parent compound. Results from z» vzvo and 
m vzïro studies showed that isoflavone at physiological level may or may not cause adverse 
effects in immune system. Clinical studies regarding immune toxicity of isoflavones are 
limited; thusfar no report shows that isoflavone intake influences immune system health in 
humans. 
Isoflavones and carcinogenesis 
Research from our laboratory has shown tumor promotion effect of high dose dietary 
isoflavone in rats. Lee et al. (1995) found that aAer 3-month feeding of 920 or 1840 prnol 
total isoflavones/kg diet, soybean extract suppressed hepatocarcinogenesis promoted by 
phénobarbital in diethylnitrosamine-initiated rats. But when rats fed 1840 fimol total 
isoflavones/kg diet for 11 months, there was a cancer promotion effect induced by 
isoflavones feeding in this group. Rao et al. (1997) also reported that a diet containing 250 
ppm genistein enhanced azoxymethane-induced (15 mg/kg body weight for 2 successive 
weeks) noninvasive adenocarcinomas in colon in male F344 rats. These studies suggested 
that soybean isoflavones may have cancer-protective effects, but the margin of safety (toxic 
dose/effective dose) maybe low. As discussed before, Helferich's research group showed 
that in vzvo and vzfro, genistein at low dose exert estrogenic effect, induced MCF-7 cells 
proliferation but at high dose, inhibited cell proliferation (Hsieh et al., 1998, Allred et al. 
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2001). Their studies suggested that genistein could be estrogen agonist or antagonist vivo 
and zm Wfro, which may highly depend on its concentration. This is important in evaluating 
the potential carcinogenic or chempreventive properties of genistein. 
So far, there is no known evidence show that isoflavones in diet are harmful to 
humans; however high dose of isoflavones may induce adverse effects. Recently, in a safety-
evaluation study by using purified unconjugated isoflavone, 24 postmenopausal women 
ingested a single dose of purified genistein at dose of 2,4, 8, or 16 mg/kg body weight, and 
there was a 7% decrease in systolic and diastolic blood pressure and a 32% decrease in the 
neutrophil count at 24 h after treatment. Nausea, pedal edema, and breast tenderness were 
found in some individuals and could be possibly related to the genistein treatment (Bloedon 
et al. (2002). This study suggested that isoflavones had minimal clinical toxicity when given 
at high dose exceeding normal dietary intake. More clinical safety studies are needed to better 
understand isoflavone toxicity-related issue. 
Metabolism of Isoflavones 
Absorption of isoflavones after ingestion 
Isoflavones occur mainly as glucosides in soybean and most of soy foods except 
fermented soy foods. The conjugated P-glucosides daidzin and genistin are still stable even 
after processing (Coward et al., 1998). Since isoflavone glucosides have never been found in 
human blood or urine using HPLC or even more sensitive ESI-MS techniques (Xu et al., 
1994,1995, Setchell et al., 2002), they seemingly cannot be absorbed by the intestine 
directly. Therefore, isoflavone glucosides must undergo a (3-glucosidic bond cleavage to 
release aglucons before being absorbed by passive diffusion from the intestine (Setchell et al., 
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2002). When rats were orally given aglucons and glucosides daidzein and genistein at 7.9 
/imol/kg body weight, the appearance of isoflavone glucosides metabolites in plasma was 
delayed compared to that of aglucons, which suggested that aglucons but not glucosides were 
absorbed in rat stomach and glucosides need undergo hydrolysis before absorption (Piskula et 
al., 1999). Both intestinal and bacterial (3-glucosidases maybe responsible for P-glucosidic 
bond cleavage. For example, bacterial P-glucosidases have been isolated from human feces 
and it is well known that gut microflora produce these enzymes (Rowland et al., 1985, 
Rowland, 1986). Daidzin shown to be metabolized to daidzein by the intestinal bacteria 
.Bacferowfa? J-37 and A-44 (Kim et al., 1998). fmferococci, one of the 
predominant species in small intestine, display the highest activity of p-glucosidases, which 
implies that even in small intestine, gut microflora are involved in hydrolysis of (3-glucosidic 
bound (Turner et al., 2003). 
Four mammalian (3-glucosidases have been purified in the small intestine. 
Glucocerebrosidase and lactase phlorizin hydrolase (LPH) are membrane-bound enzymes. 
Glucocerebrosidase is a lysosomal enzyme and LPH is found in the brush-border of the small 
intestine (Hays et al., 1996, Leese and Semenza 1973). The other two are cytosolic enzymes: 
broad-specificity p-glucosidases (Daniels et al., 1981) and pyridoxine glucoside hydrolase 
(McMahon et al., 1997). Among these enzymes, Day et al. (1998) showed that broad-
specificity cytosolic (3-glucosidases were responsible for hydrolysis of isoflavone (3-
glucosides, and later, Day et al. (2000) also found that LPH, purified from sheep small 
intestine, was capable of hydrolyzing isoflavone (3-glucosides daidzin and genistin. The 
active site is the lactase but not phlorizin hydrolase. 
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It has not been determined yet whether intestinal or bacterial P-glucosidases are 
dominant in this P-glucosidic bond cleavage. Some human feeding studies found that the 
appearance of aglucons and glucosides metabolites in plasma with only a few minutes 
difference, but the fmax (time needed to reach the highest concentration) of isoflavone 
glucosides was much longer than aglucons, which suggested that at least part of the 
hydrolysis is due to bacterial action. It seems like both mammalian intestinal and bacterial 
hydrolysis are involved in isoflavone absorption. No matter which one is dominant, 
isoflavone (3-glucosides would be cleaved after ingestion. 
Biotransformation of isoflavones 
After isoflavone aglucons absorbed from the intestine, they are conjugated with 
glucuronic acid catalyzed by UDP-glucuronosyltransferases (UGTs). This has been shown 
both in humans and rats (Zhang et al., 2003, Sfakianos et al., 1997). Some of them may also 
be conjugated with phosphoadenosylphosphosulfate (PAPS) by the action of sulfbtransferase 
(STs) (Sipes and Gandolfi, 1986). The ratio of isoflavone glucuronide versus sulfate 
conjugates is species-dependent. Zhang et al. (2003) showed that the major isoflavone 
metabolites found in urine and plasma are 7-0- glucuronides in women after consumption of 
soymilk, with the estimated percentages are 60% and 50% for plasma and urinary daidzein, 
respectively, and 70% for both plasma and urinary genistein. Sulfates were about 20% of the 
all metabolites found in plasma and urine for both daidzein and genistein. This phase II 
biotransformation of isoflavones by UGTs and STs seems to occur mainly in the intestine and 
liver. When rats infused intestinally with '^C-genistein, the predominant metabolite was its 
glucuronide in portal vein blood (Sfakianos et al., 1997), which suggested in rats, the 
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intestinal mucosa was the major biotransformation site. Further glucuronidation may occur in 
the liver. Isoflavone metabolites may undergo biliary excretion because human feeding 
studies found that urinary excretions of isoflavone were only 10—50 % of ingested dose (Xu 
et al., 1994,1995, Zhang et al., 1999b). In rats, 75% of ^C-genistein was recovered from bile 
within 4 h after duodenal infusion (Sfakianos et al., 1997). This biliary excretion has 
significance in isoflavone metabolism: it allows isoflavone glucuronides back into the 
intestine after initial absorption; given the glucuronidase activity of gut microflora, the 
isoflavone glucuronides could be deconjugated and release aglucons again. These aglucons 
might either be reabsorbed via enterohepatic recirculation, or metabolized to other 
metabolites by gut, e.g., equol and ODMA from daidzein (Bannwart et al., 1984, Axelson et 
al., 1984) or degraded because the recovery of isoflavone from feces is very low (only a few 
percent of ingested dose) and less than 50% of ingested dose excreted from urine (Xu et al., 
1994,1995). 
Equol, the metabolite of daidzein by the action of gut bacteria, is another estrogenic 
isoflavone and has been found in plasma and urine only in one-third to two-thirds of 
individuals after soy consumption which suggests not all individuals can produce equol 
(Setchell et al., 1984, Lu et al., 1996a, Hutchins et al., 1995). Some individuals seem to lack 
unidentified microbial species in the gut that catalyze this reaction (Setchell et al., 1984). 
This led to use of the term "producers" to describe people who have the bacterial enzymes or 
intestinal conditions for equal production. 
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Degradation of isoflavones 
The degradation of isoflavones by human gut microflora had been shown (Xu et al., 
1995). 7» Wfro anaerobic incubation of isoflavones with human feces showed that half-life of 
daidzein and genistein was 7.5 and 3.3 h, respectively. Four C/ojfrfdiwm strains (257,258, 
264, and 265) capable of cleaving the C-ring of flavonoids quercetin, kaempferol, and 
naringenin were isolated from human feces (Winter et al., 1989). It is reasonable to assume 
that C-ring cleavage of isoflavones also occurs. When daidzein was incubated with human 
feces for 72 h, dihydrodaidzein, and benzopyran-4, 7-diol, 3 -(4-hydroxyphenyl) were purified 
by TLC and HPLC but only dihydrogenistein was isolated from the fermentation broth of 
genistein incubated with human feces (Chang and Nair, 1995). The dihydroisoflavones may 
be an intermediate or a side product in isoflavone degradation by gut microorganisms or may 
be like equol, only produced by certain individuals because it was found in fermentations 
from some but not all individuals (Chang and Nair, 1995). Isoflavones can be broken down 
into other compounds, especially monophenolics, such as the non-estrogenic metabolite of 
genistein, p-ethylphenol (Verdeal and Ryan, 1979), but at this point, no biological role of this 
compound has been reported. 
Studies have been done in our laboratory showing that gut microorganisms play an 
important role in metabolism and bioavailability of isoflavones. Eight male subjects 
provided fresh fecal samples for in vitro anaerobic incubation with isoflavones to measure 
isoflavone disappearance rate constant. These subjects consumed a single dose of soy 
isoflavones with breakfast (1.2 mg total isoflavones/kg body weight). Plasma daidzein and 
genistein concentration was negatively correlated with daidzein and genistein disappearance 
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rate constant (r = - 0.74, P = 0.04; r = - 0.88, P = 0.01, respectively) (Hendrich and Murphy, 
2000). In 35 Asian (Chinese immigrant) women, low genistein degraders with short gut 
transit time (43 h) compared with high degraders with longer GTT (60 h), had significantly 
greater urinary genistein excretion (11 vs. 4% of ingested dose, respectively) after they 
consumed a single dose of isoflavone (4.5 /imol/kg body weight), supporting an important 
role for gut microbial activity in isoflavone bioavailability (Zheng et al., 2003). 
In conclusion, isoflavones can be metabolized extensively in some individuals. There 
is considerable evidence to show that the hydrolysis of the isoflavone glucosides is necessary 
for their absorption since glucosides have never been detected in plasma and urine. Although 
the glucosidase can be produced either by the small intestine or by gut microflora, the sites of 
hydrolysis have not been fully elucidated. Gut microflora are also involved in 
biotransformation and degradation steps which clearly have great influence on isoflavone 
bioavailability, therefore potentially affecting their biological effects. 
Isoflavone Bioavailability and Kinetics 
The bioavailability of isoflavones is clearly important in assessing the likely 
importance of these compounds to human health. Bioavailability has different interpretations 
from different research perspectives. From a pharmacological point of view, it is the 
proportion of the compound that appears in plasma over time (area under the curve) when 
administered orally compared with that when the compound is administered intravenously. 
From the nutritionist's point of view, it is the proportion of ingested compound reaching the 
sites of action. Therefore bioavailability is not indicated entirely by the extent of absorption. 
Absorption, distribution, metabolism (biotransformation in the gut, liver and other tissues) 
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and elimination all contribute to bioavailability following ingestion. Bioavailability and 
kinetics of dietary isoflavones depends upon their chemical structure, dose, and 
characteristics of their food matrices. The interactions of isoflavones with gut microflora may 
be also important in determining their bioavailability. 
Influence of chemical structure on isoflavone kinetics and bioavailability 
Isoflavones in most soy foods are more than 90% in glucosidic form, which must be 
hydrolyzed before absorption (Brown, 1988, Setchell et al., 2002). No matter which |3-
glucosidases, mammalian or gut microbial, dominates this hydrolysis, isoflavone aglucons 
seem to be more rapidly absorbed than glucosides. As discussed early, Piskula et al. (1999) 
observed that when daidzein, genistein, daidzin and genistin were orally administered to rats 
at a dose of 7.9 /imol/kg body weight in solution, isoflavone aglucons but not glucosides 
were already absorbed in the rat stomach. Human feeding studies showed similar results. 
Setchell et al. (2001) compared plasma kinetics of pure standardized 50 mg (2.8-3.5 /imol/kg 
body weight) doses of daidzein, genistein and their P-glucosides administered as a single 
bolus to 19 healthy Caucasian women. The mean time to attain peak plasma concentration 
(tmax) for genistein and daidzein was 5.2 and 6.5 h, respectively, whereas for the 
corresponding (3-glucosides, the tmax was delayed to 9.3 and 9.0 h, respectively, consistent 
with the time needed for hydrolysis before absorption. The mean maximum plasma 
concentration (Cmax) was 0.76 and 1.26 /imol/L for daidzein and genistein, and was 1.55 and 
1.22 /imol/L for daidzin and genistin, respectively. In other soy feeding studies in which 
predominantly glucosides isoflavone were fed, the results were similar to Setchell's 
isoflavone glucosides feeding study. King and Bursill (1998) gave 6 healthy men a soy flour-
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based meal providing 2.7 pmol daidzein and 3.6 funol genistein/kg body weight and reported 
that tma% was 7.4 and 8.4 h, Cmax was 3.14 and 4.09 /iM for daidzein and genistein, 
respectively. Watanabe et al. (1998) gave 7 males 60 g of kinako (baked soybean powder), 
containing 103 fmiol daidzein and 112 /imol genistein, tmax was 6 h for both daidzein and 
genistein, Cmax was 1.56 and 2.44 /iM for daidzein and genistein, respectively. Izumi et al. 
(2000) further investigated the difference in the absorption of soy isoflavone aglucons and 
glucosides by using fermented and unfermented soybean extract in Japanese men and women 
at both low and high doses. In low dose feeding trial, 4 men and 4 women consumed 110 
/imol isoflavone aglucons (48 fimol genistein and 62 pmol daidzein) or 110 fimol glucosides 
(60 fimol genistin and 50 fwnol daidzin), the dosing of the two forms separated by 2 months. 
After consumption of aglucons, tmax was 2 h for both daidzein and genistein; Cmax was 1.01 
and 0.77 for genistein and daidzein, respectively. After consumption of glucosides, the 
tmax was 4 h and Cmax was 0.40 and 0.20 pM for genistein and daidzein, respectively, which 
were significantly lower (P < 0.05) than that after aglucons intake. In high dose feeding trial 
(1700 pmol isoflavone aglucons or glucosides: 780 ftmol genistein and 920 ftmol daidzein; 
or 900 ftmol genistin and 800 /wnol daidzin), 4 men and 4 women had mean tmax 4 h for 
isoflavone aglucons daidzein and genistein, and the Cmax was 21 and 16 /iM for genistein and 
daidzein, respectively, whereas tmax was 6 and 4 h and Cmax was 4.0 and 3.5 /iM for 
isoflavone glucosides genistin and daidzin, respectively. Again Cmax for glucosides was 
significantly lower than aglucons (P < 0.05). The plasma concentrations of isoflavone 
aglucons were significantly greater than that of isoflavones glucosides at 2,4, and 6 h after 
dosing for both low dose and high dose groups. After 6 h, plasma concentrations of 
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isoflavone aglucons dropped rapidly from 0.9 to 0.2 within 24 h, whereas plasma 
concentrations of isoflavone glucosides were relatively stable at 0.3-0.4 /iM within 24 h after 
dosing (Izumi et al., 2000). These studies suggested that no matter used as pure compound or 
in food matrices, consumed by males or females, isoflavone aglucons are absorbed more 
rapidly than glucosides. 
Setchell et al. (2001) did not report significant differences in Cmax between aglucons 
and glucosides as well as the apparent bioavailability calculated as AUC but Izumi et al. 
(2000) found that Cmax was much higher after feeding aglucons than glucosides (P < 0.05), 
although the later study did not compare AUC between aglucons and glucosides directly. The 
reasons why there are differences in isoflavone bioavailability and kinetics between the two 
studies were not clear. One possible reason may be due to the different subjects used in the 
studies. Japanese are well known to consume soy foods more frequently than Western people, 
and they have different genetic characteristics and dietary habits compared to Western people 
as well. It is plausible that Japanese in this study had a somewhat different (3-glucosidases 
enzyme activity compared to Western people, thus Japanese may have lower capacity to 
hydrolyze glucosides in the intestines than did the Westerns, e.g., Western people may have 
metabolized the glucoside forms of isoflavones more efficiently than did the Japanese. Due to 
the possible difference in isoflavone metabolism between the two populations, their 
isoflavone bioavailability may be different. 
The overall bioavailability for isoflavone calculated as area under the curve (AUC) 
was not significantly different between aglucons and glucosides based on Setchell's study 
(daidzein:genistein vs. daidzin:genistin, 12:17 vs. 18:16 /imol/L h, respectively (Setchell et 
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al., 2001). Similar results were also reported by Richelle et al. (2002), where 6 European 
women were given a single dose of soy germ (Fujiflavone P 10) extract isoflavone glucosides 
and aglucons (enzymatic hydrolysis from glucosides) at 1 mg total isoflavone/kg body weight 
with 1-week between the two feedings. The AUC was not significantly different between 
aglucons and glucosides (daidzein:genistein:glycitein vs. daidzin:genistin:glycitin, 44:20:11 
vs. 50:21:11 /imol/Lh, respectively). Izumi et al. (2000), although not measuring AUC in 
their study, reported that both genistein and daidzein aglucons were absorbed significantly 
faster and greater as reflected in plasma concentration than that of glucosides within 0~24h 
after dosing in 8 Japanese. This difference was observable with either low or high doses of 
isoflavone. As discussed earlier, a variety of factors may contribute to the different results, 
including ethnic background, dietary habits and enzyme activities. Most of the studies done in 
Western people showed that whether dietary isoflavone are present as aglucons or glucosides, 
the overall bioavailability of isoflavone was not affected. But since this may not be found in 
Asians, the capacity for hydrolysis of isoflavone glucosides may be crucial in isoflavone 
absorption. 
Influence of dose and time course on isoflavone bioavailability 
Many studies have been done to assess the influence of isoflavone doses on urinary 
excretion and plasma concentrations of isoflavone. In a randomized crossover feeding trail, 
12 women were given a single dose of 2.0,4.0, and 8.0 /(mol total isoflavone /kg body 
weight from soymilk, plasma concentrations of total isoflavone showed linearly dose-
response at 6.5 h after doses (0.7,1.1, and 2.1 /iM, respectively) as well as urinary 
isoflavones (24, 58, and 79 jwmol total isoflavone, respectively (Xu et al., 1994). Later, 7 
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women were given 3 isoflavone-containing meals per day with 5-h interval at doses of 10, 20, 
and 30 /imol isoflavone /kg body weight separated by 2 weeks, total urinary isoflavone 
excretion was linearly related to dose (88,159, and 250 /(mol total isoflavone, respectively 
(Xu et al., 1995). Izumi et al. (2000) also show similar dose-dependent results as reflected in 
plasma daidzein and genistein concentration at low and high doses. Not similar to these 
studies, in a randomized, crossover (with Imo washout) feeding study, Setchell et al. (2003) 
gave 10 healthy women a single-bolus doses of 10,20 or 40 g of soy nuts containing daidzin 
(6.6,13.2 and 26.4 mg) and genistin (9.8,19.6 and 39.2 mg), respectively, and found a 
curvilinear relationship between the plasma isoflavone AUC and the amount of isoflavones 
ingested. This nonlinear relationship was also found in urinary excretion of isoflavones: 63.2, 
54.4 and 44.0 % of ingested dose, respectively, for daidzein; and correspondingly, 25.2,13.4 
and 15.8% of ingested dose for genistein, as dose increased. Although different percentage of 
plasma and urinary isoflavone were found between doses in this study, these differences were 
not significant. The 3 doses used in this study were relatively lower and within a narrow 
range compared to the other feeding studies, so that it may not have been able to distinguish 
the differences between the doses with the small number of subjects studied. In conclusion, 
human isoflavone bioavailability shows a dose-dependent response, in most studies, the 
plasma and urinary isoflavones were relatively proportional to the intake of isoflavones over 
a wide dose range of 2—30 /imol/kg body weight. 
In longer term feeding studies (up to 1 month), plasma isoflavone concentrations and 
urinary excretion may be decreased compared with single isoflavone doses. Izumi et al. 
(2000) showed that when total isoflavone at 300 /imol/d (3.7-5.2 /imol/kg body weight), was 
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given to 8 Japanese men for 1 month, plasma daidzein and genistein were 10-15% lower 
after 4 weeks compared with that of after 2 weeks. Lu et al. (1995b, 1996b) reported after 1 
month of a daily dose of 80-210 mg daidzein and genistein of each from soymilk, urinary 
isoflavone excretion was 10% lower than initial feeding in women but not in man. It is not 
clear why long term feeding may result in decreasing isoflavone bioavailability, but this may 
due to induction of isoflavone degrading gut microbial enzyme activities after frequent 
consumption of soy foods; the more isoflavone being degraded, the lower the isoflavone 
bioavailability. 
Influence of dietary factors on isoflavone bioavailability 
Soy food type may not influence isoflavone bioavailability. As mentioned before, 
isoflavone in most soy foods are glucosides, but it seems like the chemical form of isoflavone 
does not affect their bioavailability based on the studies of Setchell and Richelle (Setchell et 
al., 2001, Richelle et al., 2002). The malonyl or acetyl glucosides may also have no effect 
because when isoflavone bioavailability of tofii (relatively high in acetyl glucosides) and 
texturized vegetable protein (TVP, relatively high in malonyl glucosides) were compared in 
women, urinary and plasma isoflavones did not differ between tofu and TVP, which 
contained the same amount of isoflavones (Tew et al., 1996). In another study, a single dose 
of isoflavones from tofii, cooked soybeans, TVP and tempeh was consumed by 10 women in 
a randomized crossover feeding study. No significant difference was found in urinary 
daidzein (38-50% of ingested dose) and genistein excretion (9-16% of ingested dose) (Xu et 
al., 2000). Other dietary interventions such as different background diets did not influence 
isoflavone bioavailability (Xu et al., 2000). Three diets, an ad diet, basic foods diet 
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and self-selected diet were randomly assigned to 8 women in a crossover design with the 
same amount of isoflavone intake. Urinary and fecal isoflavone recoveries as a percentage of 
intakes were not significantly different among the three background diets (25,27, and 25%, 
respectively). Although there are few studies regarding the influence of dietary factors on 
isoflavone bioavailability, seemingly, neither soy food types nor background diet affect short-
term isoflavone bioavailability. 
Influence of gut microflora on isoflavone bioavailability 
The activities of gut microorganisms play an important role in isoflavone metabolism 
and bioavailability. Xu et al. (1995) reported that among 7 adult women who consumed a 
single isoflavone-containing meal at 3 doses of isoflavone from soymilk (2-week washout 
between each dose), two of the subjects consistently excreted significantly greater amounts of 
isoflavones in feces and had 2-3-fold greater urinary and plasma isoflavone compared with 
the other five subjects who excreted small amounts of fecal and urinary isoflavones. 
Considerable interindividual variation of isoflavone excretion was also reported in a 9-day 
feeding study with 3 doses of isoflavone from soy protein in which the variation of genistein 
excretion was 12-fbld and that of daidzein was 15-fbld even within the same dose treatment 
(Slavin et al., 1998). 
vz'fro human fecal isoflavone degradation phenotypes have been identified based on 
isoflavone degradation half-lives (Hendrich et al., 1998). In 20 human subjects, m vzfro 
anaerobic incubation of daidzein and genistein with feces showed three distinct isoflavone 
degradation phenotypes with significantly different isoflavone degradation rate constant, k, 
(the negative slope of the regression line plotted for log concentration of isoflavone of each 
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sample over time). The three daidzein degradation phenotypes were: high (n = 5, k = 0.299), 
moderate (n = 10, k = 0.055) and low (n = 5, k = 0.012). The high and moderate phenotypes 
were stable when checked 10 months later but not for the low phenotype: high (n = 5, k = 
0.326), moderate (n = 4, k = 0.073) and low (n = 5, k = 0.053). For genistein degradation, the 
rate constants were 0.299, 0.163 and 0.023 for high, moderate and low degradation 
phenotypes, and 10 months later, they were 0.400,0.233 and 0.049 for high, moderate and 
low phenotypes, respectively. When 8 men of varying degradation phenotypes were fed 
soymilk, plasma isoflavones negatively correlated with fecal isoflavone degradation rate 
constant (r = - 0.88, P = 0.04 and r = - 0.74, P = 0.01 for daidzein and genistein, respectively) 
(Hendrich and Murphy, 2000). These data suggest that part of the interindividual variability 
in isoflavone bioavailability is due to the variation of gut microbial isoflavone degradation. 
When a bioavailability study only involved moderate isoflavone degraders, the inter-subject 
variation in urinary isoflavone excretion was 5-8-fbld. Although this variation is much less 
than that reported when fecal isoflavone degradation phenotype was not controlled for, it may 
suggest that other unidentified factors may also affect isoflavone bioavailability (Zhang et al., 
1999b). 
In a subsequent study in which isoflavone degradation phenotypes were identified by 
M Wfro anaerobic incubation of isoflavone with fresh human fecal sample (Zheng et al., 
2003), three daidzein and two genistein degradation phenotypes were identified in 33 
Caucasian and 35 Asian (Chinese immigrant) women based on their isoflavone degradation 
rate constant. Daidzein degradation rate constant was < 0.15, 0.15-0.30 and > 0.30 for low, 
moderate and high phenotypes, respectively. Genistein degradation rate constant was < 0.3 
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and > 0.3 for low and high phenotypes, respectively. Fecal incubations of isoflavones were 
repeated 5 months later to check the phenotypic stability, and gut transit time (GTT) was 
measured for each subject and a single meal feeding study was conducted at the same time, 
providing 1.2 mg total isoflavone (4.5 /imol) /kg body weight. The results showed that the 
degradation phenotypes were stable except for high degradation phenotype; urinary genistein 
excretion was significantly higher in Asian low genistein degraders who had significantly 
shorter GTT (43 h) than did Asian high genistein degraders (60 h) and both Caucasian low 
and high degraders (-84 h) who had significantly longer GTT than did Asian subjects (Zheng 
et al., 2003). These results suggested that isoflavone degradation by gut microorganisms 
coupled with GTT had greater influence on isoflavone bioavailability. GTT may be a 
determinant of isoflavone bioavailability because the shorter residence time in the gut, the 
less isoflavone can be degraded, and the more isoflavone can be absorbed. 
The other aspect of isoflavone bioavailability is the production of equol and other 
metabolites. Equol was the first isoflavone to be identified in human urine and blood 
(Axelson et al., 1982, Setchell et al., 1984). It is produced by the action of gut bacteria. Some 
evidence supported this view: equol was detected and identified when soy protein incubated 
with human fecal bacteria (Setchell et al., 1984); germ-free rats did not excrete equol in urine 
on a soy diet, whereas conventional rats did (Bowey et al., 2003); a human soy feeding study 
showed the appearance of equol in the plasma was delayed 6-8 h compared with other 
isoflavones, which suggested equol produced in the large intestine (Setchell et al., 2001). 
Because of the greater binding affinity of equol for the estrogen receptor than that of daidzein 
(Shutt 1976, Shutt and Cox 1972), and because its binding to serum SHBG is much lower 
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(Nagel et al., 1998), equol has greater estrogenic potency than daidzein. But at this point, 
there is limited evidence regarding the beneficial effect of equol. Other metabolites such as 
ODMA, has been identified in urine and plasma of human subjects who consumed soy 
products (Kelly et al., 1993), but whether they have benefits to human or not is not clear. 
The bioavailability of dietary isoflavones is clearly crucial in assessing the importance 
of these compounds to human health. Bioavailability is also a major determinant of the 
safety and efficacy of dietary isoflavones. Bioavailability is the access of a compound to its 
sites of action. Gut microflora are involved in isoflavone absorption degradation and 
biotransformation to other metabolites, therefore influencing their bioavailability to a great 
extent. 
Gut Microflora and Gut Transit Time (GTT): Factors Influencing the Environment for 
Isoflavones Metabolism and Absorption 
The intestine, an extremely active and complicated system, plays an important role in 
living organisms. The basic functions of intestine include food digestion, nutrients absorption 
and defense against environmental adverse stimuli (Bourlious et al., 2003). The interactions 
between host, nutrients and microflora are dynamic, diverse and important in maintaining the 
normal functions of intestine. The gastrointestinal (GI) tract includes stomach, small 
intestine, and large intestine (colon). Small intestine can be subdivided into duodenum, 
jejunum and ileum, and is responsible for majority of digestion and absorption. The transit 
time of food through GI tract (from mouth to anus) is highly dependent on host status, usually 
3-6 h from mouth to distal part of small intestine, and at least 12 h before elimination 
through rectum and anus. Greater inter-individual variation in gut microflora species has been 
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reported, but the population distribution and colonization of gut microflora usually are the 
same from stomach to large intestine (Turner et al., 2003). The stomach has very low 
population of bacteria (10^-10^ colony forming units (CFU)/g or mL) because of the acidic 
environment. These species include facultative anaerobic Arepfococcws, Aap&y/ococcwa and 
Zacfofxzcz/fus. The small intestine contains 10^-10* CFU/g bacteria with a dramatic increase 
in ileum (10^-10*). The species are similar as found in stomach except in ileum, where a 
greater variety such as Bz/wfobacfenwrn, and members of 
.EMferobocfenacgae also can be found because the lower oxygen content allows obligatory 
anaerobes to grow. The largest bacteria population is found in colon (10*-10^), more than 
400 species have been isolated and the obligatory anaerobes including ifi/zdo&zcfenwm and 
#w6acferwm are predominant. It has been estimated that one-third of fiscal dry weight is 
viable bacteria (Turner et al. 2003). 
Factors influence gut microbes colonization 
Many factors influence microbial colonization including maternal flora, model of 
birth and feeding method, genetic background, diet composition, use of prebiotics, probities 
and antibiotic drugs, and age (Bourlious et al., 2003). Based on these factors, colonization 
could be substantially divided into several stages: from birth to before introduction of solid 
foods, from solid foods introduction to -2 y and then through adult and elderly. At birth, 
fetus is contaminated with mother's fecal and vaginal or obstetric care professional's skin 
microbes dependent on mode of birth, subsequently from air, food and environment such that 
this initial colonization develope rapidly. Then different feeding method results in different 
species distribution. In breastfed infants, are predominant, with only about 1% 
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of & co/z, i&zferococcz and lacfo&zcz/Zz. In bottle-fed infants, species such as & co/z, 
Ar^fococcz, Bacferozday, and Ew6ocferza are present in significantly greater amount than 
that of breastfed infants (Bourlious et al., 2003). After introduction of solid foods, the 
differences in species distribution between breastfed and bottle-fed infants are decreased and 
the species become rather stable up to 2 years of age. The microbes in children are similar to 
that in adults, which may be affected by many environmental factors. In elderly, 
Z?#z&)6acfena decrease, but Zacfo&zczW and C&MfrzWzwm increase (Ras tall and Mai tin, 
2002). 
Among those environmental factors, the diet composition and the use of probiotics, 
prebiotics and antibiotic drugs exert significant influence on distributions of species. For 
example, high-beef diet significantly introduced species of Bacferow/as and CZoafrwfzo, but 
lowered ^z/Wo&zcferzwfM counts (Hentges et al. 1977). High-carbohydrate diet resulted in 
larger proportion of Eubacferza, but fewer (Peach et al. 1974). Prebiotics such as 
fructooligosaccharides, added to the diet, significantly increase 2?z/z&»6acferzwm, and decrease 
AzcferozWa; (Roberfroid, 1996). Supplementation of probiotic Z?z/%#6acferz«fM 6z/Wwm has 
been shown to influence flora distribution and prevent the diarrheal disease in hospitalized 
children (Saavedra et al., 1994). Zacfo6acz7/wf rAamnams improves the digestion of lactose 
and eliminates symptoms in lacto-intolerance people. Antibiotic drugs often cause microflora 
disorder, resulting in diarrhea. Genetic background may also influence the distribution of 
species because similar species distribution was found between identical twins living apart, 
which implied that living environment was less important than host genotype in determining 
bacterial distribution (Zoetendal et al., 2001). Due to the nature of intestinal microflora being 
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diverse and dynamic, many factors may influence their colonization; but relatively, the whole 
system is stable. 
Factors influencing gut transit time. 
Gut transit time refers to the residence time in the GI tract, and reflects gut motility. 
The phases of gut motility include gastric, small intestinal and colonic. The transit time in the 
small intestine varies in individual, but usually within 3-6 h, food can be transported to 
cecum (Stanifbrth et al., 1991). The colonic phase of GTT is the longest one. Several 
methods have been used to determine GTT including visible dye, plastic pellets and radio-
opaque pellets. GTT is affected by many factors include age, gender, physical activity level 
and most importantly, dietary fiber. Dietary fiber has a variety of effects on transit time. In 
the stomach, dietary fiber tends to delay the gastric emptying, therefore food is retained in the 
stomach; in the small intestine, the effect of dietary fiber on transit time is not fully 
understood. In the large intestine, dietary fiber softens and causes bulk effect on stool, hence 
decreases transit time. Many studies have shown that increased fiber intake is associated with 
increased stool frequency, stool weights, and decreased gut transit time. When 44 human 
subjects switched from low-fiber diet containing 6 g/1000 kcal to high-fiber diet containing 
19 g/lOOOkcal, the transit time was decreased from more than 70 h to 45 h (P < 0.05), fresh 
fecal weight increased from 69 g to 184 g (P < 0.05) (Stasse-Wolthuis and Katan, 1978). In 
an observational study where 29 male and female subjects consumed self-selected diet 
containing 4-19 g dietary fiber, fecal weighs not only were correlated with fiber intake (r = 
0.524, P < 0.0001), but also correlated with caloric intake (r = 0.543, P < 0.0001), number of 
stools was correlated with fecal weight (r = 0.62, P < 0.0001) (Kelsay and Clark, 1984). 
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Another intervention study showed in 5 young males, as the dietary fiber amount increased 
from 0 to 53 g, the frequency of evacuation increased from 2.8 to 4.4 times in 4 days (Saito et 
al., 1990). Gender differences regard to gut motility can be seen in stool weights (men 162 g, 
women 83 g) and this difference could be explained entirely by differences in transit time 
(men 44.8 h, women 91.7 h) in 19 men and 11 women when they consumed basal (white 
bread) diet (Stephen et al., 1986). Age-related gut motility change is seen in elderly. In a 
retirement home, 21 subjects (18 women and 3 men), aged 68-87 y (mean = 81 y), some of 
them using laxative drugs regularly, had average transit time 3.0 days which was much longer 
than young or middle-aged subjects (Mykkanen et al., 1994). 
Physical activity level is another important factor that may influence GTT. High 
activity was associated with increase gut motility as seen in long distance runners, where 
diarrhea was reported (Sullivan, 1981). Increased mass movement after meals was seen in 
physically active individuals but not in sedentary counterparts (Holdstock et al., 1970). A 
study tried to characterize the effect of exercise on large intestine function by training 14 
sedentary men and women for 7-9 weeks on a constant diet. The monitored physical fitness 
were improved significantly but no changed was observed overall in fecal weight (124 vs. 
129 g/d), transit time (55 vs. 54 h) and fecal frequency between control and exercise period 
(Bingham and Cummings, 1989). The reason that results from this study are in conflict with 
the observational study may due to the relatively short period of training. 
Changes of GTT may alter microbial growth in human colon. The human colon 
contains about 230 g of bacteria, and bacteria account for 55% of dry fecal weight in humans 
(Banwell et al., 1981). An intervention study showed that when GTT decreased from 64 h to 
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25 h by giving laxative drug senokot in 6 subjects, stool weight increased from 148 to 285 
g/d (wet weight) and bacterial mass increased from 16.5 to 20.3 g/d (dry weight, P < 0.025). 
When GTT was prolonged by codeine from 47 to 87.6 h in 5 subjects, fecal weight decreased 
from 182 to 119 g/d, and bacterial mass decreased from 18.9 to 16.1 g/d. A significant 
correlation between transit time and bacterial mass was seen (r = - 0.77, P < 0.001) (Stephen 
et al., 1987). This study suggested that GTT has a controlling influence over the colonic 
microflora and function. The difference in gut motility and microbial function in individuals 
on the similar diet may largely be explained by the difference of GTT. If the diet is important 
in determining the intestinal function through the influence on microflora, GTT does too. 
The changes of GTT and gnt microflora influence isoflavone metabolism and 
absorption 
The subsequent changes of GTT and gut microflora may significantly influence 
isoflavone metabolism and absorption as reflected in the change of microbial enzyme 
activities. A small pilot study showed that feeding 10^° Z. acw&yMwj daily reduced fecal |3-
glucuronidase in 7 human subjects (Goldin et al., 1980), then in 21 subjects, daily 
supplementation of milk with 2% 10* per mL viable 2. acWqp/zz/ws for 4 weeks resulted in 
significant decrease of ^-glucuronidase activity compared to that when the subjects consumed 
control diet and the enzyme activity rose up back within 30 days after stopping the 
supplementation (Goldin and Gorbach et al., 1984). When 4 healthy subjects (2 males and 2 
females) consumed their regular diet supplemented with 18 g pectin, the fiber 
supplementation decreased the concentration of gut microbes in feces, in addition, fecal p-
glucuronidase and (3-glucosidase activities per g of feces were decreased 50% compare to that 
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of control diet (Mallett et al., 1987). Fiber supplementation results in decreased |3-
glucuronidase activity were also found in chicks (Indira et al., 1980) and rats (Shiau et al., 
1983). P-glucosidase and ^-glucuronidase are responsible for releasing isoflavone aglucons, 
therefore important in isoflavones absorption. It has been shown that .Efzferococcz, 
Zacfo6acz#ws, Bacfgrozdeg, and have strong P-glucosidase activity and 
^»(ero6acferza, C7cwfr%Awm, and have strong ^-glucuronidase activity (Turner et 
al., 2003). Any changes that cause significant changes in these species distribution or enzyme 
activity would cause changes in isoflavone absorption. 
The gut microflora is also important in isoflavones metabolism. Antibiotic use 
impaired the balance of gut microbes, hence when human subjects were administered 
antibiotic, the excretion of bacterial metabolites of isoflavone such as equol was decreased 
(Rowland et al., 1999). Infants fed with soy-based formula also showed lower excretion of 
equol maybe mainly due to the lack of gut bacteria during early life stage (Setchell et al., 
1997). 
It is well-known that gut microflora extensively metabolize isoflavone. GTT influence 
gut microflora species and their enzyme activity significantly. Therefore GTT and gut 
microflora play important roles in determining isoflavone bioavailability. 
Soybeans are a major source of phytochemicals including phytoestrogen^ 
isoflavones, which has been identified as having health protective effects to humans. The 
isoflavones occur predominantly as P-glucoside forms in soybeans and foods derived from 
soybeans, which affects their metabolism. The biological effects and some toxicity-related 
issue of isoflavones raised more attention and research interests. To better assess the potential 
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health effects of isoflavones as well as adverse effects, their bioavailability must be better 
understood. Optimizing isoflavone bioavailability is likely to permit more conclusive studies 
of these compounds. 
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COMPARATIVE BIOAVAILABILITY OF ISOFLAVONE GLUCOSIDES 
AND AGLUCONS IN WOMEN 
A paper submitted to Journal of Nutrition 
Yan Zheng, Sun-Ok Lee, Marian Verbruggen, Patricia A. Murphy and Suzanne Hendrich 
ABSTRACT 
The bioavailabihty of isoflavone aglucons and glucosides were compared in 25 
women from sources rich in glycitein versus a source rich in genistein. The effects of 
isoflavone degradation phenotype and gut transit time (GTT) on isoflavone bioavailability 
were determined as well. We hypothesized that individual with a high daidzein degradation 
phenotype (daidzein degradation rate constant, D% > 0.30 h"^) and GTT > 80 h would show 
less apparent isoflavone absorption as reflected in urinary excretion. The ingestion of 
isoflavone glucosides and aglucons would lead to similar urinary excretion over 24 h after 
ingestion at breakfast. Thirteen subjects with D% > 0.30 hand mean GTT 106 ± 11 h and 12 
subjects with Dk < 0.20 h"' and mean GTT 71 ± 12 h consumed unfermented soygerm (1.1 
pmol total isoflavones /kg body weight), fermented soygerm (3.3 pmol/kg) or soybean 
isoflavone extracts (1.5 pmol/kg) for 7 days with 4 or 5 subjects of each daidzein degradation 
phenotype per treatment. Urine and blood were collected on day 1 and 7. Reverse-phase 
HPLC analysis showed significant differences in urinary isoflavone excretion (% of daily 
ingested amount, mole based); between 0—12 h, fermented soygerm > soybean isoflavone 
extracts (40.2 ± 4.9 vs. 18.7 ± 4.6, P < 0.05); between 12-24 h, unfermented soygerm > 
soybean isoflavone extracts (16.0 ±1.8 vs. 7.1 ± 1.8, P < 0.05). Over 24 h, urinary excretions 
of both types of soygerm were greater than soybean isoflavone extracts (51.5 = 6.1 and 50.8 ± 
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5.6 vs. 25.7 ± 5.8, P < 0.05). Subjects of the low daidzein degradation phenotype had 
significantly greater urinary isoflavone excretion than did subjects of the high daidzein 
degradation phenotype (51.6 ± 4.8 vs. 33.8 ± 4.7, P < 0.05). Total estimated plasma 
isoflavone (% of daily ingested amount, mole based) was significantly different between 
fermented soygerm and unfermented soygerm at 3 h after feeding (1.8 ± 0.3 v. 0.5 ± 0.3, P < 
0.05). Daily urinary isoflavone excretion was similar for aglucons and glucosides, but a 
glycitein rich isoflavone source was apparently absorbed to a greater extent than an 
isoflavone source rich in genistein. Apparent absorption of isoflavones was significantly 
greater in subjects of the low daidzein degradation phenotype coupled with shorter GTT than 
in subjects of the high daidzein degradation phenotype with longer GTT as reflected in total 
urinary isoflavone excretion. 
KEY WORDS: isoflavones - aglucons - glucosides - gut transit time (GTT) - bioavailability 
Soybean isoflavones are major phytoestrogens in the human food supply. Isoflavones 
are implicated in cholesterol-lowering effects of soy protein, because soy protein containing > 
37 mg isoflavones/d lowered cholesterol in humans (1). Soy protein containing isoflavones 
also reduced bone loss from the lumbar spine in perimenopausal women (2), suggesting that 
these compounds may prevent osteoporosis. Soy intake is also positively associated with the 
lower risk of hormone-dependent cancer in premenopausal women (3). 
To better assess the potential health effects of isoflavones, their bioavailabihty must 
be better understood. Optimizing isoflavone bioavailabihty is likely to permit more 
conclusive studies of these compounds. Isoflavones exist in most soy foods and ingredients 
mainly as glucosides. Fermentation releases aglucons. Controversy exists as to what forms of 
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isoflavones are absorbed quickly and retained the longest in the body. Previous work in our 
laboratory comparing soy foods rich in isoflavone aglucons (tempeh, a fermented product) 
with soy foods rich in glucosides (cooked soybeans or tofii) supported the view that the 
aglucons and glucosides were similar in bioavailabihty as reflected in urinary isoflavone 
excretion (4). On the other hand, some studies showed that isoflavone bioavailability was 
greater when fermented soy foods rich in aglucons consumed (5, 6). Recently Izumi et al. (7) 
reported that soy isoflavone aglucons were absorbed faster and in greater amounts than their 
glucosides in humans. But Setchell et al. (8) and Zubik and Meydani (9) showed little 
difference in plasma isoflavone concentrations over time in humans fed glucosides compared 
with aglucons. Furthermore, bioavailabihty of isoflavones was not altered when aglucons 
hydrolyzed enzymatically from glucosides were consumed compared with that of glucosides 
(10). More work is necessary to better understand the bioavailabihty of the two major forms 
of isoflavones. 
Many isoflavone bioavailability studies have been done recently, and most studies 
focused on isoflavone glucosides (11, 12). King and Bursill (13) showed isoflavone excretion 
patterns and pharmacokinetics in humans given 2.7 ;wnol daidzein and 3.6 /imol genistein/kg 
body weight; of daidzein and genistein were similar in terms of plasma concentrations, not 
withstanding the greater urinary excretion of daidzein than of genistein. Watanabe et al. (14) 
fed 60 g baked soybean powder (103 ^mol daidzein and 112 /imol genistein) and concluded 
that genistein was the most important isoflavone in plasma due to its greater concentration 
and longer half-life compared with daidzein. But, insofar as urinary excretion reflects overall 
isoflavone absorption and disposition, daidzein has been shown in several studies to have 
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2-3 times greater apparent absorption than genistein (12,15,16). Glycitein and its glucosides 
are minor component in most soy products, accounting for 5-10% of total isoflavones. But in 
soygerm, glycitein accounts for about 40-50% of total isoflavone. One bioavailability study 
showed that glycitein was equal to daidzein in bioavailability, and both were more available 
than genistein in terms of urinary excretion (16). Glycitein was more estrogenic than 
genistein in mice (17), so more studies of the effects and bioavailabihty of glycitein are in 
order. 
Great interindividual variation of isoflavone bioavailability after consumption of 
isoflavone-containing products has been reported (12,16) and gut microorganisms are 
suggested to play an important role in isoflavone degradation, hence preventing isoflavone 
reabsorption after initial rapid biliary excretion. High, moderate, and low isoflavone 
degradation phenotypes have been identified in humans (18). Gut transit time was positively 
correlated with daidzein degradation rate constant (r = 0.35, P < 0.05) and negatively 
correlated with total urinary isoflavone excretion (r = - 0.24, P < 0.05) in 35 Asian (Chinese 
immigrants) and 31 Caucasian (lowan) women who were identified within high, moderate 
and low daidzein degradation phenotypes, and who consumed a single dose of soy isoflavone 
4.6 /imol/kg in soybean powder (19). Thus GTT may affect isoflavone bioavailability. 
Differences in isoflavone degradation phenotype and GTT are suggested to be responsible for 
much of the variation in isoflavone bioavailabihty between individuals (19). Further work on 
isoflavone degradation phenotype, GTT and bioavailability of isoflavones may help in 
designing human feeding studies of health effects of these compounds. 
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In the present study, we compared bioavailability of isoflavones in their two major 
forms, aglucons and glucosides, and between two isoflavone sources, one rich in glycitein 
and one rich in genistein in women fed the isoflavone sources at breakfast for 7 days. We 
determined whether daidzein degradation phenotype and GTT influenced urinary excretion 
and plasma concentrations of isoflavones over time. 
MATERIALS AND METHODS 
Experimental Procedures 
Chemicals. Isoflavone aglucons, daidzein, genistein, glycitein and 2, 4, 4'-
trihydroxybeozoin (THE), used as internal standard, were synthesized in Dr. Murphy's 
laboratory, Iowa State University (20,21). Brain-heart infusion (BHI) medium was purchased 
from DIFCO Laboratories (Detroit, MI). Cysteine and resazurin were purchased from Aldrich 
Chemical Company (Milwaukee, WI). Milli-Q HPLC grade water (Millipore Co., Bedford, 
MA) was used. Other HPLC solvents were purchased from Fisher Scientific Co. (Pittsburgh, 
PA). 
Subjects. Subject prescreening was conducted by zn vzfro anaerobic fecal 
incubation to identify high and low daidzein degradation phenotypes. Briefly, a freshly 
voided fecal sample was incubated anaerobically with autoclaved brain-heart infusion (BHI) 
culture medium (DIFCO Laboratories, Detroit, MI) and daidzein (100 /rniol/L). Daidzein 
degradation rate constant, D%, was calculated as the negative slope of the regression line 
plotted for log concentration of isoflavone of each sample over time (19). The participants in 
this study were 25 healthy women, 20 Caucasians (lowan) and 5 Chinese (immigrant); 13 of 
them of the high daidzein degradation phenotype (including 1 Chinese) (D% > 0.30 h"') and 12 
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(including 4 Chinese) of the low daidzein degradation phenotype (D% < 0.20 h"^), 18-40 year 
of age, body mass index (BMI), 23.2 ±1.0 kg/m^ (Table 1). The experimental procedures for 
this study were approved by the Human Subjects Committee of Iowa State University. 
Subjects gave their informed consent to the protocol. 
Experimental design. Three sources of soy isoflavone were used in 
this study: unfermented soygerm (Soylife®, Acatris Holding BV, Giessen, The Netherlands), 
fermented soygerm (Soylife®, Acatris Holding BV, Giessen, The Netherlands), and soybean 
isoflavone extract (Novasoy®, ADM Nutraceutical, Decatur, IL). The soygerm-derived 
products were characterized by an isoflavone mole ratio, 3 daidzein: 1 genistein: 3 - 4.5 
glycitein. The soybean-derived product showed the isoflavone mole ratio, 3 daidzein: 4.5 
genistein: 1 glycitein (Table 2). Thirteen high daidzein degraders and 12 low daidzein 
degraders were randomly assigned to the three treatments, providing 1.1 /imol total 
isoflavones/kg body weight for unfermented soygerm, 3.3 /imol/kg for fermented soygerm, 
and 1.5 pmol/kg for soybean isoflavone extracts, respectively. Isoflavone-containing powder 
was mixed with orange or apple juice given for 7 days at breakfast between 7:30 and 8:30 am 
in the Human Metabolic Unit, Iowa State University. Two gelatin capsules contained 16 
ceramic marker beads were given at the same time to measure GTT. Other foods were chosen 
from white bread, cereals, skim milk, peanut butter, jelly, apple and orange and consumed 
ZiWfwm. All subjects were instructed to consume only isoflavone-free foods for 1 week before 
and during the experiment. A list of isoflavone-containing foods was given to each subject 
(See Appendix C.). 
89 
Biological sample collection. After an overnight fast, 10 mL venous blood 
samples were collected into EDTA-containing vacuum containers by a licensed phlebotomist 
under stringent aseptic conditions before isoflavone feeding (time 0) and at 3 and 24 h after 
feeding on day 1 and 7. Blood samples were centrifuged within 1 h after collection at 3000 g 
for 30 min at 4° C (Model 4d, International Equipment Co., Needham Heights, MA). Plasma 
was stored at -20° C until analysis. Each subject gave a urine sample right before the 
breakfast test meal on the first day of the experiment (time 0). After the breakfast, urine from 
each subject was collected and pooled over the following time intervals: 0—12 h, 12-24 h on 
day 1 and 7. The volume of urine at each time interval was recorded and 50 mL aliquots were 
stored at - 80° C until analysis. To measure GTT, after ingestion of 16 ceramic beads with 
breakfast on day 7, all feces were collected until 12 or more marker beads had been excreted. 
Analytical Methods 
Soy products analysis. Samples in duplicate from each source were extracted and 
isoflavone concentrations determined by HPLC (22,23) with THB as internal standard. The 
total isoflavone content was the sum of mole amounts of total daidzein, genistein and 
glycitein normalized to the aglucon forms (Table 2). 
Plasma and urine isoflavone analysis. Urine samples were prepared by 
methods modified from Lundh et al. (24) as previously described (19). For plasma samples, 
1 mL was incubated with 1 mL 0.2 mol/L sodium acetate buffer (pH = 5.5), 50 /iL |3-
glucuronidase/sulfatase (H% type, Sigma Chemical, St. Louise, MO), and 50 ^L THB (2g/L) 
as internal standard in 37° C water bath for 18 h to release isoflavone aglucons. After 
incubation, 1 mL 10 /imol/L sodium phosphate buffer (pH = 7.0) was added to the mixture, 
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and the mixture was loaded onto 5 mL Extrelut™ QE column (EM science, Gibbstown, NJ) 
and extracted with ethyl acetate. The eluents were dried under nitrogen. Extracts were 
reconstituted in 200 /iL methanol and water (80:20 v/v). The HPLC analysis followed Zhang 
et al. (16) with minor modification: THB and three isoflavone aglucons were separated and 
quantified on a YMC-Pack ODS-AM Cig reverse-phase column (5 /im, 25 cm x 4.6 mm i.d.) 
(YMC, Wilmington, NC), the mobile phase was 1 mL glacial acetic acid /L in water (A) and 
methanol (B). 
Plasma isoflavone contents determined as a percentage of ingested dose. 
Because different doses were fed of each isoflavone source, plasma isoflavone content 
was expressed as an estimated percentage (mole based) of ingested dose present in plasma at 
the time point measured. Total plasma volume (mL) was estimated based on subject body 
weight and height (25), and multiplied by isoflavone content/mL; this total plasma isoflavone 
content was divided by the amount of isoflavone ingested at breakfast on day 1 or 7. 
Recovery study. Synthesized daidzein, genistein, glycitein, THB and blank urine 
and plasma samples from one subject were used to determine analytical recoveries for each 
isoflavone. Fifty pL of THB (2 g/L) and a series of isoflavone standards, between 6.25-100 
pmol/L for daidzein and genistein and 6.55-131.5 pmol/L for glycitein, were added to urine 
and plasma samples. Each standard was run in duplicate using the same extraction and 
analysis method as above. Analytical recoveries for urinary daidzein, genistein, glycitein and 
THB were 82.2 %, 79.3 %, and 84.5%, and 86.5 %, respectively; for plasma daidzein, 
genistein, glycitein and THB were 75.2 %, 69.2 %, 70.2 %, and 79.5 %, respectively. Plasma 
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and urinary isoflavones from the feeding study were calculated according to the internal 
standard curves for each individual isoflavones, THB used as internal standard. 
Statistical analysis. Statistical analysis was performed by SAS (SAS Institute, Inc., 
version 8.2,2001, Carry, NC). Analysis of variance using general linear model was 
conducted to determine treatment and phenotypic differences. When treatment differences 
were found, multiple comparisons using Tukey's test was performed to identify the 
difference. Clustering test (based on the simple linkage method) was used to identify 
daidzein degradation phenotypes. Pearson's correlation analysis was used to determine the 
correlation in plasma and urinary isoflavone contents between day 1 and 7, and between 
GTT, Dk, and urinary total isoflavone excretion. All results were reported as mean ± SEM, 
statistical significance at P < 0.05. 
RESULTS 
Urinary excretion of total isoflavone in the three treatments. The urinary 
isoflavone excretion expressed as % of ingested amount was calculated as the mean of day 1 
and 7 for each subject because isoflavone excretions on the two days were highly correlated 
(r= 0.94, P < 0.001). Significant differences were found in urinary total isoflavone excretions 
among the three treatment groups (Table 3). Between 0-12 h, subjects who consumed 
fermented soygerm excreted significantly greater amounts of isoflavones than did subjects 
who consumed soybean isoflavone extract, (P < 0.05). Between 12—24 h, isoflavone 
excretion from subjects fed unfermented soygerm was significantly greater than that of 
soybean isoflavone extract (P < 0.05). Total 24 h urinary isoflavone excretion from both 
groups fed soygerm was significantly greater than that from subjects fed soybean isoflavone 
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extract (P < 0.05, Table 3). Twenty-four hour urinary excretion of isoflavones from the two 
soygerm-fed groups did not differ significantly. Urinary total isoflavone excretion was 
significantly greater between 0 and 12 h than between 12 and 24 h in all treatment groups (P 
< 0.05) (Table 3). The excretion during 0 and 12 h was highly correlated with 24 h excretion 
(r= 0.97, P< 0.0001). 
Urinary excretion of isoflavone in high and low daidzein degraders. Significant 
phenotypic differences were found in overall urinary total isoflavone excretion between 0 and 
12 and 0 and 24 h between high and low daidzein degradation phenotypes (Table 4). Subjects 
within the low degradation phenotype excreted significantly greater amounts of isoflavones 
than did subjects of the high degradation phenotype (P < 0.05). Between 12-24 h, urinary 
excretion did not differ between high and low degradation phenotypes. 
For individual isoflavones, significant phenotypic differences in urinary daidzein and 
glycitein excretion were found between high and low daidzein degradation phenotypes (Table 
5). Urinary excretion of daidzein and glycitein was significantly greater in subjects of the 
low daidzein degradation phenotype than in subjects of the high degradation phenotype (P < 
0.05). Urinaiy daidzein and glycitein were excreted to a significantly greater extent than was 
genistein in all treatment groups, but excretion of daidzein and glycitein did not differ 
significantly (Table 5). 
Plasma isoflavone contents in high and low phenotypes and treatments. 
Plasma isoflavone expressed as % of ingested amount was calculated as the mean of 
day 1 and 7 for each subject. Intake of fermented soygerm caused greater plasma total 
isoflavone than did unfermented soygerm at 3 h after ingestion (P < 0.05) and greater plasma 
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daidzein than did both unfermented soygerm and soybean isoflavone extract (P < 0.05). No 
difference was found in total plasma isoflavone between high and low daidzein degradation 
phenotypes (Table 6). Total plasma isoflavone at 24 h after feeding was not detected. The 
main plasma isoflavone found at 3 h after feeding was daidzein. Genistein was only detected 
in 8 subjects (2-3/treatment) and no glycitein was detected in plasma at 3 h after feeding in 
any subject (Table 6). 
Correlations between GTT, D%, and urinary isoflavone excretion. There was 
no significant difference in GTT among the three treatments (Table 3). GTT was 
significantly different between high and low daidzein degradation phenotypes (Table 4). 
Subjects of the high daidzein degradation phenotype had significantly longer GTT than 
subjects of the low degradation phenotype (P < 0.05), and their total urinary isoflavone 
excretion was significantly less than subjects of the low daidzein degradation phenotype as 
well (P < 0.05, Table 4). Gut transit time was positively correlated with D% (r = 0.44, P < 
0.01), Dk was marginally negatively correlated with 0-12 h urinary total isoflavone excretion 
(r=- 0.29, P = 0.05). 
DISCUSSION 
In the present study, urinary isoflavone excretion was significantly greater over 0-12h 
than over 12-24h. The total urinary isoflavone excretion between 0—12 h and 0-24 h was 
highly correlated (r = 0.97, P < 0.001). These results were consistent with previous work in 
our laboratory (12,13). 
The overall daily bioavailability of isoflavones as reflected in urinary total isoflavone 
excretion did not differ between fermented soygerm (mostly isoflavone aglucons) and 
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unfermented soygerm (mostly isoflavone glucosides) (Table 3). Between 0-12 h, urinary 
isoflavone excretion in subjects fed fermented soygerm was slightly greater than that of 
subjects fed unfermented soygerm but between 12-24 h, urinary excretion of unfermented 
soygerm was greater than fermented soygerm. This different absorption and excretion pattern 
between fermented and unfermented soygerms may be due to their different chemical 
structures. Glucosides have long residence time in the gut because the glucosidic bound must 
be hydrolyzed before absorption. Setchell et al. (8) compared plasma kinetics of 50 g of pure 
daidzein, genistein and their ^-glucosides in 19 women, and found that aglucons were 
absorbed more quickly than glucosides as reflected in (mean time to attain peak plasma 
concentrations), 5-6 h for aglucons, and -9 h for glucosides, respectively. Izumi et al. (7) 
reported that soy isoflavone aglucons were absorbed faster and in greater amounts (P < 0.05) 
than isoflavone glucosides in 8 Japanese men and women at 2,4, and 6 h after feeding, 
was 2 h for aglucons, and 4 h for glucosides, respectively. At 24 h after feeding, plasma 
genistein after glucoside feeding was slightly greater than plasma daidzein after glucoside 
feeding and after feeding either aglucons. These Endings are consistent with isoflavone 
glucosides needing to undergo hydrolysis before being absorbed; therefore the absorption of 
glucosides was delayed compared with aglucons. The delayed absorption seemed to delay 
excretion as well, hence the slightly greater urinary excretion of isoflavones between 12-24 h 
for unfermented soygerm compared with fermented soygerm. In agreement with these 
observations, our plasma data also showed that at 3 h after feeding, isoflavone aglucons were 
absorbed to a significantly greater extent than were isoflavone glucosides (Table 6). 
However, Richelle et al. (10) reported that (7.2-8.3 h and 7.3-9.2 h for aglucons and 
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glucosides, respectively) did not differ between aglucons and glucosides in 6 European 
postmenopausal women after they consumed a single dose of either glucosidic isoflavone 
(soygerm-based extract contained 98% of glucosides) or isoflavone aglucons (enzymatically 
hydrolyzed from glucosides containing 57% aglucons), providing 3.6 /(mol isoflavone 
aglucon equivalent /kg body weight. The enzymatic hydrolysis of isoflavone glucosides 
seems to have been incomplete, because only 57% of the isoflavones were in aglucon form. 
Thus Richelle et al. (10) observed effects of absorption of an aglucon/glucoside mixture. 
Recently Zubik and Meydani (9) also showed similar absorption pattern between aglucons 
and glucosides. In this study, 15 American women were given a single bolus dose of either 
aglucons (32 mg or 0.12 mmol) or glucosides (51.72 mg or 0.12 mmol) of isoflavones from 
tablets in a crossover. The mean (4-5 h) for plasma daidzein and genistein after 
consumption of the aglucon tablets were not significantly different from the values after 
consumption of the glucoside tablets. They suggested that the ethnic background, intestinal 
bacterial composition and dietary habits were different compared with the study of Izumi et 
al. (7). American women, whose intestinal microfloral populations may differ from those of 
Japanese subjects, may have had a greater capacity to hydrolyze glucosides in the intestines 
than did the Japanese. But given the relative times of absorption according to Zubik and 
Meydani (9), the isoflavones would not have had time to reach the colon. This may suggest 
that a difference in human intestinal glucosidase activity but not gut microbial glucosidase 
activity was responsible for the most of the (3-glucosidic bond hydrolysis during isoflavone 
absorption in this case. Thus, American women may metabolize the glucoside forms of 
isoflavones more efficiently than do the Japanese subjects. In our study, we had 20 
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Caucasians and 5 Chinese subjects and our absorption data seem to agree with Setchell's 
study (8), which showed that aglucons absorbed faster than glucosides. 
Setchell et al. (8) also compared systemic bioavailability and Cmax (the maximum 
plasma concentration) between isoflavone aglucons and glucosides. The mean AUC (area 
under the curve) for genistein and daidzein were 4.54 and 2.94 /ig/ (mL- h), whereas, for 
genistin and daidzin were 4.95 and 4.52 /ig/ (mL- h), respectively, suggesting only slight 
difference in bioavailability between daidzein aglucons and glucosides but not for genistein. 
The Cmax for genistein and daidzein were 1.26 and 0.76 /imol/L, respectively; for genistin and 
daidzin were 1.22 and 1.55 pmol/L, respectively. Richelle et al. (10) also did not find 
differences in Cmax and AUC between aglucons and glucosides. Zubik and Meydani (9) found 
no difference in Cmax (0.5 vs. 0.5 /imol /L, respectively) and AUC over 48-hperiod (8.3 ± 4.2 
vs. 8.9 ± 4.7 ^mol/(48h-L), respectively) between the aglucons and glucosides for genistein. 
But they found a significantly higher Cmax (0.5 vs. 0.4 /imol/L, respectively, P < 0.05) and a 
larger AUC (8.3 ± 2.6 vs. 6.2 ± 1.7^mol/(48h L), respectively, P < 0.05) for plasma daidzein 
between aglucons and glucosides. But they pointed out this difference was partly due to the 
higher content of daidzein in the aglucon tablet compared with glucoside tablet (daidzein was 
0.0624 mmol in the 3 aglucon tablets and 0.0492 mmol in the 3 glucoside tablets, 
respectively). Although there exists some conflict, based on our study, isoflavone aglucons, 
being absorbed quickly, appeared in circulation earlier and in greater amounts than 
glucosides; but glucosides were absorbed to a greater extent later and persisted in circulation 
such that the total bioavailability of aglucon and glucosides as reflected in total urinary 
isoflavone excretion did not differ. 
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In either the aglucon or glucosidic form, bioavailability of an isoflavone source rich in 
glycitein (unfermented soygerm and fermented soygerm) was significantly greater than that of 
an isoflavone source rich in genistein (soybean isoflavone extract) at all time intervals as 
reflected in urinary excretion (Table 3). Comparing urinary isoflavone excretion of each of 
the three isoflavones, significantly greater amounts of daidzein and glycitein were excreted 
than genistein in all treatments (Table 5). Less excretion of genistein in urine compared with 
daidzein and glycitein may be due to structural differences. Griffiths and Smith (26) reported 
that genistein's hydroxyl group at the 5 position of the A-ring is much more susceptible to gut 
microfloral degradation in rats than are compounds without this structure (e.g., daidzein, and 
glycitein). The more that genistein is being degraded, the less that is recovered in urine. 
Sfakianos et al. (27) evaluated the intestinal uptake and biliary excretion of the isoflavone 
genistein in rats and found that the main metabolite of genistein was 7-O-fS glucuronide, 
which was excreted mainly into bile with only a small proportion into urine, therefore 
genistein may undergo more degradation by gut microflora. Zhang et al. (16) reported that 
after consumption of either soymilk (mole ratio of isoflavone was 5 daidzein: 5.5 genistein: I 
glycitein) or soygerm powder (mole ratio of isoflavone was 3 daidzein: 1 genistein: 2.6 
glycitein) by seven men and seven women with moderate fecal isoflavone degradation, 
urinary excretion of genistein (as a percentage of ingested isoflavone) was significantly lower 
(P < 0.001) than daidzein and glycitein. Glycitein showed the same excretion pattern in urine 
as did daidzein. The current findings show that bioavailability of total isoflavone from a 
source as reflected in urinary excretion depends on the molar ratio of individual isoflavones 
present in the source. 
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Due to the small number of subjects, we did not find significant differences in GTT 
and urinary isoflavone excretion between high and low daidzein degradation phenotypes 
within each treatment. But when data 6om high and low daidzein degradation phenotypes 
were combined across the three treatments, urinary total isoflavone excretion was 
significantly greater in subjects of the low degradation phenotype who had significantly 
shorter GTT than in subjects of the high degradation phenotype with significantly longer 
GTT between 0-12 h and between 0-24 h time intervals (Table 4). Furthermore, the 0-12 h 
total urinary isoflavone excretion was marginally negatively correlated with D% and GTT 
among all the subjects; urinary isoflavone excretion between 0—12 h contained the greater 
portion of isoflavones excreted over 6e day. Previous research (19) showed that 
bioavailability of genistein as reflected in urinary genistein excretion was significantly greater 
in subjects of a low genistein degradation phenotype with shorter gut transit time than in 
subjects of a high genistein degradation phenotype with longer gut transit time, after 
consumption of soybean powder providing 4.6 /imol total isoflavone/kg body weight. Gut 
transit time and gut microflora may play a crucial role in isoflavone degradation, and 
therefore in determining isoflavone bioavailability. Xu et al (12) reported that among seven 
adult women who consumed three doses of isoflavone in soymilk, two of them excreted 
significantly greater amounts of isoflavone in feces and also had greater isoflavone in urine 
and plasma compared with the other five subjects who excreted small amount isoflavone in 
feces and urine, suggesting an influence of gut microbial degradation on isoflavone 
bioavailability. The low isoflavone degradation phenotype coupled with shorter GTT seemed 
to prevent isoflavone degradation; therefore isoflavones are apparently absorbed to a greater 
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extent in such individuals. No phenotypic differences were found in total and individual 
plasma isoflavone either within each treatment or across the three treatments at 3 h after 
feeding. This observation was expected because during this short a time period, gut 
microflora would not exert an effect on isoflavone degradation or absorption. 
We did not detect glycitein in plasma at 3 h or 24 h after feeding. Glycitein may be 
absorbed more slowly than daidzein such that it is undetectable at 3h after feeding. As 
observed in a previous study, at 6 h after soymilk and soygerm consumption, Zhang et al. 
(16) reported that plasma glycitein concentrations were significantly lower than that of 
daidzein. Genistein was detected in only 8 subjects in plasma at 3 h after feeding, and 
genistein intakes were less, especially in subjects fed soygerm, probably explaining why only 
a few subjects had detectable plasma genistein at 3 h after feeding. At 24 h after soy feeding, 
no isoflavones were detected in plasma probably due to the detection limit (0.5 jwmol/L or 
-150 ng/mL). 
In this study, we showed that the daily bioavailability of the two major forms of 
isoflavone, aglucons and glucosides, derived from soygerm, did not differ as reflected in total 
urinary excretion over 24 h, but that genistein was less absorbed than glycitein or daidzein as 
reflected in total urinary isoflavone excretion. Isoflavone aglucons were absorbed more 
rapidly than glucosides as reflected in total and individual plasma isoflavone content at 3 h 
after feeding. Bioavailability of isoflavone was significantly greater in subjects of a low 
daidzein degradation phenotype with shorter GTT than in subjects of a high daidzein 
degradation phenotype with longer GTT as reflected in higher total urinary isoflavone 
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excretion. This phenomenon should be taken into account to better control human feeding 
studies of the effects of isoflavones. 
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TABLE 1 
Subject characteristics^ 
Treatment Daidzein 
degradation 
phenotype 
n Age Weight Dk BMI 
Y 
Unfermented High 5 22.4 ± 2.3 61.3 ±7.1 0.35 ± 0.02' 22.1± 2.1 
soygerm Low 4 24.0 ± 2.6 71.4 ±8.0 0.14 ±0.02^ 26.2 ± 2.4 
Combined 9 23.2 ± 1.7 66.4 ± 5.4 0.26 ±0.01 24.1 ± 1.6 
Fermented High 4 23.8 ±2.6 74.6 ±8.0 0.39 ± 0.02' 25.7 ±2.4 
soygerm Low 4 27.3 ± 2.6 59.4 ± 8.0 0.14 ±0.02^ 21.9 ±2.4 
Combined 8 25.5 ± 1.8 67.0 ±5.7 0.27 ± 0.02 23.8 ± 1.7 
Soybean High 4 21.2 ±2.3 57.0 ±7.1 0.36 ± 0.02" 20.8 ±2.1 
isoflavone Low 4 22.0 ±2.6 61.9 ± 8.0 0.13 ±0.02^ 23.2 ±2.4 
extract Combined 8 21.6±1.7 59.4 ±5.4 0.25 ±0.01 22.0 ± 1.6 
Mean High 13 22.5 ± 1.4 64.3 ± 4.3 0.36 ±0.01" 22.9 ± 1.3 
Low 12 24.4 ± 1.5 64.2 ± 4.6 0.14 ±0.01^ 23.8 ±1.4 
Combined 25 23.3 ± 1.0 64.2 ±3.1 0.26 ±0.01 23.1 ±2.4 
^ Values are mean ± SEM. Within a treatment, daidzein degradation rate constant, Dk, bearing 
different letters (a, b) was significantly different according to daidzein degradation 
phenotype, P < 0.05. 
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TABLEZ 
Isoflavone composition of the three isoflavone-containing products' 
Source Daidzein Genistein Glycitein Total' 
% of fofa/ ^  
% ag/wco/M ^ 
% of fo^a/ 
% aj/wco/u 
% of fofaZ 
% agZwco/zj 
% of ^ofaZ 
% G^/WCOM^ 
Unfermente 
d soygerm 
20.0 ± 0.7 
40.0 
4 
7.0 ±0.2 
14.0 
5 
23 ± 0.5 
46.0 
9 
50 ±0.6 
100.0 
6.4 
Fermented 
soygerm 
22.0 ± 0.6 
50.0 
91 
7.0 ±0.3 
16.0 
83 
15.0 ±0.5 
34 
84 
44 ± 0.7 
100.0 
87.5 
Soybean 
isoflavone 
extract 
450.0 ±5.2 
38.0 
3 
617.0 ±7.3 
53.0 
2 
107.0 ±3.5 
9.0 
11 
1174.0 ±5.5 
100.0 
3.2 
' Values are mean ± SD. The total isoflavone content was the sum of mole amounts of total 
daidzein, genistein and glycitein. 
^ % of total = mole % of total isoflavones. 
^ % of aglucons = mole % of total isoflavones. 
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TABLES 
Urinary excretion of total isoflavones during 0-12,12-24 h and over 24 h from three 
isoflavone sources fed to women for 7 days'' ^ 
Collection 
period^ 
Unfermented 
soygerm 
Fermented 
soygerm 
Soybean 
isoflavone extract 
Mean 
0-12 h 
mo/e % wigesfed 
34.7±4.5"^ 
ma/g % mg&sïed 
40.2± 4.9" 
TMoZe % mgesfaf 
18.7±4.6^ 
/MoZe % 
30.4 ±3.2 
12-24 h 16.0 ± 1.8" 11.3 ±2.0"-^ 7.1 ± 1.8" 11.7 ± 1.2 
0-24h 50.8 ±5.6" 51.5 ±6.1 25.7 ± 5.8^ 42.1±3.9 
' Values are mean ± SEM of day 1 and 7. Urinary excretion of total isoflavones was 
expressed as a mole percentage of ingested doses. Within a row, urinary excretion of total 
isoflavones with different superscripts (a, b) were significantly different. 
^ Urinary excretion of total isoflavones was significantly greater between 0—12 h than that of 
12-24 h, P < 0.05. 
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TABLE 4 
Urinary excretion of total isoflavones during 0-12,12-24 h, and over 24 h in women of high 
and low daidzein degradation phenotypes fed isoflavone sources for 7 days' 
Treatment Daidzein 
degradation 
phenotype 
n 0-12 h 12-24 h 0-24 h GTT 
% zMgeaW % mgesW h 
Unfermented High 5 20.5 ± 6.0 17.2 ±2.4 37.7 ±7.5 130± 18 
soygerm Low 4 49.0 ± 6.7 14.9 ±2.7 63.8 ± 8.4 67 ±20 
Fermented High 4 33.0 ±7.1 8.2 ±2.9 41.1 ±9.0 83 ±20 
soygerm Low 4 47.5 ± 6.7 14.3 ±2.7 61.8 ±8.4 71 ±20 
Soybean High 4 15.1 ± 6.3 7.3 ±2.5 22.4 ± 7.9 102 ±20 
isoflavone Low 4 22.2 ± 6.7 6.8 ± 2.7 29.0 ± 8.4 76 ±20 
extract 
Mean High 13 22.8 ± 3.7" 10.9±1.5 33.8 ± 4.7" 106± 11' 
Low 12 39.6 ±3.9' 12.0 ±1.6 51.6 ±4.8" 71 ± 12" 
' Values are mean ± SEM. Urinary excretion of total isoflavones was the mole % of ingested 
dose, mean of day land 7. The urinary excretion of total isoflavone and GTT with different 
superscripts (a, b) were significantly different between high and low daidzein phenotypes, P < 
0.05. 
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TABLES 
Urinary excretion of individual isoflavone over 24 h in high and low daidzein phenotypes and 
among three treatments' 
Treatment Daidzein 
degradation 
phenotype 
n Daidzein Genistein Glycitein 
% wzgesW dare % ffzgeafed 
Unfermente High 5 40.9 ± 7.9 10.1 ±4.0 43.4 ± 10.2 
d soygerm Low 4 64.0 ±8.9 18.2 ±4.5 77.6 ± 11.4 
Mean 52.5 ± 5.9 14.1 ±3.0 60.5 ± 7.7 
Fermented High 4 51.7 ±9.5 7.7 ±4.8 41.2 ± 12.2 
soygerm Low 4 70.1 ±8.9 14.2 ±4.5 72.0 ± 11.4 
Mean 60.9 ± 6.5 10.9 ±3.3 56.6 ± 0.4 
Soybean High 4 36.8 ± 8.3 9.0 ±4.3 39.7 ± 10.8 
isoflavone Low 4 47.6 ± 8.9 10.7 ±4.5 56.3 ± 11.4 
extract Mean 42.2 ±6.1 9.8 ±3.1 48.0 ±7.8 
Mean High 13 43.1 ± 5.0^ 8.9 ±2.5 41.4 ±6.4" 
Low 12 60.6 ±5.1" 14.3 ±2.6 68.6 ±6.6' 
Mean 51.1 ±3.8 11.6± 1.8 54.5 ±4.8 
' Values are mean ± SEM of day 1 and 7. Urinary excretion of individual isoflavone was the 
mole % of ingested dose. Urinary excretion of daidzein and glycitein were significantly 
greater than that of genistein, P < 0.05. Urinary excretion of daidzein and glycitein with 
different superscripts (a, b) were significantly different between high and low daidzein 
degradation phenotypes, P < 0.05. 
109 
TABLE 6 
Estimated plasma total and individual isoflavone at 3 h after feeding in women of high and 
low daidzein degradation phenotypes fed three isoflavone sources for 7 days' 
Phenotype Isoflavone n Unfermente Fermented Soybean 
d soygerm isoflavone 
soygerm extract 
Mean 
% wzgacfed % zMgasW % ZMggfW 
High Daidzein 
Genistein 
Glycitein 
Total 
13 0.59 ± 0.47 
1.53 ±0.95 
ND% 
0.51 ±0.41 
3.43 ± 0.53 
0.28 ± 1.06 
ND 
1.76 ±0.45 
1.48 ±0.50 
1.31 ± 1.0 
ND 
1.26 ±0.43 
1.83 ±0.29 
1.04 ±0.58 
ND 
1.17 ±0.25 
Low Daidzein 
Genistein 
Glycitein 
Total 
12 0.73 ±0.53 
1.63 ±1.06 
ND 
0.52 ± 0.45 
3.13 ±0.53 
1.50 ± 1.06 
ND 
1.80 ±0.45 
1.21 ±0.53 
1.00 ± 1.06 
ND 
0.99 ± 0.44 
1.69 ±0.31 
1.37 ±0.61 
ND 
1.10 ±0.26 
Mean Daidzein 
Genistein 
Glycitein 
Total 
25 0.66 ± 0.36" 
1.58 ±0.71 
ND 
0.51 ±0.30" 
3.28 ±0.38" 
0.89 ± 0.75 
ND 
1.78 ±0.32" 
1.34 ±0.36" 
1.16 ±0.73 
ND 
1.12 ±0.31"'" 
1.71 ±0.25 
1.22 ±0.40 
ND 
1.12±0.19 
' Values are mean ± SEM of day 1 and 7. Plasma total and individual isoflavones was the 
mole % of ingested dose. Plasma volumes were estimated based on subject body weight and 
height (22). Within a row, plasma total isoflavone and plasma daidzein contents with 
different superscripts (a, b) were significantly different among treatment groups, P < 0.05. 
^ ND = not detected. 
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GUT TRANSIT TIME AND GUT MICROBIAL ISOFLAVONE 
DEGRADATION INFLUENCE APPARENT ISOFLAVONES ABSORPTION IN 
WOMEN 
A paper submitted to Journal of Nutrition 
Yan Zheng, Patricia A. Murphy, Suzanne Hendrich 
ABSTRACT 
Greater apparent absorption of isoflavones from high and doses of isoflavone-
containing supplements fed for 7 days was hypothesized to depend upon relatively rapid gut 
transit time (GTT) and low daidzein degradation rate, D% < 0.15 h"\ as determined from 
anaerobic incubation of human feces with daidzein. Twenty Caucasian women, 21 ± 1 y, 70 
± 3 kg, and BMI of 24 ± 1 kg/m^ were studied: 10 of high daidzein degradation phenotype 
and GTT 130 ± 9 h, 10 of low daidzein degradation phenotype and GTT 86 ± 9 h. Isoflavone 
doses (54 or 163 pmol total isoflavones/d) were fed daily for 7 days at breakfast in a 
randomized crossover design with doses separated by a 1-week washout period. Reverse-
phase HPLC analysis of urine samples from subjects indicated the expected significant dose 
response in 24-h urinary excretion of isoflavones (high vs. low dose: 197 ± 11 vs. 72 ± 11 
Hmol/day, P < 0.05). Degradation phenotype and GTT differences were significant among 
the 10 subjects who consumed the high isoflavone dose initially. Low daidzein degraders had 
greater total urinary isoflavone excretion than did high degraders (189.0 ± 16.3 vs. 119.0 ± 
5.0 pmol/d, P < 0.05). Urinary isoflavone excretion decreased 20-30% in week 2 of 
isoflavone feeding compared with week 1. Plasma glycitein showed significant dose 
difference, phenotypic difference and repeated dosing difference. These data suggest that 
I l l  
microbial degradation of isoflavones is dose-dependent and inducible. Isoflavone degradation 
phenotype coupled with GTT and repeated dosing significantly affect apparent absorption of 
isoflavones, which is of importance for design of human feeding trials of isoflavones. 
KEY WORDS: isoflavone bioavailability gut transit time - microbial degradation 
Isoflavones stimulate research interest in the Geld of nutraceuticals and functional 
foods because of the potential health benefits from consumption of these phytoestrogens 
found primarily in soybeans. Epidemiologic studies have suggested that the consumption of 
soy products lower the incidence of hormone-dependent cancer (1-3), prevent osteoporosis (4) 
as well as menopausal symptoms (5), and coronary heart disease (6). There is little evidence 
about isoflavone dose-response in exerting these effects. Messina et al. (7) has suggested that 
as little as 1 serving/d of soy products can protect against chronic diseases. A few 
randomized crossover dose-response feeding studies have been done in human subjects (8-10) 
with either soy protein isolate or soymilk powder as isoflavone sources. The doses ranged 
from 2-30 fimol/kg body weight, and 1-9-day feeding periods. All these studies showed 
dose-response in isoflavone bioavailability as reflected in urinary excretion. 
Urinary isoflavone excretion varies considerably among individuals. In one study, the 
variation of genistein excretion was -12-fbld and that of daidzein -15-fbld within the same 
dose after 9-day isoflavone feeding with different doses (8). This variability is probably due 
to individual differences in isoflavone absorption and degradation, which we propose to be 
influenced significantly by gut microorganisms and gut transit time (GTT) (11, 12). 
Isoflavone degradation phenotypes have been identified in women based on the m vzfro rate 
of fecal disappearance of these compounds (11,13). More rapid gut transit time was one 
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factor identified to be related to increased apparent genistein absorption as reflected in 
urinary excretion in Asian and Caucasian women (11). Chronic soy product consumption 
may modulate the metabolism and disposition of ingested isoflavones, hence affecting the 
bioavailability of these compounds (14). 
In the present study, we examined the bioavailability as a function of urinary and 
plasma content of high and low doses of isoflavone among individuals of varying GTT and 
isoflavone degradation phenotype as measured by isoflavone disappearance during anaerobic 
fecal incubations. 
MATERIALS AND METHODS 
Experimental Procedures 
Subjects. Subjects were screened to identify high and low daidzein degradation 
phenotypes. Daidzein, at 100 pmol/L, was incubated in anaerobic Brain-Heart Infusion media 
for 12 h with a fresh fecal sample provided by each subject as described in Zheng et al. (11). 
Daidzein degradation rate constant D% < 0.15 h"' was the criterion for the low daidzein 
degradation phenotype; D% > 0. 20 h"' was the criterion for the high daidzein degradation 
phenotype. Twenty healthy Caucasian women (lowan), 18-30 y, 70.1 ±3.0 kg, body mass 
index (BMI) of 23.7 ± 0.9 kg/m^ were recruited for this study, 10 of each degradation 
phenotype (Table 1). The experimental procedures for this study were approved by the 
Human Subjects Committee of Iowa State University. Subjects gave their informed consent 
to the study. 
Experimental design. The experiment was divided into two phases (week 1 
and week 2) separated by a 1 -week washout period. Low and high doses of isoflavones were 
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given for 7 days in a randomized crossover design (Table 2). The isoflavone source was a 
mixture of soy protein and dietary isoflavone supplement (General Nutrition Corporation, 
Pittsburgh, PA) (Table 3). The high dose contained 291 mg isoflavone supplement and 18 g 
soy protein which provided a total of 43 mg (163 /imole) isoflavone; the low dose contained 
97 mg supplement and 6 g soy protein providing 14 mg (54 fimole) isoflavone, yielding a 3-
fbld dose difference between the two treatments. The daily dose of isoflavone was mixed 
with orange juice given at breakfast between 7:30 and 9:00 am in Human Metabolic Unit, 
Iowa State University. Other foods including white bread, bagel, cereal, skim milk, cream 
cheese, peanut butter, jelly, apple and orange were consumed ad Zz'Mwm. On day 7 (the last 
day of feeding) of each feeding period, 2 gelatin capsules containing 16 marker beads were 
given to each subject with breakfast for measuring GTT (11). All subjects were asked to 
avoid any isoflavone-containing foods one week before and during the study including the 
washout period. A list of isoflavone-containing foods was given to each subject (See 
Appendix C.). 
Biological sample collection. One blank urine sample (time 0) was collected 
from each subject in the morning on day 1 right before initial feeding in both feeding periods. 
Urine was collected for 24 h on day 6, 7 and 8 and the first urination on day 9 in both weeks. 
Subjects were instructed to keep the urine samples in the ice chests provided or in 
refrigerators on each collecting day. Immediately after collection, 24 h urine from each 
subject was mixed well, and after recording the volume, 50 mL aliquots were stored at -80 C 
until analysis. After ingesting marker beads at breakfast on day 7 in both feeding periods, 
feces were collected until 12 out of 16 beads were excreted (11). After an overnight fast, 10 
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mL venous blood samples were collected into EDTA-containing vacuum containers by a 
licensed phlebotomist under stringent aseptic conditions before isoflavone feeding (time 0) 
and at 24 h after feeding on day 7 and 8. Blood samples were centrifuged within 1 h after 
collection at 3000 g for 30 min at 4° C (Model 4d, International Equipment Co., Needham 
Heights, MA). Plasma was stored at -20° C until analysis. 
Analytical Methods 
Chemicals. Isoflavones, daidzein, genistein, glycitein and 2,4,4'-
trihydroxybenzoin (THE), used as internal standard, were synthesized in Dr. Murphy's 
laboratory, Iowa State University (15, 16). Other HPLC solvents and extraction agents were 
purchased from Fisher Scientific Co. (Pittsburgh, PA). 
Soy products analysis. Samples from each isoflavone source were analyzed in 
duplicate in Dr. Murphy's laboratory, Iowa State University. Isoflavone extraction and 
HPLC analysis were performed as described before (17,18). The total isoflavone content 
was the sum of total daidzein, genistein and glycitein on a mole basis (Table 3). The overall 
mole ratio among the three isoflavones fed was 3 daidzein: 3.5 genistein: 1 glycitein. 
Urinary and plasma isoflavone analysis. Details of isoflavone extraction and 
HPLC analysis have been described previously by Zheng et al. (11). Recovery studies were 
done as reported previously by Zheng et al. (11). The analytical recoveries of urinary daidzein, 
genistein, glycitein, and THB were 84.3%, 80.6%, 86.5%, and 88.6%, respectively. The 
recoveries of plasma daidzein, genistein, glycitein and THB were 79.2 %, 72.2 %, 74.0% and 
82.5 %, respectively. Reported urinary and plasma isoflavones were calculated according to 
the internal standard curves of each individual isoflavone, THB used as internal standard. 
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Statistical analysis. Statistical analysis was conducted by SAS program 
(Version 8.2, 2001, SAS Institute, Carry, NC). Crossover effect was not significant after 
statistical examination; data were combined cross the two feeding periods. General linear 
model was used to test effects of treatment, phenotypic, repeat dosing and the difference of 
GTT. Pearson's correlation analysis was conducted to describe the correlation between 
urinary and plasma isoflavone. Clustering test (based on simple linkage method) was used to 
identify daidzein degradation phenotypes. All results were reported as mean ± SEM, P < 0.05 
for all analyses. 
RESULTS 
Urinary and plasma isoflavones in all subjects. Only daidzein degradation rate 
constant was significantly different between high and low phenotypes (P < 0.001, Table 1). 
Urinary excretions of individual and total isoflavones were the mean of day 6 and 7 because 
they were highly correlated (r = 0.76, P < 0.0001) and there was no significant difference 
between the two days. Urinary isoflavone excretion on day 8 was significantly less than that 
of day 6 and 7 (P < 0.05), representing a small amount of carryover from the last day of 
isoflavone dosing (data not shown), and isoflavones from the first urination on day 9 were 
undetectable in most subjects (data not shown). Therefore, only results from day 6 and 7 
were used in analysis. Concentrations of plasma isoflavone were the mean of day 7 and 8 at 
24 h after feeding. Urinary isoflavone excretion was slightly but significantly correlated with 
plasma isoflavone concentration (r = 0.23, P < 0.05). 
Dose-response, phenotypic difference, GTT, and repeated dosing influence 
urinary excretion of isoflavones in all subjects. Urinary excretion of individual and total 
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isoflavones was shown according to dose, daidzein degradation phenotype, and feeding 
period (Table 4). As expected, significant dose effects were found in urinary excretion of 
individual and total isoflavones (Table 4). Urinary excretion of isoflavones was significantly 
greater (-3-fold) after the high dose than the low dose (P < 0.0001). Phenotypic differences 
were significant for urinary genistein excretion between the two phenotypes (P = 0.01) (Table 
4), which excretion in subjects of the low daidzein degradation phenotype was greater than in 
subjects of the high phenotype. GTT (mean of week 1 and week 2) was positively correlated 
with Dk (r = 0.71, P < 0.001) and differed significantly between the two phenotypes, such that 
subjects within the low phenotype had shorter GTT than did subjects of the high phenotype 
(P < 0.05) (Table 4). Significant effects of repeated dosing were seen in urinary excretion of 
daidzein (P = 0.002) and total isoflavones (P = 0.006), where the excretions of isoflavones in 
week 1 were greater than in week 2. The decreases were 30%, 29%, 21%, and 29% for 
daidzein, genistein, glycitein and total isoflavone excretions in week 2 compared to week 1, 
respectively (Table 4). 
Effects of phenotypic difference and GTT on urinary excretion of isoflavones in 
10 subjects who were given the high dose during week 1. Among the 10 subjects (6 
high and 4 low phenotype) who were given a high isoflavone dose in week 1, urinary 
excretion of total isoflavone (P = 0.005), daidzein (P = 0.009) and genistein (P = 0.006) were 
significantly greater in subjects of the low degradation phenotype than in subjects of the high 
degradation phenotype (Table 5), and GTT was significantly more rapid in subjects of the 
low degradation phenotype as well (P <0.05). In addition, in this group, total urinary 
isoflavone excretion was negatively correlated with D% (r = - 0.32, P < 0.05). These 
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differences were not found in the 10 subjects who were given a low isoflavone dose in week 
1 (Table 5). 
Dose-response, phenotypic difference, GTT, and repeated dosing influence 
plasma isoflavones in subjects. Only plasma glycitein was found to be significantly 
different between high and low dose, high and low phenotype, and between week 1 and week 
2 (P < 0.05) (Table 6). Plasma daidzein was significantly greater during week 1 than in week 
2 (P < 0.05) (Table 6). In the 10 subjects who given a high isoflavone dose in week 1, plasma 
glycitein was significantly greater in low degradation phenotype compared with high 
degradation phenotype (P < 0.05) (Table 7). No difference was found in the 10 subjects 
given a low dose of isoflavone during week 1 (Table 7). 
DISCUSSION 
Our results showed that there was 3-fold greater urinary excretion of both individual 
and total isoflavones in subjects after consuming a high dose of isoflavones compared to a 
low dose, consistent with the 3-fold difference between the two doses (Table 4). This agreed 
with previous feeding studies (9,10) that the apparent absorption and urinary excretion of 
isoflavones is dose-dependent. 
Phenotypic and GTT differences found between high and low daidzein degradation 
phenotypes are important in determining isoflavone bioavailability as reflected in plasma 
isoflavone and urinary isoflavone excretion. In the current study, we examined the effects of 
daidzein degradation phenotype coupled with GTT on urinary isoflavone excretion and 
plasma isoflavone concentration. Among all subjects, D% and GTT were positively correlated 
(r = 0.71, P < 0.001). Urinary genistein excretion, plasma glycitein and GTT were 
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significantly different between high and low daidzein degradation phenotypes (P < 0.05) 
(Tables 4 & 6). Furthermore, among the 10 subjects who were given a high dose of 
isoflavones during week 1, subjects of the low degradation phenotype with shorter GTT had 
greater urinary excretion of daidzein, genistein and total isoflavone and plasma glycitein 
compared with subjects of the high degradation phenotype and long GTT (P < 0.05) (Table 5 
& 7). But we did not find similar results in the 10 subjects who were given a low dose of 
isoflavones during week 1 for several reasons (Table 5 & 7). First, GTT was not significantly 
different between the high and low degradation phenotypes in this group of subjects (Table 5), 
even though as a whole, GTT differed between two phenotypes (Table 4). This suggests that 
GTT is a crucial factor that influences isoflavone bioavailabihty. Secondly, the phenotypic 
differences may only be found under certain conditions (i. e., an isoflavone dose greater than 
a certain amount seemed to be needed to induce microbial degradation phenotypic effect), 
therefore, a low isoflavone dose during week 1 may not have "triggered" a phenotypic 
difference. This remains speculative because of the limited number of human feeding studies 
done with varying isoflavone doses and the lack of isoflavone degradation phenotypic data. 
Setchell et al. (19) determined bioavailabihty and dose-response effects of soy isoflavone in 
10 healthy women after single bolus ingestion of 10,20, or 40 g of soy nuts providing 
daidzein (6.6, 13.2, and 26.4 mg) and genistein (9.8,19.6 and 39.2 mg), respectively, in a 
randomized crossover design. They found a nonlinear relationship between the plasma 
isoflavone AUC as well as urinary excretions of isoflavone and the amount of isoflavones 
ingested because the urinary excretions of isoflavone decreased with increasing intake when 
expressed as a percentage of the administered dose (63.2, 54.4 and 44.0%, respectively, for 
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daidzein, and correspondingly, 25.2, 13.4 and 15.8 % for genistein). They also found the great 
variability in urinary excretion among the subjects but they did not describe this 
interindividual variability. Although different percentage of plasma and urinary isoflavone 
content between doses were reported in SetchelTs study, they were not significant, which still 
suggested the dose-dependent response in these subjects. 
Xu et al. (9) showed that after 7 women consumed three doses of isoflavone-
containing soymilk (3.4, 6.9, or 10.3 ^mol isoflavones/ kg body weight) with 3 meals on each 
feeding day separated by 2-week washout periods, 2 of them excreted 10—20 times more fecal 
isoflavones and 2 - 3-fbld greater urinary isoflavones than did the other five subjects: the 
urinary recoveries of ingested daidzein and genistein were 16% and 10% in the five subjects, 
and 32% and 37% in the other 2 subjects, respectively. This suggested that isoflavone 
bioavailability depended upon the ability of gut microorganisms to degrade isoflavones. 
Different isoflavone degradation phenotypes (high, moderate, and low) have been identified 
in humans (11, 13) based on in vitro anaerobic incubation degradation half-life or 
degradation rate constant. Zheng et al. (11) also reported that significant differences in 
degradation phenotype and GTT significantly affected urinary genistein excretion in 35 Asian 
(Chinese immigrant) women after a single dose of isoflavones (4.6 /imol/kg body weight) 
(11). In another study (12), total urinary isoflavone recoveries differed significantly between 
subjects of high and low daidzein degradation phenotypes among 25 women after 7-day 
dosing of three sources of isoflavones with 8-9 subjects/ treatment (unfermented soygerm 1.1 
/wnol/ kg body weight, fermented soygerm: 3.3/imol/kg, soybean extract: 1.5 fimol/kg). All 
these studies showed that low daidzein degradation phenotype coupled with more rapid GTT 
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resulted in greater urinary isoflavone excretion compared with a high degradation phenotype 
with long GTT. 
We also found that repeated feeding of isoflavone with a short washout period 
intervening (1 week) may decrease isoflavone bioavailability as we observed in the current 
study: urinary isoflavone excretion was 20-30% less in week 2 (Table 4) compared with 
week 1 and plasma daidzein and glycitein were significantly less in week 2 compared to week 
1 (Table 6). Similar results have been reported by Lu et al. (14). After daily doses to women 
of 80-210 mg of each isoflavone (daidzein and genistein) in soymilk for one month, urinary 
excretion of isoflavones was 10% less than during initial excretion in women. This may 
suggest that the ability of gut microorganisms to degrade isoflavones is inducible. Therefore 
after repeated exposures to isoflavones, even with a brief washout period, the host gut 
microorganisms retain greater ability to degrade isoflavones, hence decreasing isoflavone 
bioavailability. This finding may be important for designing clinical feeding trials and 
evaluating potential isoflavone toxicity ;» Wvo, especially for chronic exposure. 
Identification of isoflavone degrading microorganisms in the human gut and of the microbial 
ecologies and environmental factors that stimulate or inhibit isoflavone degradation is likely 
to be an important next step in understanding isoflavone bioavailability. This has 
implications for bioavailability of other dietary phenolics with potential health effects as well. 
We observed that bioavailability of glycitein as reflected in urinary excretion was 
similar to daidzein, but was greater than genistein. The mole ratio of the three isoflavones 
was 3 daidzein: 3.5 genistein: 1 glycitein in the mixture of soy protein and isoflavone 
supplement, and was 4 daidzein: 1.5 genistein: 1 glycitein in urinary excretion. Urinary 
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excretion of genistein was much less than daidzein and glycitein, relative to dietary content. 
Daidzein and genistein were abundant in the isoflavone sources in the current study (Table 3); 
glycitein is a minor component of isoflavones in soy products except for soygerm. Because 
glycitein is more bioavailable than genistein, its biological effects may also be important. 
Genistein may be more bioactive than the other isoflavones. For example, as cancer 
chemopreventive agents, genistein (IC50 = 25 /imol/L) and daidzein (IC;o= 150 fimol/L) 
inhibited H2O2 formation in 12-O-tetradecanoylphorbol-13-acetate (TPA)-activated HL-60 
cells (20). Wang et al. (21) also demonstrated that genistein at 0.01 /imol/L and biochanin A, 
at 1.0 /imol/L, induced quinone reductase, a phase II enzyme that detoxifies some chemical 
carcinogens, six fold and two fold, respectively. But genistein is also associated with 
potential toxicities such as thyroid peroxidase (TPO) inhibition in rats (22). Sprague-Dawley 
rats were exposed to genistein at doses of 0,5,100, and 500 ppm in soy-free basal diet, the 
estimated genistein intake was 0.04, 0.4, 8,40 mg/kg body weight per day. In both male and 
female rats, dose-dependent decreases in microsomal TPO activity were observed with as 
much as 80% loss of TPO activity in thyroid in female rats fed 500 ppm genistein. Even at 
the lowest dose of 5 ppm, 40 - 55% of TPO activity in thyroid was lost. But this TPO 
inhibition had not effect on thyroid hormone status in these rats (22). Perhaps the lesser 
bioavailability of genistein is a health protective mechanism, showing symbiosis of gut 
microorganisms with respect to isoflavone metabolism. 
The results from this study suggested that the effects of gut microflora on absorption 
of isoflavone probably relate strongly to gut transit time, i. e., the length of time gut microbial 
species have to exert their effects on isoflavones. Repeat feeding soy isoflavones for a period 
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of time may decrease their bioavailability as reflected in urinary excretion due to induced gut 
microbial degradation of these compounds. Isoflavone degradation phenotype coupled with 
GTT had significant influence on apparent isoflavone absorption, and GTT may be a crucial 
factor to control for in future clinical trials of isoflavone efBcacy. 
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TABLE 1 
Subject characteristics' 
Daidzein 
degradation 
phenotype 
n Dk Age Body weight BMI 
Y % 
High 10 0.24 ± o.or 20.9 ± 0.8 69.9 ± 4.3 24.1 ±1.3 
Low 10 0.07 ± 0.01^ 19.9 ±0.9 70.2 ± 4.5 23.4 ± 1.4 
Mean 0.15 ± 0.01 20.4 ± 0.6 70.1 ±3.0 23.7 ±0.9 
^ Values are mean ± SEM. Daidzein degradation rate constant, D%, with different superscripts 
(a, b) were signiûcantly different between the two phenotypes (P < 0.001). 
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TABLE 2 
Experimental design' 
Daidzein Week 1 Week 2 
degradation High dose Low dose High dose Low dose 
phenotype (n) M (n) (n) 
High 6 4 4 6 
Low 4 6 6 4 
Total number 10 10 10 10 
of subjects 
Dose of 163/(mol 54pmol 163//mol 54/imol 
isoflavones/d 
'The subjects given high dose of isoflavones in the first week was switched to the low dose in 
the second week and vice verse. 
TABLES 
Isoflavone content of the two sources' 
Isoflavone 
source 
Daidzein Genistein Glycitein Total 
of of of fofa() ^Mo/g% of /OfO^) 
Soy protein 3.1 ±0.2 3.6 ±0.1 0.99 ± 0.05 7.6 ± 0.4 
(40.3) (46.8) (12.9) (100.0) 
Supplement 29.9 ± 1.7 43.1 ±2.5 9.7 ± 0.8 81.4 ±6.9 
(36.2) (52.1) (11.7) (100.0) 
' Values are mean ± SD. 
128 
TABLE 4 
Urinary excretion of total and individual isoflavones during high and low dose treatments, 
according to high and low daidzein degradation phenotypes, and during week 1 and 2' 
Isoflavone 
dose 
obs GTT Daidzein Genistein Glycitein Total 
A /(mo//# 
High 20 105 ±9 124.5 ± 6.7' 44.0 ± 4.8" 28.3 ± 1.9* 196.8 ± 11.2* 
Low 20 111 ±9 46.5 ± 6.7* 14.8 ± 4.8* 10.3 ± 1.9* 71.5 ± 11.2* 
Daidzein 
degradation 
phenotype 
obs GTT Daidzein Genistein Glycitein Total 
A 
High 20 130 ±9' 82.1 ± 6.8 20.5 ± 4.8^ 17.9 ± 1.9 120.5 ±11.3 
Low 20 86 ±9^ 88.9 ± 6.6 38.3 ±4.8' 20.7 ± 1.9 147.9 ± 11.1 
Week obs GTT Daidzein Genistein Glycitein Total 
A 
1 20 108 ±9 100.6 ±6.7" 34.4 ±4.8 21.6 ± 1.9 156.5 ± 11.2' 
2 20 108 ±9 70.4 ± 6.7^ 24.4 ± 4.8 17.0 ± 1.9 111.8± 11.2' 
' Values are mean ± SEM. Urinary excretion of isoflavones was the mean of day 6 and 7. 
Urinary excretion of total and individual isoflavones with different superscripts (a, b) were 
significantly different between the high dose and low dose treatments, P < 0.0001. Urinary 
excretion of genistein and GTT with different superscripts (c, d) was significantly different 
between high and low phenotypes, P < 0.05. Urinary excretion of daidzein and total 
isoflavones with different superscripts (e, f) were significantly different between week 1 and 
2,P<0.01. 
TABLES 
Urinary excretion of total and individual isoflavones in the 10 subjects given the high dose 
of isoflavone in week land low dose in week 2' 
Daidzein 
degradation 
phenotype 
Dose obs GTT Daidzein Genistein Glycitein Total 
# jwmoZ/# 
High High 6 126±15 130.3±11.6 29.2±9.4 31.0±3.3 190.6±21.2 
High Low 6 142 ±15 30.9±11.6 7.6±9.4 8.9±3.3 47.4±21.2 
Low 
Low 
High 
Low 
4 
4 
69±19 
61±19 
174.4±13.6 
57.5±13.6 
76.9±11.0 
20.3±11.0 
35.9±3.8 
12.8±3.8 
287.2±25.9 
90.6±24.9 
Mean of high phenotype 134±14" 80.6±8.2* 18.4±6.6* 20.0±2.3 119.0±5.0* 
Mean of low phenotype 
00 
116.0±9.6* 48.6±7.8" 24.3±2.7 189.0±16.3" 
10 subjects given the low dose of isoflavone in week 1 and high dose in week 2 
Daidzein 
degradation 
phenotype 
Dose obs GTT Daidzein Genistein Glycitein Total 
AT /wo//# 
High High 4 138=1:19 116.3±15.3 32.8±9.9 22.7±4.3 171.8±23.9 
High Low 4 111±19 50.9±15.3 12.3±9.9 8.9±4.3 72.1±23.9 
Low High 6 87=1=15 77.0±12.5 36.9±8.1 23.5±3.5 137.5±19.5 
Low Low 6 113±15 46.8±12.5 19.0±8.1 10.5±3.5 76.1±19.5 
Mean of high phenotype 125±18 83.6±10.9 22.5±7.0 15.8±3.0 121.9±16.9 
Mean of low phenotype 100±16 61.9.0±8.9 27.9±5.7 17.0±2.5 106.8±13.8 
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' Values are mean ± SEM. Urinary excretion of isoflavone was the mean of day 6 and 7. The 
urinary excretion of daidzein, genistein, total isoflavones and GTT with different superscripts 
(a, b) were significantly different between high and low daidzein degradation phenotype in 
the subjects who given high dose of isoflavone during week 1, P < 0.05. 
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TABLE 6 
Concentration of plasma total and individual isoflavones during high and low dose 
treatments, according to high and low daidzein degradation phenotypes, and during week 1 
and 2^ 
Isoflavone 
dose 
obs GTT Daidzein Genistein Glycitein Total 
High 20 105 ±9 0.18 ±0.05 2.05 ± 0.26 0.33 ± 0.09= 2.57 ± 0.28 
Low 20 111 ±9 0.08 ± 0.05 1.73 ±0.25 0.08 ± 0.08* 1.88 ±0.27 
Daidzein 
degradation 
phenotype 
obs GTT Daidzein Genistein Glycitein Total 
h /WMoZ/Z, 
High 20 130 ±9' 0.16 ±0.05 1.84 ±0.27 0.08 ± 0.09^ 2.07 ± 0.28 
Low 20 86 ±9^ 0.09 ± 0.04 1.95 ±0.25 0.33 ± 0.08' 2.37 ± 0.26 
Week obs GTT (h) Daidzein Genistein Glycitein Total 
A /WMoZ/Z, 
1 20 108 ±9 0.18 ±0.04' 1.77 ±0.25 0.32 ± 0.08= 2.27 ± 0.26 
2 20 108 ±9 0.07 ± 0.05' 2.01 ± 0.27 0.09 ± 0.09' 2.17 ±0.28 
' Values are mean ± SEM. Concentration of plasma isoflavones was the mean of day 7 and 8 
at 24 h after dose. Concentration of plasma total and individual isoflavones with different 
superscripts (a, b) was significantly different between the high dose and low dose treatments, 
P < 0.05. Concentrations of plasma glycitein and GTT with different superscripts (c, d) were 
significantly different between high and low phenotypes, P < 0.05. Concentration of plasma 
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daidzein and glycitein with different superscripts (e, f) were significantly different between 
week 1 and 2, P < 0.05. 
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TABLE 7 
Concentration of plasma total and individual isoflavones in the 10 subjects given the high 
dose of isoflavone in week land low dose inn week 2^ 
Daidzein 
degradation 
phenotype 
Dose obs GTT Daidzein Genistein Glycitein Total 
A 
High High 6 126615 0.2260.08 2.0860.33 0.1160.12 2.4260.34 
High Low 6 142615 0.0660.09 1.9860.35 0.0060.12 2.0460.36 
Low 
Low 
High 
Low 
4 
4 
69619 
6U:19 
0.2760.10 
0.0060.11 
2.0460.41 
1.9860.28 
0.8660.14 
O.OOtO.15 
3.1760.42 
1.9860.45 
Mean of high phenotype 134±14* 0.1460.06 2.0360.24 0.0660.08* 2.2360.25 
Mean of low phenotype 65.0618* 0.1460.07 2.0160.30 0.4360.10* 2.5860.31 
10 subjects given the low dose of isoflavone in week 1 and high dose in week 2 
Daidzein 
degradation 
phenotype 
Dose obs GTT Daidzein Genistein Glycitein Total 
A 
High High 4 138619 0.2260.11 1.8060.80 0.0060.23 2.0260.85 
High Low 4 111619 0.1460.09 1.4860.68 0.1960.22 1.8160.71 
Low High 6 87615 0.0060.07 2.3160.52 0.3460.11 2.6560.55 
Low Low 6 113615 0.1060.07 1.4760.52 0.1160.17 1.6960.55 
Mean of high phenotype 125618 0.1860.07 1.6460.52 0.1060.17 1.9260.55 
Mean of low phenotype 100616 0.0560.05 1.8960.37 0.2360.12 2.1760.39 
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' Values are mean ± SEM. Concentration of plasma isoflavone was the mean of day 7 and 8 
at 24 h after dose. Concentration of plasma glycitein and GTT with different superscripts (a, 
b) were significantly different between high and low phenotypes in the subjects given high 
dose of isoflavone during week 1, P < 0.05. 
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CONFOUNDING EFFECTS OF CALORIC INTAKE AND TIME COURSE ON 
MODULATION OF APPARENT ABSORPTION OF ISOFLAVONES BY DIETARY 
FIBER INTAKE IN WOMEN 
A paper submitted to Journal of Nutrition 
Yan Zheng, Patricia A. Murphy, Suzanne Hendrich 
ABSTRACT 
In this study we hypothesized that accelerating gut transit time (GTT) by feeding a 
high fiber diet would increase apparent isoflavone absorption. Nine Caucasian women, 
18-35 year of age, identified by anaerobic incubation of feces with daidzein as low degraders 
(daidzein degradation rate constant, D%< 0.15 h"') with mean GTT 108 ± 9 h, consumed 
either high fiber (45g/d) or moderate fiber (15g/d) diets for 7 days in a randomized crossover 
feeding trial with a 1-week washout period between treatments. Isoflavones (4.5 pmol/kg 
body weight) were given in a drink with breakfast each of the 7 days. From fecal marker bead 
counts, GTT did not differ significantly after either high or moderate fiber diets were fed, 
perhaps because subjects fed moderate fiber in week 1 experienced increased caloric intake 
during treatment compared with pre-treatment which may have accelerated their GTT. No 
significant dietary fiber treatment effect was found in urinary isoflavone excretion over 24 h 
after the 6^ and 7* daily dose of soy. Plasma daidzein was less at 24 h after the 6^ and 7^ 
daily doses of soy after high fiber compared with moderate fiber feeding. The second week 
of isoflavone feeding showed less total urinary isoflavone excretion (week 1 vs. week 2, 9.0 ± 
0.9 vs. 4.8 ± 0.9 ^mol/kg, mean of day 6 and 7, P = 0.02) and plasma isoflavone (week 1 vs. 
week 2,4.8 ± 0.7 vs. 1.8 ± 0.7 /imol/L, mean of day 7 and 8, P = 0.005). The lack of 
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différence between moderate or high dietary fiber in effect on GTT coupled with the apparent 
decrease of isoflavone absorption with repeated feeding (week 2 < week 1) obscured the 
proposed ability of high dietary fiber intake to improve apparent isoflavone absorption by 
accelerating GTT. Randomization based on pre-treatment caloric intake and sufficient 
numbers of subjects to compensate for the apparently decreased absorption of isoflavones 
over time may be needed to effectively test the effects of modulation of GTT on isoflavone 
absorption. 
KEY WORDS isoflavone bioavailability - gut transit time - dietary fiber 
The health effects of consuming foods containing phytoestrogens, especially 
isoflavones, have been discussed widely (1-2). Soybean isoflavones raise considerable 
interest because epidemiological studies have shown that lower mortality from hormone-
dependent cancer correlated with greater urinary isoflavone excretion in some populations (1, 
3). The U.S. Food and Drug Administration also approved a health claim about soy protein 
intake and cardiovascular disease prevention, implicating isoflavones as a factor in this effect 
(4). But there is little evidence about required doses for isoflavones to exert their biological 
effects in humans. Considerable interindividual variation of urinary isoflavone excretion was 
reported in a 9-day feeding study with 3 doses of isoflavone from soy protein in which the 
variation of genistein excretion was 12-fbld and that of daidzein was 15-fold even within the 
same dose treatment (5). Previous studies in our laboratory of Caucasian (lowan) and Asian 
women (Chinese immigrant), providing 1-5 /imol/kg body weight of total isoflavones per 
day, indicated that variability in isoflavone degradation phenotype (measured by assessing 
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disappearance of isoflavones from in vitro anaerobic incubations with feces) and gut transit 
time (GTT) were partly responsible for this interindividual variation (6-8). 
Gut transit time is determined in part by age, sex and physical activity and can be 
modified by drugs or foods (9). Dietary fiber is thought to be one of the most significant 
determinants of GTT. In numerous studies, gut transit time was decreased by wheat bran 
supplementation and addition of fruits and vegetables to the diet (10). In the present study, 
we hypothesized that high dietary fiber intake could improve apparent isoflavone absorption 
by speeding GTT compared with moderate dietary fiber intake in women who were identified 
as the low daidzein degraders according to fecal daidzein degradation rate constant but who 
also had relatively slow GTT. The acceleration of GTT could prevent isoflavone degradation 
in such women, permitting them to absorb more isoflavones as reflected in urinary excretion 
and plasma concentrations. 
MATERIALS AND METHODS 
Experimental Procedures 
Subjects. Female subjects were prescreened for GTT by marker bead counts and 
low daidzein degradation phenotype by anaerobic fecal incubation and HPLC analysis as 
described previously (6). The criteria for inclusion were daidzein degradation rate constant, 
D% < 0.15 h"' and GTT > 84 h. Nine healthy Caucasian women (lowan) 18-35 years of age, 
with body weight 71.5 ± 3.3 kg, body mass index (BMI) 25.1 ± 0.8 kg/m\ D% 0.06 ± 0.01 h"' 
and GTT 108 ± 9 h were recruited for this study. The pretreatment diet information was 
collected from each subject based on 24-h Food Recall and analyzed by Nutritionist V™ 
(version 1.5,1998, First DataBank Inc., San Bruno, CA). Based on whether high or moderate 
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fiber diet was fed during week 1, 9 subjects were randomly divided into two groups (Table 1). 
The subjects consuming a high fiber diet during week 1 were identified as group 1, and 
subjects consuming a moderate fiber diet during week 1 constituted group 2. The 
experimental procedures for this study were approved by the Human Subjects Committee of 
Iowa State University, subjects gave their informed consent to the study. 
Experimental design. The experiment was divided into two 7-day phases 
separated by 1 week. With a randomized crossover design, either high or moderate fiber 
diets were randomly given to the 9 subjects for 7 days. During each feeding period, 1.2 mg 
(4.5 /wnol) total isoflavones (Novasoy®, ADM Nutraceutical, Decatur, IL)/ kg body weight 
was given for 7 days. The isoflavone-containing supplement was mixed with orange juice 
given with breakfast between 7:30 and 8:30 am. The subjects consumed breakfast and dinner 
in the Human Metabolic Unit, Iowa State University, and carried out their lunch and snacks. 
All foods including three meals and three snacks /d were provided and the subjects were 
asked to finish all foods and not to consume any other foods except for water, which was 
consumed at/ On day 7 (the last day of feeding) of each feeding period, 2 gelatin 
capsules containing 16 marker beads were given to each subject with breakfast for measuring 
GTT (6). All subjects were asked to maintain their regular diet during the one-week washout 
period and to avoid any isoflavone-containing foods one week before and during the entire 
study. A list of isoflavone-containing foods was given to each subject (see Appendix C.). 
Nutrition history was obtained from each subject at the beginning of the experiment. 
Experimental diets. The experimental diets were two high fiber diets (type 1 
and type 2) and two moderate fiber diets (type 1 and type 2) (Table 3) designed with 
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Nutritionist V™, (version 1.5,1998, First DataBank Inc., San Bruno, CA) (see Appendix D.). 
All type 1 diets were consumed on Monday, Wednesday, Friday and Sunday; type 2 diets 
were consumed on Tuesday, Thursday and Saturday. Nutrient intakes/d were based on 
recommended intakes for 18 - 40 y females: 9196 kj (2200 kcal) energy, 110 g protein, 275 
g carbohydrate, 73 g total fat, respectively. For the fiber source in designed diets, 52 % of the 
fiber was from whole wheat, 40 % was from fruits and vegetables, and 8% from other fiber 
sources. The high and moderate fiber diets differed significantly only in dietary fiber content 
(Table 3). 
Biological sample collection. One blank urine sample (time 0) was collected 
from each subject in the morning on day 1 before initial feeding in both feeding periods. 
Urine was collected for 24 h on day 6,7 and 8, as well as the first urination on day 9 in both 
feeding periods. Subjects were instructed to keep the urine samples in ice chests or 
refrigerators. Immediately after collection, 24 h urine from each subject was mixed well, and 
50 mL aliquots were transferred and stored at - 80° C until analysis. After overnight fast, 10 
mL venous blood was collected into EDTA-containing vacuum containers in the morning 
before initial feeding (time 0) and on day 7 and 8 before breakfast in both feeding periods. 
Blood samples were centrifuged within 0.5 h after collection at 3000 g, 30 min, and 4° C 
(Model 4D, International Equipment, Needham Heights., MA). Plasma was removed and 
stored at - 20° C until analysis. After ingestion of marker beads with breakfast on day 7, 
feces were collected until 75% of beads were excreted (12 out of 16) during both feeding 
periods (6). 
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Analytical Methods 
Chemicals. Daidzein, genistein, glycitein and 2,4,4-trihydroxybeozoin (THB), 
used as internal standard, were synthesized in Dr. Murphy's laboratory, Iowa State University 
(11, 12). Other HPLC solvents and extraction agents were purchased from Fisher Scientific 
Co. (Pittsburgh, PA). 
Soy product analysis. Novasoy® was analyzed for isoflavone content in Dr. 
Murphy's laboratory, Iowa State University. Isoflavone extraction and HPLC analysis were 
performed as described (13,14). The isoflavone content was the sum of total daidzein, 
genistein and glycitein, expressed on a molar basis as the aglucon forms (450 ± 15.1, 608 ± 
20.3, and 111 ±7.9 /wnol/g for daidzein, genistein and glycitein, respectively). 
Plasma and urinary isoflavone analysis. Urinary and plasma isoflavone 
extraction, HPLC analysis and recovery studies were performed as described previously (6). 
The analytical recoveries of urinary daidzein, genistein, glycitein and THB were 85.3%, 
83.6% and 82.5%, and 86.0% respectively. The recoveries of plasma daidzein, genistein, 
glycitein and THB were 79.5, 75.2%, and 74.4%, and 80.6% respectively. Reported urinary 
and plasma isoflavones were calculated according to the internal standard curves of each 
individual isoflavone, THB used as internal standard. 
Statistical analysis. Statistical analysis was conducted with SAS (Version 8.2, 
2001, SAS Institute, Carry, NC). Crossover effect was not significant after statictical test; 
data were combined across the two feeding periods. General linear models, multiple 
comparisons with Tukey's test were used to test effects of fiber treatment and repeated dosing. 
All results were reported as mean ± SEM, significance level P < 0.05 for all analyses. 
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RESULTS 
Subject characteristics and diet comparisons before and during treatment. 
There was no significant difference between the high fiber group (group 1) and 
moderate fiber group (group 2) fed during week 1 in age, D%, body weight, BMI or 
pretreatment GTT (Table 1). But the pretreatment daily energy and total fat intake were 
significantly greater in group 1 than in group 2 (P < 0.05, Table 2). The pretreatment dietary 
fiber intake of both groups 1 and 2 was significantly less than the high fiber treatment diet (P 
< 0.0001), but not different from the moderate fiber treatment diet. In group 1, other 
pretreatment daily nutrient intakes were not significantly different from either high fiber or 
moderate fiber treatment diets except that carbohydrate intake was less compared with the 
high fiber diet may due to the fiber supplementation (P < 0.05) (Tables 2 & 3). In group 2, 
the pretreatment daily energy and carbohydrate intake were significantly less than both high 
fiber and moderate fiber dietary treatments (P < 0.05) (Tables 2 & 3). 
GTT comparisons before and after treatment. Before dietary treatments, subjects' 
GTT was 108 ± 9 h (Table 1). After high fiber diet treatment, GTT was significantly less by 
41% compared with pretreatment GTT (64 ± 9 vs. 108 ± 9 h, P < 0.05, respectively); after 
moderate fiber diet treatment, GTT was 19% less than pretreatment (87 ± 9 vs. 108 ± 9 h, 
respectively), but this difference was not significant (P > 0.05). Consuming the high fiber 
diet caused 26 % more rapid GTT compared with the moderate fiber diet, but this difference 
was not significant (P > 0.05) (Table 4). Pretreatment GTT was significantly longer than GTT 
measured after week 1 and week 2 (108 ± 9, 77 ± 9 and 75 ± 9 h, P < 0.05, respectively) and 
there was no difference in GTT between week 1 and week 2 (Table 4). 
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Effects of dietary fiber and repeated isoflavone dosing on urinary isoflavones. 
There were no significant differences in 24 h urinary isoflavone excretion between the high 
and moderate dietary fiber treatments. But urinary isoflavones were significantly greater in 
week 1 than in week 2 (P < 0.05) (Table 4). 
Effects of dietary fiber and repeated isoflavone dosing on plasma isoflavones. 
At 24 h after soy meal feeding, plasma daidzein was significantly greater after 
moderate fiber diet compared with high fiber diet (P < 0.05) (Table 5). Plasma genistein and 
total isoflavones were significantly greater in week 1 compared with week 2 (P < 0.05) 
(Table 5). No plasma glycitein was detected. 
The details about the 24 h urinary excretion and concentration of plasma (24 h after 
dosing) total and individual isoflavones according to the order of fiber feeding were shown in 
Appendix A. by group. 
DISCUSSION 
Diet, GTT and isoflavone absorption. Previous studies showed that significant 
differences in GTT corresponded with significant differences in urinary isoflavone excretion 
(6). Among 35 Asian (Chinese immigrant) women, 25 high genistein degraders had GTT of 
63 h, which was significantly longer than that of 10 low genistein degraders who had GTT of 
40 h (P < 0.05). The 10 low degraders had significantly greater urinary genistein excretion 
than that of 25 high degraders after a single dose providing 4.6 /imol total isoflavone/kg. But 
Caucasian low and high genistein degraders did not differ in their GTTs or in urinary 
isoflavone excretion (6). In another study comparing isoflavone bioavailability between 6 
high daidzein degraders and 4 low daidzein degraders after two 7-day feeding trials providing 
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either 54.3 pmol or 162.6 fimol total isoflavone daily, subjects who had a low daidzein 
degradation phenotype coupled with signiGcantly shorter GTT, compared with subjects who 
had a high degradation phenotype with longer GTT (65 vs. 131 h, P < 0.05) had significantly 
greater total urinary isoflavone excretion (189 vs. 119 pmol/d, P < 0.05) (8). In a single day 
crossover study of the effects of dietary fiber intake on apparent isoflavone absorption in 7 
women who consumed a single dose of total isoflavones (0.9 mg/kg body weight, high fiber 
intake (40 g/d) reduced total urinary genistein by 20% compared to fiber intake of 15 g/d (P < 
0.03) as well as total plasma genistein by 55%, but only at 24 h after dosing (P < 0.05) when 
plasma levels were quite low (< 0.2 pmol/L). Urinary daidzein was not affected (15). Based 
on these studies, seemingly both GTT and increased dietary fiber intake influenced isoflavone 
bioavailability but in opposite ways. Increased dietary fiber intake over time decreases GTT 
to some extent. Theoretically, if GTT can be decreased significantly after high fiber intake for 
a period of time, isoflavone bioavailability should be increased as well. The previous 
observation of modestly decreased genistein bioavailability due to high fiber intake for a 
single day was probably not due to any effect of the dietary fiber on GTT but due to direct 
dietary fiber-isoflavone interactions in the gut. Such interactions would need to be accounted 
for in attempting to use dietary fiber as an approach to modifying GTT and isoflavone 
absorption. 
We attempted to modify subjects' GTT in the present study. We gave subjects high 
fiber diets for a week, which reduced GTT significantly by 41% (P < 0.05) compared with 
their pretreatment GTT. During week 1 and week 2, GTT was reduced by 29% and 31%, 
respectively (P < 0.05), compared with pretreatment GTT. GTT after week 1 was not 
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different from that after week 2. Surprisingly, moderate fiber diet also decreased GTT (it was 
neither significantly different from pre-treatment nor high dietary fiber treatment). Especially 
subjects of group 2 who were fed moderate fiber during week 1 increased daily energy intake 
significantly by both dietary treatments compared with their pre-treatment energy intake 
(Table 2 & 3). Perhaps increased energy intake and increased fiber intake had similar effects 
to speed GTT. 
Before treatment, subjects in the group l(fed high fiber during week 1) had the mean 
daily energy intake and total fiber intake of 8632 kj and 19 g, respectively. When they 
consumed a high fiber diet in week 1, only the fiber intake was significantly different 
between their pre-treatment and high fiber diets. This difference in fiber intake resulted in a 
32% more rapid GTT compared with their pretreatment GTT (72 ± 17 vs. 106 ± 13 h, P < 
0.05), which indicated that 3-fold greater dietary fiber intake accelerated GTT based on -
8360 kj (- 2000 kcal) daily energy intake. When these subjects switched from high fiber 
during week 1 to moderate fiber during week 2 (i.e., back to their usual diet), their GTT was 
24% slower than when they consumed high fiber diets (89 ± 18 vs. 72 ± 17 h), but still 16% 
more rapid than their pre-treatment GTT (89 ± 18 vs. 106 ± 13 h). There may be some 
carryover effect of the high fiber diet although it was not statistically significant (P = 0.23). 
For subjects in the group 2 (fed moderate fiber diets during week 1), not only high 
fiber intake, but also the increased daily energy intake seemingly sped GTT. These subjects 
had mean daily energy intake of - 6300 kj (-1600 kcal) before the treatments, which was 
significantly less than the energy content of both treatment diets. After 1-week moderate 
fiber treatment, these subjects' GTT was 25% faster compared with their pretreatment GTT 
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(84 ± 19 vs. 112 ± 14 h, P > 0.05), suggesting an effect of increased energy intake to speed 
GTT although this effect was not significant. The additional effect of high fiber diets in week 
2 caused a 30% more rapid GTT than in week 1 (59 ± 20 vs. 84 ± 19 h, P > 0.05), again, this 
was significantly different compared with their pretreatment GTT but not significantly 
different from week 1, which may due to the small number of subjects studied. 
Seemingly both increased energy and Sber intakes may be important variables in 
attempting to better control GTT, which also suggested by previous studies. In one 
observational study, 13 male and 16 females consumed self-selected diets and collected 
duplicate portions of all food consumed for measuring fiber intake and all feces for 7 days 
four times during the year. Fecal weight was significantly correlated with fiber intake (r = 
0.524, P < 0.0001), and they were also significantly correlated with caloric intake (r= 0.543, 
P < 0.001). Although this study did not collect GTT information from each subject, fecal 
weight (which is related to GTT) seemed to be related to total food intake as well as fiber 
intake (16). Another study used a crossover design to determine the relationship between 
fecal weight, GTT and fiber intake. Forty-four subjects consumed a high fiber diet containing 
19 g of dietary fiber per 1000 kcal and a low fiber diet containing 6 g/1000 kcal for 3 weeks 
of each. About 55% of the dietary fiber was provided by fruits and vegetables and the rest by 
bread and other cereal products. Feces were collected for 4—5 days of each period. GTT were 
measured using radio-opaque plastic pellets. There was a strong influence of the amount of 
fiber intake on both GTT and fecal fresh weight. GTT went down as fecal weight went up 
and continued to decrease as fecal weight increased above 140 g/d (17). In a similar study, 
significantly linearly inverse relationship between GTT and stool weight was found (r = 0.8, 
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P < 0.05) in 19 men and 11 women when they consumed 30, 60,110, or 170 g/d bran-
enriched wholemeal bread for 3 weeks (9). From theses studies, we know that fecal weight 
significantly positively correlated with caloric intake and fiber intake, and GTT significantly 
inversely correlated with fecal weight and fiber intake, therefore GTT is inversely related to 
caloric and fiber intakes. We suspect that pretreatment apparent isoflavone absorption would 
have been less than both dietary treatments based on the observed difference in GTT. As 
mentioned above, our previous studies have shown greater apparent isoflavone uptake to be 
related to more rapid GTT (6, 8). 
Repeated isoflavone dosing decreased apparent isoflavone uptake. Apparent 
isoflavone uptake as reflected in urinary excretion was greater in week 1 than in week 2 of 
our study (Table 4). GTT in both week 1 and week 2 was significantly shorter than pre­
treatment GTT in all subjects (77 ± 9 and 75 ± 9 vs. 108 ± 9 h, P < 0.05). Because GTT was 
significantly more rapid in week 1 and week 2 than pre-treatment, we would expect greater 
urinary isoflavone excretion after dietary treatments than before; that remains to be seen in 
future studies. 
Lu et al. (18-19) showed that after daily dose of 80-210 mg of each isoflavone 
(daidzein and genistein) as in soymilk for one month, urinary excretion of isoflavone was 
about 10% lower than that of initial excretion in women but not in men. A previous 7-day 
crossover high and low dose of isoflavones study using a 1 week washout period between the 
two doses similar to the present study's washout period between the two dietary fiber 
treatments, also showed a significant 20-30% decrease in urinary isoflavone excretion from 
week 1 to week 2 across doses (8). We know that isoflavones can be degraded by gut 
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bacteria. It is possible that the isoflavone degrading microorganisms adapt over time to 
increase activity. This remains to be proven, and characterization of isoflavone metabolizing 
gut microflora is an important research need. 
Plasma and urinary isoflavones. Concentrations of plasma isoflavone showed 
similar effect of repeated dosing as did urinary isoflavone excretion: plasma isoflavone 
contents were generally greater in week 1 than in week 2. As mentioned above, Tew et al. 
(15) found that the fiber-rich diet produced 55% lower plasma genistein at 24 h after soy 
dosing (P < 0.05). We also found decreased plasma isoflavone, but only daidzein, after high 
fiber diet compared with moderate fiber diet. The lesser plasma daidzein in the current study 
may be due to reduced ^-glucuronidase activity caused by high fiber intake, therefore 
lessening daidzein reabsorption in the intestine. But there is no explanation as to why this 
effect should be selective for daidzein and not for genistein. Rose et al. (20) observed a 
suppression of estrogens bioavailability after doubled fiber intake of 62 premenopausal 
women from about 15 g to 30 g with wheat bran for 2 months: serum estrone (P < 0.002) and 
estradiol (P < 0.02) were significantly reduced by 15-20%. Isoflavones are structurally 
similar to estrogen, which high fiber intake may have the same suppression effect on 
isoflavone absorption. Similar to estrogens, isoflavones are conjugated with glucuronic acid 
in liver and intestine and then maybe 50-70% of conjugated isoflavones are excreted in bile. 
The reabsorption of isoflavones requires the hydrolysis of ^-glucuronidase, releasing free 
form of isoflavones. Fiber intake has been shown to reduce ^-glucuronidase activity in rats 
and chicks (21-22). Male F344 rats were fed either fiber-free basal diet or this basal diet 
mixed with 5 and 15% of fiber diet for 12 days. Specific activity and total output of |3-
glucuronidase were significantly lower in those fed 15% fiber diet and higher in rats fed 
fiber-free diet (21). In another study, when dietary fiber was given at 30% level of diet to 
chicks for 2-week, significantly lowered bacterial ^-glucuronidase activity (22). Thus we 
would expect this also to happen in humans; therefore high fiber intake may result in lower 
plasma isoflavone. Furthermore, the binding of fiber with unconjugated isoflavones may also 
prevent isoflavone reabsorption in the intestine. 
We did not find urinary isoflavones to be different after high fiber diet compared with 
moderate fiber diet. This may have occurred because of opposing effects of high fiber 
treatment on urinary isoflavone excretion. First, high fiber intake decreased GTT, and 
increased fresh fecal weight (17), lowering bacterial ^-glucuronidase and P-glucosidase 
concentrations (21-22,15), resulting in lower opportunity for isoflavone reabsorptions. On 
the other hand, this greater excretion of intestinal bacteria and more rapid GTT may also 
decrease the degradation of isoflavones by these bacteria, therefore increasing the absorption 
and reabsorption of isoflavones. The overall influence of high fiber treatment on urinary 
isoflavone excretion may depend on which effect is significant, the lowering bacterial 
enzyme activities or the lowering degradation of isoflavones; and if GTT is accelerated 
significantly, which was not the case when the two treatments were compared. 
In the present study, although GTT may be a determinant of isoflavone absorption, the 
strategy of speeding GTT by increasing dietary fiber intake must be done in a very carefully 
controlled manner, e.g. both treatment groups need to have similar total energy and other 
nutrient intakes before dietary treatment. Isoflavone uptake may be also affected by repeated 
dosing due to the induction of isoflavone degradation by the gut microflora. The probable 
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adaptation of isoflavone degrading microorganisms to increase their activity over time must 
also be taken into account in designing feeding trials. 
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TABLE 1 
Subject characteristics' 
Dietary Gber n D% Age Body BMI Initial GTT 
treatment weight 
A" Y Ag Ag/m A 
High in week 1 5 0.07 ±0.02 22.4 ±2.3 75.8 ±4.0 25.8 ±1.2 106 ±13 
(group 1) 
Moderate in 4 0.05 ±0.02 21.5 ±2.6 66.1 ±4.5 24.0 ±1.3 112 ±14 
week 1 (group2) 
Mean 0.06 ±0.01 22.0 ±1.6 71.5 ±3.3 25.1 ±0.8 108 ±9 
' Subjects who consumed high Gber diets in week 1 were designated as group 1, subjects who 
consumed moderate Gber diets in week 1 were designated as group 2. 
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TABLEZ 
Pre-treatment nutrient intakes of subjects based upon 24-h food records''^ 
Subject 
ID 
Energy intakes Protein Carbohydrate Total fat Total dietary 
Gber 
Gm gm gm gTM 
1 8857 (2119) 127 232 77 13 
4 8864 (2162) 96 286 69 14 
6 8414 (2013) 64 276 77 20 
7 10149 (2428) 147 272 84 15 
9 6705 (1604) 56 250 47 32 
Mean of group 
1 
8632 ± 598^ 
(2065±143) 
98=1= 14 263 =1= 14 71 ±8^ 19=1=3 
2 6492 (1553) 54 273 28 24 
3 5204 (1245) 46 222 26 19 
5 8515 (2037) 76 294 67 23 
8 5693 (1362) 65 204 30 21 
Mean of group 
2 
6475± 673" 
(1549±161) 
60=1= 15 248 ± 16 W 00
 
H- 00
 22=L 3 
Mean 8347 =t 564 
(1836±135) 
81 ± 12 257 ± 10 56 =t 8 20 ±2 
'Subjects # 1, 4,6, 7 and 9 consumed high fiber diets in week 1 (group 1), subjects # 2, 3, 5, 
8, consumed moderate Gber diets in week 1 (group 2). 
^ The energy intakes, and total fat intake with different superscripts (a, b) differed 
significantly between group 1 and group 2, P < 0.05. 
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TABLE 3 
Nutrient composition of treatment diets ^ 
Diet (Type) Energy intakes Protein Carbohydrate Total fat Total 
dietary 
Gber 
gm gTM 
High Gber (1) 8729 (2088) 77 345 56 45 
High Gber (2) 8895 (2128) 113 338 48 45 
Moderate Gber 8966 (2145) 76 302 69 15 
(1) 
Moderate Gber 8736 (2090) 100 298 59 15 
(2) 
Mean of high 8811± 84 95± 18 342 ±3.5 52 ±4 45 ±0^ 
Gber diets (2108 ±20) 
Mean of moderate 8851 ±117 88± 12 300 ±2 64 ± 5 15 ±0= 
Gber diets (2118 ±28) 
' The diets were designed by using Nutritionist V (Nutritionist V ™, version 1.5,1998, First 
DataBank Inc., San Bruno, CA) based on 18-40 y female, the recommended nutrients intakes 
are: energy: 9196 kj/d (2200 kcal/d), protein: 110 gm/d, carbohydrate: 275 gm/d, total fat 73 
gm/d, and total dietary Gber: 24 gm/d. 
^ All Type 1 diets were consumed on Monday, Wednesday, Friday and Sunday and all Type 2 
diets were consumed on Tuesday, Thursday, and Saturday. 
^ Dietary Gber bearing different superscripts (a, b) differed signiGcantly between the high 
Gber and low Gber diets, P < 0.05. 
155 
TABLE 4 
The 24-h urinary excretion of total and individual isoflavones during high and moderate fiber 
treatment, and during week 1 and 2, compared with gut transit time (GTT) ^ 
Fiber 
treatment 
GTT Daidzein Genistein Glycitein Total 
A 
High 64 ± 9 4.21 ± 0.68 2.10 ±0.40 0.79 ±0.11 7.10± 1.16 
Moderate 87 ±9 4.20 ± 0.66 2.35 ±0.39 0.60 ±0.10 7.15 ± 1.13 
Week GTT Daidzein Genistein Glycitein Total 
A 
1 77 ±9 5.65 ± 0.56^ 2.85 ± 0.36^ 0.94 ± 0.09^ 9.43 ± 0.97^ 
2 75 ±9 2.68 ±0.58" 1.57 ±0.37" 0.43 ± 0.09* 4.68 ± 1.00" 
' The urinary excretion of isoflavones was the mean of day 6 and d 7. 
^ The urinary excretions of total and individual isoflavones with different superscripts (a, b) 
were significantly different between the week 1 and week 2, P < 0.05. 
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TABLES 
The plasma concentration of total and individual isoflavones during high and moderate fiber 
treatments, and during week 1 and 2^' ^ 
Fiber treatment GTT Daidzein Genistein Glycitein Total 
A 
High 64 ±9 0.0 ±0.11' 2.81 ±0.82 ND* 2.81 ± 0.86 
Moderate 87 ±9 0.24 ± 0.10^ 3.88 ± 0.80 ND 4.12 ±0.83 
Week GTT Daidzein Genistein Glycitein Total 
A /WMof/Z, 
1 77 ±9 0.22 ±0.10 4.91 ± 0.74" ND 5.13 ±0.78" 
2 75 ±9 0.03 ±0.11 1.89 ±0.72= ND 1.93 ±0.75' 
' The plasma concentration of isoflavones was the mean of day 7 and 8 at 24 h after dose. 
^ The plasma concentration of daidzein with different superscripts (a, b) was significantly 
different between high Gber and moderate Gber diet, P < 0.05. 
^ The plasma concentration of genistein and total isoGavone with different superscripts (c, d) 
was signiGcantly different between week 1 and week 2, P < 0.05. 
* ND = not detected. 
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GENERAL CONCLUSIONS 
To better assess the potential health effects of isoflavones, their bioavailability must 
be better understood. Optimizing isoflavone bioavailability is likely to permit more 
conclusive studies of these compounds. All the three human feeding studies I have done 
demonstrated that isoflavone degradation phenotypes coupled with GTT significantly 
influence the bioavailability of isoflavone (apparent absorption) as reflected in urinary 
excretion and GTT is a crucial factor. 
We compared bioavailability of isoflavones in their two major forms (aglucons vs. 
glucosides) and between two sources (rich in glycitein vs. genistein) in women fed the 
isoflavone for 7 days. We showed that the daily bioavailability of the two major isoflavone 
forms (aglucons vs. glucosides) did not differ as reflected in total urinary excretion over 24 h, 
but that genistein was less well absorbed than glycitein or daidzein as reflected in total 
urinary isoflavone excretion. Isoflavone aglucons were absorbed more rapidly than 
glucosides as reflected in total and individual plasma isoflavone content at 3 h after feeding, 
which might have implications for choice of isoflavone source when a rapid effect is desired. 
We examined the bioavailability (urine and plasma content) of high and low doses of 
isoflavone among individuals of varying GTT and daidzein degrdation phenotype. The results 
from this study suggested that the effects of gut microflora on absorption of isoflavone 
probably relate strongly to gut transit time, i. e., the length of time gut microbial species have 
to exert their effects on isoflavones. Repeated feeding soy isoflavones for a period of time 
may decrease their bioavailability due to induced gut microbial degradation of these 
compounds. 
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In order to further investigate the importance of GTT, in the third study, we 
hypothesized that high dietary 6her intake could improve apparent isoflavone absorption by 
speeding GTT compared with moderate dietary Gber intake in women who were identiGed as 
low daidzein degraders but also had relatively longer GTT. The acceleration of GTT could 
prevent isoGavone degradation in such women, permitting them to absorb more isoGavones 
as reGected in urinary excretion and plasma concentrations. We found that although GTT 
may be a determinant of isoGavone absorption, it can be modiGed by many factors. The 
strategy of speeding GTT by increasing dietary Gber intake must be done in a very carefully 
controlled manner, e.g. both treatment groups need to have similar total energy and other 
nutrient intakes before dietary treatment. Again we found isoGavone uptake may be affected 
by repeated dosing due to the induction of isoGavone degradation by the gut microGora. 
In conclusion, bioavailability of isoGavone was signiGcantly greater in subjects of a 
low isoGavone degradation phenotype with shorter GTT than in subjects of a high isoGavone 
degradation phenotype with longer GTT as reGected in total urinary isoGavone excretion. 
This phenomenon should be taken into account to better control human feeding studies of the 
effects of isoGavones. The probable adaptation of isoGavone degrading microorganisms to 
increase their activity over time must also be taken into account in designing feeding trials. 
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APPENDIX A. URINARY EXCRETION OF ISOFLAVONES IN GROUP 1 AND 
GROUP 2 
The 24-h urinary excretion of total and individual isoflavones according to order of feeding 
treatments and compared with gut transit time (GTT)'' ^ 
Group Week Fiber 
treatment 
GTT Daidzein Genistein Glycitein Total 
A 
1 1 High 72± 17 5.66 ±0.56'' 2.90 ±0.42 1.09 ±0.10'' 9.64± 1.02*" 
2 Moderate 89 ± 18 3.06 ±0.56' 2.00 ± 0.42 0.48 ±0.10' 5.54 ±1.02' 
2 1 Moderate 84± 19 5.63 ± l .W 2.78 ±0.64 0.75 ±0.14 9.16 ± 1.85 
2 High 59 ±20 2.14± 1.18' 0.95 ± 0.68 0.35 ±0.15 3.45 ± 1.98 
Mean of group 1 80± 16 4.36 ±0.49 2.45 ± 0.30 0.78 ±0.10 7.59 ±0.84 
Mean of group 2 72 ± 18 4.00 ±0.90 1.93 ±0.51 0.57 ±0.11 6.50 ± 1.51 
' The urinary excretion of isoflavones was the mean of day 6 and 7. 
^ Subjects consumed high fiber diet during week 1 was assigned to group 1, subjects 
consumed moderate fiber diet during week 1 was assigned to group 2. 
^ The urinary excretion of daidzein, glycitein, and total isoflavones with different superscripts 
(a, b) were significantly different between high and moderate Gber diet in group 1, P < 0.05. 
^ The urinary excretion of daidzein with different superscripts (c, d) was significantly 
different between high and moderate fiber diet in group 2, P < 0.05. 
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APPENDIX B. PLASMA CONCENTRATION OF ISOFLAVONES IN GROUP 1 AND 
GROUP2 
The plasma concentration of total and individual isoflavones according to order of feeding 
treatments and compared with gut transit time (GTT) ^ 
Group Week Fiber 
treatment 
GTT Daidzein Genistein Glycitei 
n 
Total 
A /ITMO/XZ, /amoZ/L fimoZ/L 
1 1 High 72=1= 17 ND' 3.74 ±0.80 ND 3.74 ±0.82 
2 Moderate 89± 18 0.06 ± 0.04 2.00 ±0.76 ND 2.06 ± 0.76 
2 1 Moderate 84 ± 19 0.64 ± 0.23 5.65 ± 1.39" ND 6.28 ± 1.42" 
2 High 59 ±20 0.0 ± 0.23 1.43 ± 1.39" ND 1.43 ± 1.42' 
Mean of group 1 80 ± 16 0.03 ± 0.03 2.82 ± 0.57 ND 2.85 ±0.58 
Mean of group 2 72± 18 0.32 ± 0.17 3.54 ± 1.09 ND 3.86 ± 1.16 
' The plasma concentration of isoflavones was the mean of day 7 and 8 at 24 h after dose. 
^ Subjects consumed high Gber diets during week 1 was assigned to group 1, subjects 
consumed moderate Gber diets during week 1 was assigned to group 2. 
^ The concentration of plasma genistein, and total isoGavones with different superscripts (a, 
b) was signiGcantly different between high and moderate Gber diet in group 2, P < 0.05. 
^ ND = not detected. 
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APPENDIX C. FOODS CONTAIN ISOFLAVONES 
I Soy Protein Isolate 
Soybeans 
Tofu 
Soymilk, Soymilk powder 
Soybean sprouts 
Tempeh 
Miso soup 
Special K 6ozen waffles 
Carnation Instant Breakfast-chocolate malt flavored 
II. Food Containing Texturized Vegetable Protein 
Frozen pizza 
burritos 
Momingstar Farm breakfast links, patties, strips 
Za C&py lobster egg rolls 
liquid non-diary creamers 
m. Foods Containing Hydrolyzed Vegetable Protein (HVP) 
Most chip dips (French onion and some others) 
Garden vegetable flavored cheese spreads 
Many frozen entree's 
TbmAgfoMe frozen pizza with meat 
Some franks (JbA/z Mbrre/, //bozeZ Light & Lean, etc.) 
Many sauce mixes-gravy (usually brown), chill, etc. 
Avzorr soup mixes 
Khorr dry sauce mixes except "Pesto" 
Some canned soups(usually those containing vegetable & meat, like chicken and mushroom) 
Many la C&qy foods as well as oriental style mixes, etc. (containing HVP or soy sauce) 
Soy sauce has soybeans pr protein extracts from soybeans 
/fame/; noodles containing HVP and /or soy sauce powder 
f/ezfzz worestershire sause(containing HVP in soy sauce) 
Red Hot Piplets(most other chips and snacks were fine) 
C/inc/g Ben'j Rice mix 
Some herbal magic salad dressing, Girad's salad dressing 
Most bacon flavored bits 
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APPENDIX D. TREATMENT DIETS 
Type I high fiber diet: 
Breakfast 
Whole wheat bread: 2 slices 
Jam: 2 tbsp 
Fat free milk: 16 fl oz 
Peanut butter: 2 tbsp 
Orange juice: 8 fl oz 
Apple: 1 item 
Morning snack 
Potato chips: 1 small package 
Lunch 
Smoked turkey breast: 2 slices 
Whole wheat bread: 2 slices 
Iceberg lettuce leaves: 1 piece 
Tomato: 2 slices 
Low calorie mayonnaise: 2 tbsp 
Afternoon snack 
Whole grain wheat crackers: 6 items 
Dinner 
Baby carrots: 0.5 cup 
French onion dip: 2 tbsp 
Whole wheat spaghetti: 2 cups 
Tomato sauce: 1 cup 
Orange: 1 item 
Evening snack 
Whole wheat onion cracker: 6 items 
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Type II high Gber diet: 
Breakfast 
Whole grain cereal: leup 
Fat Gee milk: 16 G oz 
Wheat bran mufGn: 1 item 
Orange juice: 8 G oz 
Apple: 1 item 
Morning snack 
Com tortilla: 1 small package 
Lunch 
Smoked ham: 2 slices 
Whole wheat bread: 2 slices 
Tomato: 2 slices 
Low calorie mayonnaise: 2 tbsp 
Afternoon snack 
Whole grain wheat crackers: 6 items 
Dinner 
Celery: 1 cup 
Broccoli: 1 cup 
French onion dip: 2 tbsp 
Whole wheat pizza: 1 slice 
Chicken noodle soup: 1 cup 
Orange: 1 item 
Evening snack 
Whole wheat onion cracker: 6 items 
Type I moderate fiber diet: 
Breakfast 
White bread: 2 slices 
Jam: 2 tbsp 
Fat free milk: 16 fl oz 
Peanut butter: 2 tbsp 
Orange juice: 8 fl oz 
Morning snack 
Milk chocolate bar: 1 item 
Lunch 
Smoked turkey breast: 2 slices 
White bread: 2 slices 
Iceberg lettuce leaves: 1 piece 
Low calorie mayonnaise: 2 tbsp 
Afternoon snack 
Potato chips: 1 small package 
Dinner 
Spaghetti: 1 cup 
Tomato sauce: 1 cup 
Chocolate cake 1 slice 
Evening snack 
Nonfat plain yogurt: 1 cup 
Type II moderate fiber diet: 
Breakfast 
Honey nut cereal: 1 cup 
Small muffin: 1 item 
Fat free milk: 16 fl oz 
Orange juice: 8 fl oz 
Morning snack 
Potato chips: 1 small package 
Lunch 
Ham: 2 slices 
White bread: 2 slices 
Tomato: 2 slices 
Low calorie mayonnaise: 2 tbsp 
Afternoon snack 
Vanilla Pudding: 1 cup 
Dinner 
Pizza: 1 slice 
Chicken noodle soup: 1 cup 
Banana I item 
Evening snack 
Nonfat plain yogurt: 1 cup 
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